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Background: Acute liver failure (ALF) is characterized by overwhelming hepatocyte death and liver 
inflammation where the infiltration of myeloid cells in areas of necrosis is contrasted by immune cell 
depletion and dysregulation in the systemic circulation. The mechanisms underlying resolution of 
acute hepatic inflammation are largely unknown to date. In this thesis, I used both human and murine 
experimental models in order to investigate the impact of Mer Tyrosine Kinase (MerTK) during ALF 
and examine how the micro-environmental mediator, Secretory Leukocyte Protease Inhibitor (SLPI), 
governs this immunological response. 
 
Methods: Flow cytometry, immunohistochemistry, confocal imaging and gene expression analyses 
determined the phenotypic, functional and transcriptomic profile and tissue topography of MerTK+ 
monocytes and macrophages in ALF, healthy and disease controls. The temporal evolution of 
macrophage MerTK expression and its impact on hepatic resolution was examined in APAP-induced 
acute liver injury using wild-type (WT) and Mer-deficient (Mer−/−) mice. Furthermore, SLPI effects 
on hepatic myeloid cells were determined in vitro and in vivo using APAP-treated WT mice. 
 
Results: I demonstrate a significant expansion of resolution-like MerTK+HLA-DRhigh cells in both 
circulatory and tissue compartments of ALF patients. Compared to WT mice, that show an increase of 
MerTK+MHCIIhigh hepatic macrophages during the resolution phase in ALF, APAP-treated Mer−/− 
mice exhibit persistent liver injury and inflammation, characterized by a decreased proportion of 
liver-resident Kupffer cells and increased number of hepatic neutrophils. Both in vitro and in APAP-
treated mice, SLPI reprograms macrophages towards resolution responses through induction of a 
MerTK+HLA-DRhigh phenotype which promotes neutrophil apoptosis and their subsequent clearance. 
 
Conclusions: The work presented in this thesis has identified a prorestorative, MerTK+, macrophage 
phenotype that evolves during the resolution phase of APAP-induced ALF and represents a novel 
immunotherapeutic target to promote resolution responses following acute liver injury.  
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Significance of this study 
 
 
What is already known about this subject:  
• Liver inflammation is central to the pathogenesis of ALF where infiltration of myeloid cells in areas of 
hepatic necrosis is contrasted by systemic immune cell depletion and dysregulation. 
• MerTK regulates innate immune responses and promotes the clearance of apoptotic cells following 
acute tissue injury. 
• SLPI is produced within the inflamed liver in ALF and is a key modulator of monocyte anti-
inflammatory responses. 
What are the new findings:  
• ALF patients have an expansion of resolution-like MerTK+HLA-DRhigh monocytes and hepatic 
macrophages, characterized by suppressed innate and enhanced efferocytic/phagocytic responses.  
• MerTK+ monocytes exhibit a distinct pattern of adhesion, phagocytosis, pattern-recognition and 
cytokine receptors and genes associated with antigen presentation and macrophage polarization. 
• A similar phenotype (MerTK+MHCIIhigh) with enhanced phagocytic capabilites evolves during the 
resolution phase of APAP-induced acute liver injury in mice.  
• MerTK-deficient mice exhibit persistent liver injury and inflammation after APAP overdose and are 
characterized by a depletion in MHCIIhigh-bearing prorestorative resident Kupffer cells and by 
increased numbers of activated neutrophils. 
• SLPI reprograms myeloid cells towards resolution responses by inducing the prorestorative 
MerTK+HLA-DRhigh phenotype which promotes neutrophil apoptosis and their subsequent clearance. 
How might it impact on clinical practice in the foreseeable future? 
• SLPI is a pivotal pro-resolving mediator in ALF that promotes MerTK-dependent hepatic resolution 
responses following acute liver injury. 
• Harnessing the prorestorative capabilities of MerTK+ cells represents a novel therapeutic strategy to 
promote resolution following acute hepatic inflammatory disorders. 
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1.1 Acute liver failure 
 
1.1.1 Acute liver failure as a clinical syndrome 
 
Acute liver failure (ALF) is a clinical syndrome that was initially defined as the simultaneous 
appearance of hepatic encephalopathy and coagulation defects in the setting of an acute liver insult, in 
the absence of pre-existing liver disease (Trey and Davidson, 1970). Over the years, definitions have 
varied in regard to duration from time of onset to signs of liver failure. ALF is characterized by 
overwhelming hepatocyte death, that exceeds the regenerative capacity of the liver, combining the 
clinical features of an acute severe liver insult with the rapid development of hepatic encephalopathy, 
coagulopathy, jaundice and progression to multi-organ failure (Bernal et al., 2013). ALF is a rare 
disease with an incidence in the developed world of fewer than 5 cases per million population per 
year (Bernal et al., 2015).  
 
Over the last decades, the causes have changed with hepatitis A and B declining in incidence and 
acetaminophen (paracetamol) toxicity increasing at least in Western Europe and the United States 
(Bernal et al., 2010). The differences in aetiology between developing and developed countries are 
well characterized. In Europe and the United States, acetaminophen(APAP)-induced ALF (AALF) 
and drug-induced liver injury (DILI) form a significant proportion of ALF whilst acute viral hepatitis 
(e.g. hepatitis B, Hepatitis E) is more common in South Asia, Hong Kong and Australia (Acharya et 
al., 2002). Seronegative ALF (SALF) is another increasingly well-recognized cause of ALF due to yet 
unknown etiology. Its clinical diagnosis is based on exclusion of other causes of hepatocellular injury 
such as viral, autoimmune or drug-induced hepatitis (Bernal et al., 2010; Bernal et al., 2013). It is 
currently hypothesized that SALF could be due to a dysregulated immune response to an unidentified 
hepatotropic or environmental trigger (Donaghy et al., 2013).  
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The relationship of injury pattern, as determined by the etiology, course of illness and its duration, is 
key in understanding the clinical features and prognosis in ALF. Thus, the terms hyper-acute, acute 
and sub-acute ALF have been adopted in clinical practice (O'Grady et al., 1993).  The period of active 
injury in ALF is self-limited and the overall pattern of illness is short, there is rapid onset and offset, 
and a finite period of necrosis. These patients are characterized by a hyper-acute pattern, and, in many 
cases, a rapid recovery despite developing massive multi-organ failure (Bernal et al., 2015). In acute 
or sub-acute forms of ALF, injury evolves over one to four weeks, it is not self-limited, but long 
lasting. DILI, autoimmune hepatitis and most indeterminate ALF cases will have a sub-acute pattern 
and a worse survival (Bernal et al., 2015).  
 
1.1.2 Immune-mediated liver injury  
 
1.1.2.1 The liver as an immunological and tolerogenic organ 
 
The liver is the largest organ of the human body (1.2–1.5kg) and plays a central role in the immune 
responses against invading pathogens. It has a dual blood supply, with oxygenated blood entering 
through the hepatic artery (20%) and blood rich in nutrients and bacterial endotoxin coming through 
the portal vein (80%) (Liaskou et al., 2012). The liver is constantly exposed to circulating antigens 
and endotoxins derived from the gut, thus it is prerequisite for its immune system to be appropriately 
equipped to protect itself from pathogens and tolerate self and foreign antigens (Zimmermann et al., 
2012). The liver capillary system is lined with different specialized cells: parenchymal cells including 
hepatocytes and biliary epithelial cells (BECs) but also non-parenchymal cell, such as hepatic stellate 
cells (HSCs) and hepatic sinusoidal endothelial cells (HSECs), that act as primary sensors of immune 
responses (Crispe, 2009). Importantly, the liver contains a large number of immune cells that take part 
in maintenance of homeostasis but are equally relevant in responses to hepatic injury, thereby playing 
key roles in both initiation and progression of liver diseases. It contains a high density of myeloid 
[liver-resident Kupffer cells (KCs), macrophages and neutrophils] and lymphoid (natural killer (NK) 
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cells, T or B lymphocytes) cells that initiate and shape both innate and adaptive immune responses 
(Heymann and Tacke, 2016). 
 
1.1.2.2 Sterile inflammation in acute liver failure 
 
Innate immune activation can be etiology-specific; pathogen-associated molecular patterns (PAMPs) 
are more important in ALF caused by hepatotropic viruses whereas damage-associated molecular 
patterns (DAMPs) are more important in toxic etiologies such as AALF. Recognition of pathogens by 
a coordinated interaction of innate immune cells (monocytes, macrophages, dendritic cells (DCs) and 
NK cells) expressing PAMP and DAMP recognition receptors eventually leads to the activation of 
adaptive immunity (Chung et al., 2012). Sterile inflammation occurs in tissues in response to different 
stimuli and can cause tissue stress and injury. This is a key process in drug-induced liver injury 
including AALF and also in nonalcoholic steatohepatitis (NASH), liver fibrosis and cancer (Kubes 
and Mehal, 2012).  
 
The liver is primed to respond to injurious stimuli through the release of endogenous damage-
associated molecular patterns (DAMPS) that are usually hidden from the extracellular environment, 
but are released upon tissue injury and which activate receptors on immune cells (Kubes and Mehal, 
2012). Following AALF, paracetamol toxic metabolites induce oxidative stress and direct damage to 
hepatocytes which consequently release DAMPs (e.g. HMGB-1 and histone-associated DNA) that are 
recognized by liver-resident KCs and neutrophils, leading to their activation. In turn, activated KCs 
release various pro-inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6) and chemokines (e.g. CCL2), 
thereby enhancing hepatic inflammation and increasing the influx of bone-marrow derived immune 
cells like monocytes and neutrophils (Heymann and Tacke, 2016; Kubes and Mehal, 2012). DCs, the 
major antigen-presenting cells, exert immune tolerance in the liver in collaboration with KCs by 
suppressing effector T cells and promoting regulatory T cells (Heymann and Tacke, 2016). During 
AALF, DCs exhibit increased expression of MHC-II, TLRs and secretion of high IL-6, CCL2 and 
TNF-α levels (Connolly et al., 2011), however, their role in the pathogenesis is yet obscure, due to the 
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fact that several liver cells types can express “DC markers” like MHC-II and CD11c (Krenkel et al., 
2014). Besides myeloid cells, distinct lymphoid populations, especially gamma-delta (γδ) T cells, are 
linked to the inflammatory response in ALF, and the role of NK, NK (NKT) cells and T cells is still 
not fully elucidated, as further reviewed in (Heymann and Tacke, 2016; Krenkel et al., 2014) and will 
be discussed below.  
 
In contrast to the pathogenesis of AALF, SALF is associated with a lymphocytic infiltrate of effector 
T cells, NK cells and to a lesser extent B cells (Tuncer et al., 2013), suggestive of driving immune-
mediated cytotoxic damage to hepatocytes and culminates in massive hepatic necrosis and liver 
failure (Tuncer et al., 2013; Wu et al., 2010). These histological features and the detection of 
increased circulating levels of autoantibodies in SALF patients suggest an autoimmune-mediated 
disorder (Stravitz et al., 2011). In both underlying etiologies of ALF, the recruited immune cells 
themselves can contribute to hepatocyte damage mediated via direct activation of death receptors or 
the secretion of cytokines (Bernal et al., 2010; Quaglia et al., 2008). Thus, mechanisms designed to 
orchestrate liver regeneration and tissue repair can further amplify liver injury and the progression of 




Numerous clinical studies suggest that although the inciting event is overwhelming hepatocyte death 
in ALF, mortality occurs due to the presence of systemic inflammatory response syndrome (SIRS) 
and its attendant complications of multi-organ failure, immune dysfunction and recurrent infections 
(Antoniades et al., 2008; Rolando et al., 2000; Schmidt and Larsen, 2006; Vaquero et al., 2003). This 
condition shares striking similarities with sepsis with regard to the features of systemic inflammation, 
multi-organ failure and immuneparesis, thus may also share pathogenic mechanisms (Antoniades et 
al., 2008). Immuneparesis is considered the predominant driving force for morbidity and mortality in 
septic patients. Accumulating evidence showed that sepsis causes major immunological defects that 
impair host immunity (Hotchkiss et al., 2013b). These patients exhibit increased apoptosis-induced 
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loss of innate and adaptive immune cells that leads to immunosuppression and compromises the 
host’s ability to kill pathogens (Hotchkiss et al., 2013a). Another hallmark of sepsis is that monocytes 
have a diminished ability to produce pro-inflammatory cytokines (e.g. TNF-α, IL-6 and IL-12)  in 
response to endotoxin, TLR agonists or other bacterial compounds, findings that are consistent with 
the phenomenon of endotoxin tolerance (Hotchkiss et al., 2013b) whereas their anti-inflammatory 
mediator (e.g. IL-10) release is unaltered or enhanced (Biswas and Lopez-Collazo, 2009; Cavaillon 
and Adib-Conquy, 2006). Consequently, the increased release of immune-suppressive mediators and 
decreased antigen presentation due to reduced HLA-DR expression might augment susceptibility to 
secondary infections; both are associated with a worse outcome in sepsis (Hotchkiss et al., 2013b). 
 
Central to the pathogenesis of ALF is hepatic inflammation where infiltration of myeloid cells in 
necrotic areas of the liver is contrasted by immune cell depletion and dysregulation in the circulation 
(Antoniades et al., 2014; Antoniades et al., 2012). ALF patients exhibit features of immuneparesis, 
mainly characterized by innate immune suppression, in particular of monocytes and neutrophils, that 
causes deleterious effects on anti-microbial responses and may account for increased susceptibility to 
infections encountered in these patients (Antoniades et al., 2006; Antoniades et al., 2014; Antoniades 
et al., 2012; Taylor et al., 2013). Of note, circulating monocytes in ALF show an immunosuppressive 
phenotype, with reduced HLA-DR expression, and exhibit impaired phagocytic and NF-kB dependent 
pro-inflammatory responses following microbial challenge (Antoniades et al., 2006; Antoniades et al., 
2014; Bernsmeier et al., 2015). Recent work in ALF proposed that anti-inflammatory/regenerative 
mediators produced within the inflamed liver are of sufficient magnitude to “spill-over” into the 
systemic circulation, where they can dampen monocyte anti-microbial responses (Antoniades et al.; 
Possamai et al., 2014b).  
 
1.1.3 Treatment strategies for ALF  
 
The disease’s rarity, severity and phenotypic heterogeneity result in a uniquely challenging illness, 
particularly in relation to its study and the development of effective treatments. The last decades have 
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seen major changes in ALF patients’ care approach, resulting to decreased mortality rate, with the 
most visible impact coming from the use of emergency orthotopic liver transplantation (OLT) and 
improved organ support (Bernal et al., 2013). A recent retrospective review study on ALF cases in the 
United Kingdom showed improvement in hospital survival of ALF patients from 17% (mid-1970s) to 
62% (mid-2000s) (Bernal et al., 2013). Despite of established treatment modalities, such as N-
acetylcysteine (NAC) and OLT, ALF still presents a high mortality rate over 40 % (Bernsmeier et al., 
2014). The immune system contributes crucially to the pathophysiology of ALF. Thus, future studies 
aiming to a better understanding of the mechanisms regulating immune cell function during ALF will 
be an essential step towards new treatments. These potential immune-modulatory therapies could be 
developed such as to re-orientate the immune system to promote the desirable functions of attenuating 








1.2.1.1 Macrophage origin 
 
Monocytes and macrophages are members of the human mononuclear phagocytic system. Although 
historically known for their functions in host defense and clearance of apoptotic cells, they are now 
considered central to tissue development, homeostasis and inflammation, contributing to a broad 
variety of inflammatory pathologies (Ginhoux et al., 2016). Three major human monocyte subsets are 
reported to exist in the blood and liver (Ingersoll et al., 2010; Liaskou et al., 2013); the “classical” 
(CD14+CD16-), “non-classical” (CD14lowCD16+) and “intermediate” (CD14++CD16+) monocyte 
subsets (Wong et al., 2011). Different tissue macrophage populations do not necessarily have the 
same origin; tissue macrophages can arise either from embryonic yolk sac progenitors or adult bone-
marrow derived monocytes (Ginhoux and Jung, 2014).  
 
The human liver contains 80% of all body macrophages and is patrolled by myeloid cells which scan 
the liver vasculature and eventually infiltrate into the organ (Tacke and Zimmermann, 2014). During 
steady state, bone marrow-derived monocytes traffic to the liver and develop into monocyte-derived 
macrophages (MoMFs), a process that is markedly increased following acute liver injury (Holt et al., 
2008; Varol et al., 2009) (Fig. 1.1). It is proposed that MoMFs do not contribute to the pool of liver-
resident self-renewing Kupffer cells (KCs) which are exclusively derived from embryonic progenitors 
(Gomez Perdiguero et al., 2015; Schulz et al., 2012). However, a recent study using a diphtheria 
toxin-mediated resident KC depletion to generate niche availability, demonstrated that monocytes 
engraft in the liver and can gradually adopt the transcriptional profile of their depleted counterparts 






Figure 1.1 The origin of hepatic macrophage subsets. 
Murine CD11b+F4/80+ Kupffer cells (KCs) originate from erythromyeloid progenitors that express macrophage colony-
stimulating-factor-1-receptor (CSF1R) and are derived from the embryonic yolk sac and/or fetal liver. KCs are capable of 
self-replication during homeostasis and after liver injury. In adult mice, liver-infiltrating monocytes express LY6C, CC-
chemokine receptor 2 (CCR2) and CX3C-chemokine receptor 1 (CX3CR1) can give rise to monocyte-derived macrophages 
(MoMFs) or myeloid dendritic cells (DCs). During steady state, the contribution of monocytes to hepatic macrophages is 
low but following liver injury monocytes are strongly recruited to areas of inflammation. Directly after tissue infiltration, 
monocytes are CD11b+F4/80− and mature into CD11b+F4/80+ MoMFs. If KCs are fully depleted, MoMFs can acquire a 
KC-like state (‘monocyte-derived KC’) with the ability to self-renew. Infiltrating peritoneal GATA6+ macrophages might 
contribute to the pool of hepatic macrophages during liver injury. Dashed arrows indicate cell migration or infiltration. 
cMoP, common monocyte progenitor; HSC, haematopoietic stem cell; ID3, inhibitor of DNA binding 3; LSEC, liver 
sinusoidal endothelial cell; MHCII, MHC class II; PDCA1, pDC antigen 1; PDL1, programmed cell death protein 1 ligand 




1.2.1.2 Macrophage plasticity 
 
Characteristic features of macrophages are their diversity and plasticity in function (Ginhoux et al., 
2016). When macrophages encounter pathogens, they secrete pro-inflammatory cytokines and 
reactive oxygen and nitrogen species that aid their antimicrobial and immune function to eliminate 
pathogens. In contrast, during homeostatic conditions, different micro-environmental cues induce 
macrophages to adopt phenotypes linked with tissue repair and remodeling functions. Macrophages 
were traditionally categorized into either pro-inflammatory (M1), wound-healing (M2) or immune-
suppressive (Mreg) (Mosser and Edwards, 2008). However, recent transcriptomic analyses of human 
monocyte-derived macrophages cultured with different stimuli revealed a spectrum of macrophage 
activation states, that challenges the M1/M2 classification (Xue et al., 2014). The signals received by 
macrophages are diverse, temporally and spatially dynamic. Macrophages not only respond with 
diverse phenotypes and various activation states, but  also reversibly switch from one phenotype to 
another (Epelman et al., 2014; Sica and Mantovani, 2012). A newly proposed way of looking at the 
activation state of macrophages is to consider a multidimensional model that includes the different 
local signals to which they are exposed, their specific microenvironments and a collection of 
macrophage activation markers (Ginhoux et al., 2016; Murray et al., 2014).  
 
1.2.2 Macrophages and liver inflammation 
 
1.2.2.1 Macrophage functions 
 
Macrophages are a key component of liver inflammation and exhibit great functional diversity, thus 
they are involved in tissue homeostasis, inflammation but also regression of liver injury. Due to their 
great inherent plasticity, hepatic macrophages flexibly respond to differential environments and adopt 
to the educative signals arising from parenchymal and immune cells within the liver (Davies et al., 
2013; Lavin et al., 2014). Hence, they execute diverse functions during liver inflammation, ranging 
from tissue-destructive to resolution/pro-restorative roles (Sica and Mantovani, 2012). Macrophages 
secrete high levels of reactive oxygen/nitrogen species and inflammatory cytokines and chemokines, 
therefore are able to propagate both innate and adaptive immune responses. They critically influence 
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the different phases following liver injury, by promoting the clearance of cell debris, extracellular 
matrix remodeling, tissue regeneration and resolution of inflammation (Heymann and Tacke, 2016). 
Moreover, hepatic macrophages isolated from injured murine livers express M1 and M2 markers 
simultaneously (Ramachandran et al., 2012), which contradicts the M1/M2 dichotomic approach 
discussed above. 
 
1.2.2.2 Macrophages in chronic liver disease 
 
Macrophages critically influence inflammation and insulin resistance in different metabolic disorders 
and alcoholic liver disease (McNelis and Olefsky, 2014). Patients characterized by obesity and heavy 
alcohol drinking exhibit similar patterns in expression of macrophage activation markers, that are 
related to severity of liver steatosis and fibrosis (Wan et al., 2014). Macrophages play a central role in 
fibrogenesis in murine models of alcoholic steatohepatitis and NASH, where they propagate liver 
inflammation through TNF-α secretion and leukocyte recruitment via ICAM-1 and VCAM-1 (Tomita 
et al., 2006). In contrast, predominance of M2-polarized, IL-10-expressing macrophages was found to 
be protective in experimental alcoholic liver disease or non-alcoholic fatty liver disease (NAFLD) 
(Wan et al., 2014). Macrophage activation during NASH in mice is also related to accumulation of 
toxic lipids, such as ceramide, that promotes activation of NLRP3 and AIM2 in both infiltrating and 
liver-resident macrophages (Csak et al., 2014; Leroux et al., 2012; Miura et al., 2010). During 
metabolic disorders, CCR2+ bone-marrow derived monocytes traffic to the liver where they promote 
NASH while CCL2 inhibition is shown to diminish monocyte liver infiltration and steatohepatitis in 
chronic hepatic injury (Baeck et al., 2012; Miura et al., 2012).  
 
Although hepatic macrophages show several features for antiviral immunity, for example expression 
of TLR and NOD-like receptors or secretion of IL-12 and IL-18, their role against viral hepatitis 
remains controversial (Boltjes et al., 2014). Both HBV and HCV infections modulate some of the 
macrophage antiviral effector mechanisms, through inhibition of TLR activation or induction of anti-
inflammatory pathways (e.g. PD-L1) (Boltjes et al., 2014; Tu et al., 2010). In addition, macrophages 
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may even promote HCV entry in a TNF-dependent manner in vitro (Fletcher et al., 2014). By 
contrast, both KCs and MoMFs isolated from human livers explants of HCV patients are described as 
a primary source of IL-1β, (Negash et al., 2013). 
 
Hepatic macrophages are central to the pathogenesis of chronic liver injury. They are numerically 
expanded in patients with hepatic cirrhosis and fibrosis (Zimmermann et al., 2011) where both 
profribrotic and antifibrotic roles have been described (Tacke and Zimmermann, 2014). Intermediate 
CD14highCD16+ monocytes accumulate in the chronically inflamed liver due to the enhanced 
recruitment and local differentiation from classical CD14+CD16− monocytes, a process mediated by 
chemokines (e.g. CX3CL1) (Aspinall et al., 2010; Liaskou et al., 2013). CD14highCD16+ macrophages 
are highly phagocytic, secrete inflammatory mediators and can activate the collagen-producing HSCs, 
thus playing a crucial role in fibrogenesis (Zimmermann et al., 2010). Also, monocytes infiltrate the 
chronically inflammed liver of mice, in a CCL2–CCR2 and CCL1–CCR8 chemokine-dependent 
manner, and differentiate into inflammatory macrophages that enhance fibrosis by activating HSCs 
activation and enhancing myofibroblast survival while also promote angiogenesis (Baeck et al., 2012; 
Ehling et al., 2014; Heymann et al., 2012; Karlmark et al., 2009; Pradere et al., 2013).  
 
Prorestorative hepatic macrophages, characterized by Ly6C low expression, were recently identified 
in mice as key players in resolving fibrosis and accumulated in the liver during the restorative phase 
after tissue damage (Ramachandran et al., 2012). These Ly6Clow  hepatic macrophages derive from 
infiltrating Ly-6Chigh monocytes/macrophages (Ramachandran et al., 2012), thus undergo a functional 
switch during the course of liver injury, the mechanisms of which warrant further investigation. Gene 
expression analysis revealed that Ly6Clow cells displayed a profile that cannot be classified based on 
the M1/M2 nomenclature, and importantly secreted matrix metalloproteinases (e.g. MMP9, MMP12 
and MMP13) needed for matrix degradation and favor resolution of liver fibrosis (Ramachandran et 
al., 2012; Tacke and Zimmermann, 2014). Another  feature of those restorative macrophages is that 
they are post-phagocytic and administration of liposomes boosted the degradation of extracellular 
matrix (Ramachandran et al., 2012). Of note, even after cessation of liver injury, a sustained Ly-6Chigh 
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macrophage influx was observed, that dampens spontaneous fibrosis regression through secretion of 
pro-inflammatory cytokines (e.g. TNF-α). Blocking the CCR2/CCL2-dependent influx during the 
resolution phase of fibrosis therefore even enhances clearance of scar fibers (Baeck et al., 2012; 
Ehling et al., 2014). Together, these findings suggest that freshly infiltrating macrophages worsen 
liver injury whereas restoration is elicited by locally matured MoMFs. Further studies to understand 
the regulatory mechanisms underlying hepatic macrophage heterogeneity may help to develop novel 
macrophage subset-targeted therapies for liver injury and fibrosis (Krenkel and Tacke, 2017). 
 
1.2.3 Macrophages in acute liver failure 
 
The role of macrophages during acute liver injury is controversial, which is not surprising given the 
several functions of these cells at different phases of sterile liver inflammation. This can be attributed 
to their great heterogeneity and difficulty in distinguishing between the subpopulations, especially 
under inflammatory stress. Initial studies using Gadolinium Chloride (GdCl3) to deplete KCs prior to 
paracetamol (APAP) dosing was protective mice from liver injury (Laskin et al., 1995; Michael et al., 
1999). Subsequent studies used CCR2-/- knockout mice, thus preventing monocyte recruitment into 
the liver. Here, inhibition of monocyte infiltration to the liver following APAP dosing, exacerbated 
inflammation and delayed recovery (Dambach et al., 2002; Hogaboam et al., 2000). Two other studies 
using clodronate-loaded liposomes, that deplete the liver-resident macrophages, revealed that 
macrophage inhibition had either no effect or a detrimental effect on liver injury (Ju et al., 2002a; 
Karlmark et al., 2009). However, the past years several researchers using advanced experimental 
approaches, such as intravital multiphoton microscopy, flow cytometry based sorting of immune cells 
and gene expression analyses, have shown that hepatic macrophages orchestrate both pro-
inflammatory/tissue-destructive and resolution/tissue-repair responses during acute liver injury 
(Antoniades et al., 2014; Antoniades et al., 2012; Mossanen et al., 2016; Zigmond et al., 2014). 
 
KCs initiate immune-mediated injury but also exhibit a protective role and play an important part in 
removal of apoptotic cell debris (Heymann and Tacke, 2016; Krenkel et al., 2014; Krenkel and Tacke, 
2017). Following liver injury, DAMPS released from injured hepatocytes activate KCs which release 
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an array of pro-inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6), reactive oxygen species (ROS) and 
chemokines, thus promoting influx of circulating immune effector cells to sites of tissue damage (Fig. 
1.2) (Kubes and Mehal, 2012). Patients with AALF exhibit an expansion of hepatic macrophages, that 
localize in areas of necrosis, which is not only due to the proliferation of the resident KCs but also 
through a chemokine, CCR2 and CCR5, dependent recruitment of circulating monocytes to the liver 
(Antoniades et al., 2012; Choi et al., 2015a; Dambach et al., 2002; Holt et al., 2008; Mossanen et al., 
2016; Zigmond et al., 2014). 
 
Experimental studies revealed that after KC activation, there is an expansion of hepatic macrophages 
at 12 hours post paracetamol-induced liver injury in mice, and this is mainly due to MoMFs rather 
than proliferation of KCs (Holt et al., 2008; Karlmark et al., 2009; Zigmond et al., 2014). In parallel 
to the monocyte influx, KCs are decreased numerically between 24-48 hours post injury while full 
recovery takes place by 120 hours, which does not rely on CCR2+Ly6Chigh infiltrating monocytes but 
is achieved through self-renewal of KCs (Dambach et al., 2002; Ramachandran et al., 2012; Zigmond 
et al., 2014). These findings concur with previous human data demonstrating a significant 
proliferative activity of CD68+ KCs in explanted liver tissue (Antoniades et al., 2012). Moreover, 
gene expression analysis of KCs during the recovery stages of acute liver injury revealed a pro-
restorative phenotype that express a repertoire of tissue-repair associated genes (Zigmond et al., 
2014). 
 
It is proposed that F4/80 and CD11b expression levels can be used to define developmentally distinct 
macrophage populations. Cells that are F4/80high CD11blow represent the liver-resident KCs while 
F4/80low CD11bhigh cells represent the MoMFs (Holt et al., 2008; Ramachandran et al., 2012). 
Differential Ly6C expression was recently suggested as marker of the differentiation state of MoMFs 
(Zigmond et al., 2014). In addition to liver KCs and Ly6Chigh infiltrating monocytes, a third distinct 
Ly6Clow hepatic macrophage population exists in the liver of mice following APAP-induced liver 
injury. These CX3CR1+F4/80highLy6Clow macrophages are entirely derived from Ly6Chigh monocytes 
and are characterized by a gene expression profile distinct from both infiltrating monocytes and 
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resident KCs (Zigmond et al., 2014). Ly6Chigh infiltrating monocytes have a mixed “M1/M2” 
phenotype, and upon differentiation into Ly6Clow MoMFs, reprogramming occurs towards a pro-
restorative phenotype with increased expression of “M2” genes. 
 
MoMFs are important for tissue-repair/resolution processes in acute liver injury: firstly, through 
secretion of mediators involved in extracellular matrix remodeling, angiogenesis and hepatocyte 
regeneration, and secondly by neutrophils suppression and their subsequent clearance. Accordingly, 
selective ablation of MoMFs results in impaired recovery manifested by greater hepatotoxic damage 
and significantly increased neutrophil numbers (Holt et al., 2008; Zigmond et al., 2014). In line with 
this, recent studies employing murine models of sterile liver injury demonstrate that the initially 
inflammatory monocytes topographically form ring-like structures around the injured liver areas and 
can differentiate into CCR2lowCX3CR1+Ly6Clow MoMFs, which promote resolution and tissue-repair 
processes (Dal-Secco et al., 2015; Ramachandran et al., 2012). 
 
As discussed above, during sterile liver injury MoMFs and KCs contribute to tissue inflammation and 
regeneration (Rehermann, 2017). Recently, Wang and Kubes using a model of thermal sterile liver 
injury, where hepatocyte necrosis results in DAMP release (e.g. cytosolic ATP, mitochondrial DNA) 
and innate immune activation, identified peritoneal macrophages as a third population that responds to 
liver injury (Wang and Kubes, 2016). They demonstrate that wound healing and tissue regeneration 
are aided by a specialized subset of GATA6+ peritoneal macrophages that moves directly through the 
visceral endothelium of the liver and not through the vasculature. These cells arrive at the injury site 
within 1 hour, in a chemokine independent manner, undergo rapid expansion and up-regulate CD273, 
CD206, and arginase-1 expression along with a tissue-repair macrophage transcriptional profile. They 
dismantle the nuclei of necrotic cells, thereby releasing DNA to cover the necrotic area and 
contributing to liver regeneration (Wang and Kubes, 2016). Thse findings are not limited to thermal 
injury close to the surface of the liver but may extend to other models of acute or chronic liver injury, 
hence this new paradigm of avascular recruitment of mature macrophages opens many avenues for 




Figure 1.2 Role of monocytes and hepatic macrophages in acute liver failure. 
KCs detect hepatocyte death through DAMP/TLR signaling and initiate a pro-inflammatory response. Bone-marrow derived 
monocytes traffic to the liver to contribute to an expanded macrophage population which are initially pro-inflammatory. 
During the propagation phase, immune activation is self-perpetuating with recruitment of effectors driving further cytokine 
and chemokine production. The release of cytokines and vasoactive mediators into the systemic circulation provokes SIRS. 
Macrophage-derived mediators contribute to vascular endothelial dysfunction and microcirculatory disturbances that result 
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1.3 Neutrophils and NK/NKT cells during liver injury 
 
1.3.1 Neutrophil functions 
 
Neutrophils are large polymorphonuclear cells that belong to the granulocyte family of leukocytes. 
They are derived from the bone marrow, where they remain for 4–6 days, and then circulate in the 
peripheral blood surviving for a short period of time (12-18 hours half-life) (Liaskou et al., 2012). The 
profound susceptibility to bacterial and fungal infections resulting from neutropenia or defects in 
neutrophil trafficking demonstrates their essential role in host defense (Heymann and Tacke, 2016; 
Kubes and Mehal, 2012). Neutrophils are key effectors of the innate immune system during infective 
and sterile inflammation that result in their trafficking and localization to sites of tissue injury. These 
cells are uniquely endowed with high phagocytic capacity and a vast arsenal of rapidly synthesized 
cytotoxic antimicrobial molecules stored in their cytoplasmic granules, e.g. perforin and granzyme 
(Xu et al., 2014). However, this potent arsenal exhibits poor specificity and can cause collateral 
damage to host tissues.  
 
1.3.2 Neutrophils and liver inflammation 
 
1.3.2.1 Neutrophil recruitment  
 
 
Immunity is beneficial when is well contained and tightly regulated. Excessive neutrophil recruitment 
at sites of liver injury contributes fundamentally to the pathogenesis of a variety of liver diseases (Fig. 
1.3). Neutrophils do not always functionally contribute to liver inflammation but they can aggravate 
liver disease through secretion of pro-inflammatory cytokines (e.g. IL-1β and TNF-α) and cytotoxic 
reactive oxygen and nitrogen species (Xu et al., 2014). Tissue damage and hepatocyte death result in 
the release of DAMPs that guide neutrophils to injury site, leading to a multistep process that involves 
activation of the inflammasome, adhesion molecule upregulation (ICAM-1 and VCAM-1), formation 
of a chemokine gradient (CXCL1, CXCL2, CXCL8) and formyl-peptide signals in areas of necrosis 
(Kubes and Mehal, 2012; Marra and Tacke, 2014; McDonald et al., 2010). In a recent study Slaba et 
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al. used multichannel spinning disk microscopy which enabled them to track platelets and neutrophils 
in a model of sterile thermal liver injury; interestingly they noted a rapid accumulation of platelets 
within blood vessels (Slaba et al., 2015). Whereas their initial intuition was that platelets were 
occluding the sinusoids and preventing perfusion, their data revealed that neutrophil recruitment in 
areas of necrosis depends on platelets which can aid and/or erminate the recruitment of the first (Slaba 
et al., 2015). Furthermore, studies using murine models of acute and chronic liver injury show that 
neutrophils are directly activated by nuclear DNA through TLR-9 signaling and patrol DNA-rich 
necrotic areas (Marques et al., 2012). Also, a TLR-2 and S100A8–S100A9 signaling pathway acts as 
key regulator of intrahepatic CXCL2 and TNF-α expression that drive subsequent neutrophil liver 
infiltration (Moles et al., 2014). However, the molecular mechanisms that allow neutrophils to home 
to the liver, and affect their functions therein, are yet not fully understood. 
 
1.3.2.2 Neutrophils in chronic liver disease 
 
 
Due to their early activation and distribution in the circulation, neutrophils also trigger recruitment of 
other leukocytes, such as monocytes, therefore are of great importance in the overall initiation of the 
intrahepatic immune responses (Heymann and Tacke, 2016). In addition to bacterial phagocytosis and 
release of antimicrobial proteins, neutrophils form extracellular traps (NETs) which are composed of 
DNA decorated with histones and proteases that can trap and kill bacteria (Sorensen and Borregaard, 
2016). Following systemic infections, NETs are formed within the liver sinusoids, remaining 
anchored to the vascular wall via von Willebrand factor, thus enabling the liver to protect the body 
from infection, by efficiently clearing bacteria (Kolaczkowska et al., 2015; McDonald et al., 2012) 
and viral particles (Jenne et al., 2013). Furthermore, in experimental acute liver injury (ischaemia-
reperfusion model), NETs were recently described to exacerbate acute tissue damage through 
activation of the inflammasome (Huang et al., 2015). The role of neutrophils in other chronic liver 
diseases remains unclear. Although infiltration of neutrophils is commonly seen in sterile 
inflammatory conditions of the liver, such as alcohol-induced steatohepatitis (Jaeschke, 2002), NASH 
(Liang et al., 2014), ischaemia reperfusion injury and toxin mediated halothane hepatitis (You et al., 
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2006), Concanavalin-A (ConA) induced hepatitis (Bonder et al., 2004), these cells seem to be 




Figure 1.3 Neutrophils in liver inflammation. 
Neutrophils respond to primary liver injury as well as TLR-mediated signaling and are subsequently recruited via and LFA-
1–ICAM-1 into the tissue. Their activation leads to secretion of oxidative stress response mediators (ROS, MPO), which can 
further aggravate hepatocellular damage. During bacterial infections, neutrophils release DNA to form NETs, which are 
involved in antimicrobial defence. ALD, alcoholic liver disease; CLD, chronic liver disease; DC, dendritic cell; HMGB1 
high mobility group box protein 1; ICAM-1, intracellular adhesion molecule 1; LFA, lymphocyte function associated 
antigen; LSEC, liver sinusoidal endothelial cell; MPO, myeloperoxidase; NET, neutrophil extracellular traps; ROS, reactive 
oxygen species; TLR, Toll-like receptor [from (Heymann and Tacke, 2016)]. 
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1.3.3 Neutrophils in acute liver failure 
 
The role of neutrophils in acetaminophen-induced ALF remains controversial, with some studies 
suggesting they promote while others that they have no effect on the severity of acute liver injury 
(Jaeschke et al., 2013). The early recruitment of neutrophils into the liver of mice, within 6 hours post 
paracetamol, is well documented (Liu et al., 2006; Marques et al., 2012; Williams et al., 2014a). Early 
studies indicated that neutrophils are not activated following APAP-induced liver injury, showing that 
circulating neutrophils did not up-regulate CD11b/CD18 expression levels, the β integrins required 
for endothelial adhesion and adhesion-dependent target cell killing (Lawson et al., 2000). Also, mice 
treated with anti-CD18 blocking antibody or CD18-/- mice are not protected from liver injury (Lawson 
et al., 2000; Williams et al., 2010a). Another recent report showed that CD11b is up-regulated in both 
circulating and hepatic neutrophils between 24-48 hours post APAP and they exhibit a lack of ROS 
priming, suggesting they cannot exert cytotoxic effects and do not contribute to liver injury (Williams 
et al., 2014b). Moreover, strategies administrating endotoxin and a pharmacological dose of IL-1β as 
‘second hits’ following APAP dosing augmented neutrophil recruitment to the liver, with no changes 
in the extent of liver injury (Williams et al., 2010a; Williams et al., 2010b).  
 
In contrast, research from others demonstrates that neutrophils exert cytotoxic effects on hepatocytes 
during the initial phases of paracetamol toxicity and thus contribute to the severity of liver injury. 
Mice treated with neutropaenia-inducing antibodies prior to paracetamol dosing are partially protected 
from liver damage (Ishida et al., 2006; Liu et al., 2006; Marques et al., 2012), however there is not 
such an effect if neutropaenia is induced after paracetamol dosing (Cover et al., 2006). Of note, this 
work has received criticism for likely off-target effects of the neutropaenia-inducing antibodies 
supporting that the documented protection is due to priming of liver-resident KCs by circulating 
cellular debris from depleted neutrophils that may induce the expression of protective genes in the 
liver, thus attenuating the response to the secondary inflammatory insult of paracetamol-induced 
hepatocyte damage (Jaeschke and Liu, 2007). Recently, in a model of carbon tetrachloride induced 
acute liver inflammation, neutrophil depletion dramatically reduced liver damage in mice underlying 
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their critical role in this type of liver injury (Moles et al., 2014). In addition, strategies aimed to inhibit 
neutrophil recruitment to liver have shown amelioration of liver injury. Combined blockade of 
CXCR2 and formyl peptide receptor 1 (FPR1) was found to be protective in APAP-treated mice 
(Marques et al., 2012). ICAM-1 deficient mice also exhibit reduced neutrophil recruitment following 
liver injury and reduced indices of liver injury (Liu et al., 2006). 
 
1.3.4 NK and NKT cell functions 
 
NK cells are enriched in the human liver representing the ~30–50% of total lymphocytes and consist a 
key component of hepatic innate immunity having unique phenotypic and functional features  (Tian et 
al., 2013). Human NK cells are defined as CD56+CD3- lymphocytes and are classified into CD56-
low-expressing (CD56dim) with preferential cytolytic activities and CD56-high-expressing (CD56bright) 
with release of immune-modulatory cytokines (Zimmermann et al., 2013). Liver NK cells are distinct 
from circulating NK cells with respect to their origin, phenotype and function (Heymann and Tacke, 
2016). Approximately 90% of circulating NK cells are CD56dim whereas in the liver only 50% of NK 
cells are CD56dim and the other 50% are CD56bright (Tian et al., 2013). The underlying mechanisms of 
their enrichment and special characteristics remain largely unknown, however these differences may 
relate to the high hepatic expression of NK cell-recruiting chemokines and the cross-talk of NK cells 
with other hepatic cell types (Krueger et al., 2011; Maghazachi, 2010). Compared to their circulatory 
counterparts, liver-resident NK cells display an increased killing activity, secrete high concentrations 
of cytotoxic mediators and express higher levels of CD69 (Tian et al., 2013).  
 
Liver NK cells share many similarities with innate lymphoid cells (ILCs), a subpopulation of 
lymphocytes with immune-regulatory properties that are commonly found on mucosal surfaces (Peng 
and Tian, 2015). In the mouse liver, liver NK cells seem to be similar to mucosal ILC1 cells since 
they depend on T-bet, express NK1.1 (CD161), NKp46, CD69 and TRAIL, but not DX5 (CD49d) or 
T-cell and/or B-cell markers (Heymann and Tacke, 2016). These ILCs secrete IFN-γ and TNF, but 
have a poor cytolytic capacity. The human counterpart of mouse liver NK cells is probably the 
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CD49a+ NK-cell subset, which expresses high levels of CD69 and granzyme B and produces high 
amounts of IFN-γ, TNF and GM-CSF (Marquardt et al., 2015).  
 
NK cells exert a key effector function by killing target cells through their cytotoxicity and cytokine 
production, that is pivotal for host defense against pathogens and tumors (Heymann and Tacke, 2016). 
This ability is determined by the opposing signals from inhibitory and stimulatory NK cell receptors 
and their interactions with their respective ligands on target cells (Lanier, 2005). NK cell inhibitory 
receptors (e.g. CD94 and Ly49A) interact with inhibitory ligands [e.g. major-histocompatibility-
complex-class 1 (MHC-1)] expressed on the target cells and suppress NK cell function whereas 
stimulatory receptors [e.g. NK group 2D (NKG2D) NKp46, NKp30, and NKp44] interact with the 
stimulatory ligands on target cells and promote NK cell activity (Lanier, 2005). The expression of 
inhibitory/stimulatory NK cell receptors and their ligands on hepatocytes and non-parenchymal cells 
is altered during a variety of liver disease and contributes to their pathogenesis (Tian et al., 2013). NK 
cells also act as regulatory cells by interacting directly (cell-to-cell contact) or indirectly (cytokine 
production) with other liver cell types such as tumor cells, stressed hepatocytes and HSCs (Tian et al., 
2013). They can influence DCs, KCs/macrophages, T/B cells and endothelial cells by producing 
various cytokines (IFN-γ, TNF-α and IL-10), chemokines and growth factors or through innate 
immune recognition, as summarized in (Fig. 1.4). 
 
Natural killer T (NKT) cells is a subpopulation of T cells, expressing surface markers and cytokines 
characteristic for NK cells, that is particularly enriched in the liver and regulates hepatic immune 
responses in the context of autoimmunity, cancer and microbial infection (Heymann and Tacke, 
2016). During homeostasis, mouse liver NKT cells crawl along the sinusoids and can interact with the 
hepatic endothelium (Krenkel et al., 2014); for example CXCR6+ NKT-cell trafficking into the liver 
is guided by CXCL16 secreted from HSECs and KCs (Wehr et al., 2013). Liver DCs also interact 
with patrolling NKT cells via glycolipid receptors such as CD1d, triggering both IL-4 and IFN-γ 
secretion from NKT cells (Schmieg et al., 2005; Trobonjaca et al., 2001). In contrast to the highly 
abundant CD1d-restricted Vα14Jα18 mouse liver NKT cells, which can constitute up to 40% of 
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hepatic lymphocytes, their human counterpart, Vα24Vβ11 NKT cells are less frequent in the human 
liver and represent a minority (0.5–10%) of hepatic lymphocytes (Tian et al., 2013). Vα14Jα18 NKT 
cells are highly restricted to antigen presentation via non-classic glycolipid antigen receptors such as 
CD1d. Tumour-infiltrating human NKT cells express CD56, NK1.1 and show signs of activation by 
expressing CD69 and pro-inflammatory cytokines such as TNF and IFN- γ, indicating a role in anti-
tumour defence (Kenna et al., 2003) . Furthermore, invariant mouse NKT cells are substituted by 
mucosal-associated invariant T (MAIT) cells in human liver. MAIT cells are clearly enriched in 








Figure 1.4 Regulation and functions of liver NK cells. 
Top panel: regulation of NK cells. The left side of the top panel illustrates that activated KCs, DCs, and NKT cells can 
induce NK cell activation by the production of a variety of cytokines. Several cytokines that activate NK cells are also listed. 
The right side of the top panel illustrates that Tregs and activated HSCs can inhibit NK cell functions by the production of 
several cytokines. TGF-b is a potent inhibitor of NK cell functions. Bottom panel: functions of NK cells in the liver. 
Activated NK cells target hepatocytes, HSCs, and cholangiocytes and perform a variety of important functions in the 







1.3.5 NK/NKT cells in chronic liver disease 
 
Accumulating evidence suggests that NK/NKT cells play beneficial roles in controlling viral hepatitis, 
liver fibrosis and cancer while contribute to the pathogenesis of acute liver inflammation and injury 
(Heymann and Tacke, 2016; Tian et al., 2013). In viral hepatitis, human and murine studies propose 
an NK-cell-mediated immunity both for controlling viral infection and for mediating cytopathogenic 
effects. Evidence shows an NK-cell-mediated control of HCV replication by NKp46bright NK cells but 
also for harmful NK-cell activation, that is, HCV-associated loss of anti-fibrotic activity by 
CXCR3+CD56bright NK cells and increased fibrogenesis (Eisenhardt et al., 2012; Kramer et al., 2012) 
Upon HBV infection, NK cells are demonstrated to limit viral infection by targeting HBV-infected 
hepatocytes (Dunn et al., 2007), however they can deplete HBV-antigen specific CD8+ T cells via 
TRAIL-receptor 2, therefore suppressing the cytotoxic T-cell response against the virus (Peppa et al., 
2013). In mice, NKT cells enhance T and B cell responses in a model of HBV infection, probably 
through sensing of HBV-induced modified self-lipids on infected hepatocytes (Zeissig et al., 2012). 
 
NK cells exert crucial hepatoprotective functions in chronic liver disease. Hepatocyte-derived DNA 
leads to engagement of TLR9 and following CpG-mediated NK cell activation, pro-fibrotic HSCs 
were efficiently killed by NK cells, thereby attenuating liver fibrosis in vivo (Abu-Tair et al., 2013). 
NKT cells infiltrating in areas of necrosis via the CXCL16/CXCR6 axis are mostly pro-inflammatory 
and lead to increased liver inflammation and fibrosis (Wehr et al., 2013), however, dependent on the 
stimulus and the stage of fibrosis progression, NKT cells can also exert anti-inflammatory functions 
(Park et al., 2009). These contradictory findings may be explained by the fact that NKT cells release 
IL-4 and IFN-γ that mediate partially opposing effects on neutrophil recruitment and liver injury 
(Wang et al., 2013). Accumulation of invariant NKT cells in human livers has been associated with 
disease progression especially in NASH-related cirrhosis (Syn et al., 2010) while NKT might promote 
steatosis through increased hepatocyte lipid uptake and contribute to progression from steatohepatitis 
to hepatocellular carcinoma, by activating the canonical and non-canonical NF-κB pathway (Wolf et 
al., 2014). 
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1.3.6 NK/NKT cells in acute liver failure 
 
The role of NK cells in acute liver inflammation is yet not fully explored. In principle, lymphoid cells 
contribute to APAP-induced liver injury by secreting IFN-γ and depleting the glutathione storages in 
hepatocytes via Fas/FasL; of note, IFN-γ and FasL expression are two effector mechanisms of hepatic 
NK/NKT cells (Heymann and Tacke, 2016). Murine studies that suggested a direct pathogenic role 
for NK/NKT cells after APAP overdose (Liu et al., 2004) could later be linked to the use of dimethyl-
sulfoxide (DMSO) as a solvent, as DMSO alone leads to the activation of NK/NKT cells which are 
characterized by increased IFN-γ and granzyme B expression (Masson et al., 2008). These findings 
suggest a role of IFN-γ in the pathogenesis of ALF and mice treated with anti-IFN-γ antibodies or 
IFN-γ deficient mice show attenuated liver injury after APAP overdose (Ishida et al., 2002).  
 
NKT cells show immunogenic or protective functions in acute liver inflammation. In mice, hepatic 
inflammation induced by α-galactosylceramide results in IL-17 secretion by NKT cells and IL-17 
blocking leads to increased liver inflammation, enhanced influx of neutrophils and monocytes and 
upregulation of CXCL5/CCL2 (Wondimu et al., 2010). Furthermore, mice lacking Stat4, a negative 
regulator of NKT cells, were found more susceptible to ConA-induced hepatitis (Wang et al., 2014) 
while retinoic acid was shown to alleviate ConA-induced hepatitis and differentially regulate effector 
production in NKT cells inducing IL-4 and IFN-γ but not TNF (Lee et al., 2012a). Murine studies 
using NKT deficient mice revealed they are more susceptible to APAP-induced acute liver injury, 
however the exact underlying mechanisms remain unclear (Martin-Murphy et al., 2013). 
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Inflammation is a pathophysiological response to infection and tissue injury and a key component of 
many human diseases such as rheumatoid arthritis, asthma, cancer and in liver injury, as discussed 
above (Heymann and Tacke, 2016; Ortega-Gomez et al., 2013). Local and systemic inflammatory 
responses aim to eliminate the inciting stimulus, promote tissue-repair and wound healing processes, 
and in the case of infection to establish immune memory for the host’s future encounter of pathogens 
(Fullerton and Gilroy, 2016). An acute inflammatory response is a complex but highly coordinated 
sequence of events that involves molecular, cellular and physiological alterations and which unfolds 
in several phases.  
 
Initially, tissue-resident cells including macrophages, DCs, lymphocytes, endothelial cells and mast 
cells produce soluble mediators such as complement, chemokines, cytokines and free radicals in the 
injured or infected tissue, thus alarming the innate immune system (Ortega-Gomez et al., 2013). 
Concomitantly, cell adhesion molecules are upregulated on circulating leukocytes and endothelial 
cells that promote the exudation of proteins and recruitment of neutrophils from the blood. Upon their 
arrival, neutrophils become activated and primarily act to phagocytose tissue debris and eliminate 
microorganisms, through intracellular mechanisms including degranulation and ROS production 
(oxidative burst) and extracellular mechanisms such as NET formation (Fullerton and Gilroy, 2016). 
Recruited neutrophils further promote the recruitment of inflammatory monocytes and neutrophils to 
the injured site and potentiate the pro-inflammatory environment. Monocytes follow, able to link the 
innate and adaptive immune responses, and govern whether the intial insult can be overcome with or 
without adaptive immunity. The type and number of effector cells as well as their ability to neutralize 
the inciting stimuli probably signal the resolution phase that follows (Gilroy and De Maeyer, 2015).  
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1.4.2 Principles of resolution 
 
In order to prevent the progression from acute to chronic inflammation, the inflammatory response 
must be actively resolved in order to quell further tissue damage and restore organ function and 
homeostasis. The period between peak inflammatory cell influx and their clearance from the injured 
site and the restoration of functional homeostasis, classically defined as resolution, is no longer 
considered a passive process (Buckley et al., 2014). This involved chemokine gradients’ dilution over 
time, thus circulating leukocytes would no longer sense gradients and be recruited to the site of injury 
(Gilroy and De Maeyer, 2015). Instead, nowadays resolution of inflammation is considered a complex 
and tightly regulated active process while deficiency in any of its steps may lead to uncontrolled 
persistent inflammation. Resolution occurs in overlapping phases and is governed by the spatial and 
temporal production of pro-resolving mediators present in the microenvironment (Headland and 
Norling, 2015). Molecules which fall under this umbrella are diverse in nature including: lipid 
mediators [lipoxins (A4 and B4), resolvins (E1, D1 and D2) protectin D1, maresins and PGD2], 
proteins (D6, galectin1 and annexin A1), gaseous mediators (hydrogen sulphide and carbon 
monoxide), adenosine as well as changes of NF-κB, PI3K, ERK1/2, CDKs and cAMP intracellular 
signaling pathways, the function of which is extensively reviewed in (Fullerton and Gilroy, 2016; 
Headland and Norling, 2015). 
 
Macrophages and neutrophils are key cellular components of the resolving process following acute 
tissue inflammation, the interplay between which is critical for resolution (Fig. 1.5). First, elimination 
of the inciting stimulus is a critical requirement for the inflammatory response to switch off, failure of 
which may lead to chronic inflammation (Gilroy and De Maeyer, 2015). Effectively dispensing of the 
injurious insult will signal a cessation of pro-inflammatory/toxicant mediator synthesis and increase 
of their catabolism, in parallel with counter-regulation of chemokines, through proteolytic cleavage, 
and abrogation of neutrophil influx (Ortega-Gomez et al., 2013). Induction of neutrophil apoptosis 
and their subsequent clearance next take place, followed by a macrophage functional switch towards a 
resolution-like type, return of non-apoptotic cells to the vasculature or lymphatics and initiation of the 
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healing processes (Fullerton and Gilroy, 2016; Headland and Norling, 2015). Multiple intricate 
signaling mechanisms and factors control each of these processes and the balance between them, 
including cell-to-cell receptor binding and humoral mediators, that culminate in a return to tissue 






Figure 1.5 Neutrophil/macrophage interplay during resolution of inflammation. 
Overview of cellular processes during onset (left) and resolution (right) of inflammation. During the early phases of 
inflammation tissue-resident cells sense damage/insult and launch the release of signals that induce a rapid neutrophil and 
delayed monocyte recruitment. Resolution is initiated when neutrophils become apoptotic, thus secreting mediators that 
inhibit continued neutrophil infiltration. Ingestion of apoptotic neutrophils changes the macrophage phenotype towards a 
resolution-phase macrophage, which promotes return to tissue homeostasis. [Adapted from: (Ortega-Gomez et al., 2013)]  
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1.4.3 Neutrophil apoptosis and tissue clearance  
 
Aborted neutrophil influx and their apoptosis is but one of the steps required to restore tissue 
homeostasis. Neutrophils are short-lived cells but once extravasated into specific tissue sites, they 
reprogram their gene and product repertoire and can extend their lifespan considerably, influenced by 
the local inflammatory environment (Fox et al., 2010; Geering and Simon, 2011). Within an inflamed 
tissue, many extracellular signals can extend the lifespan and functional longevity of neutrophils, 
including cytokines, bacterial products and low oxygen tensions (Headland and Norling, 2015). 
Macrophages can importantly control the lifespan of neutrophils by secreting death receptor ligands 
such as TNF-α, Fas (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) (Renshaw et al., 
2000; van den Berg et al., 2001). At low concentrations FasL prolongs neutrophils’ lifespan but also 
recruits neutrophils to injured tissue sites. TRAIL is a type II membrane protein that is expressed by 
leukocytes and while its genetic deletion delays neutrophil apoptosis and resolution responses 
(McGrath et al., 2011). In this regulatory pathway, phosphoinositide 3-kinase (PI3K)-mediated ROS 
production is the key event in controlling cell survival and triggering apoptosis (Geering and Simon, 
2011). Physiological hypoxia induces increased neutrophil lifespan via oxygen-sensing enzymes that 
stabilize hypoxia-inducible factor pathways (e.g. HIF-1) (Walmsley et al., 2011). Other micro-
environmental mediators such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
neutrophil-derived proteins including annexin A1 and lactoferrin are also reported to regulate 
neutrophil lifespan (Fullerton and Gilroy, 2016; Headland and Norling, 2015). 
 
Apoptotic neutrophils promote their own clearance by macrophage, termed efferocytosis, by 
producing “find-me” and “eat-me” signals. Find-me signals are secreted factors that attract scavengers 
and to date, four of them have been identified including lysophosphatidyl-choline (LPC), sphingosine 
1-phosphate (S1P), fractalkine (CX3CL1), and the nucleotides ATP and UTP (Ortega-Gomez et al., 
2013). These find-me signal gradients guide the macrophage towards the dying cell through the 
involvement of G2A, S1P1-5, CX3CR1, and P2Y2 receptors, respectively. During apoptosis, the 
dying cell loses surface expression of repellent “don’t-eat-me” cell-surface molecules such as CD31 
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and CD47 (Brown et al., 2002; Gardai et al., 2005) and upregulates expression of various “eat-me” 
signals such as phospholipids, nucleotides and phosphatidylserine (PtdSer) (Fadok et al., 2001). The 
interaction between macrophages and these signals ensures that apoptotic cells are efficiently 
removed from the tissue before membrane rupture and the release of cytotoxic mediators that could 
perpetuate the inflammatory response (Fadok et al., 2001; Fadok and Henson, 2003; Gregory and 
Pound, 2010). 
 
1.4.4 Macrophage reprogramming following efferocytosis of apoptotic cells 
 
Recruitment of monocytes and their differentiation into macrophages at sites of inflammation are key 
events in determining the outcome of the inflammatory response and restoring tissue homeostasis. 
One of macrophages’ primary roles during resolution is clearance of apoptotic cells. This process is 
essential to prevent further tissue injury, with a great impact on macrophage reprogramming that is 
crucial for efficient resolution (Gilroy and De Maeyer, 2015). Macrophages exhibit great functional 
and phenotypic plasticity and that becomes apparent during the resolution phase of inflammation 
(Ginhoux et al., 2016). Phagocytosis of apoptotic cells triggers the functional switch of phagocytosing 
macrophages towards an immune-regulatory or pro-resolution phenotype (Bellingan et al., 2002; 
Bystrom et al., 2008), maintaining immune tolerance both locally and in draining lymphoid organs, 
and limiting potential collateral tissue damage (Bellingan et al., 1996; Bellingan et al., 2002; Schif-
Zuck et al., 2011). This post-phagocytosis macrophage phenotype is typified by: a) increased 
expression of co-inhibitory molecules (PDL1 and ICOS ligand), b) release of anti-inflammatory 
cytokines/mediators such as IL-10, TGF-β and SLPI, c) secretion of PCNA-associated factor, PGE2 
and cAMP and d) release of reduced levels of pro-inflammatory cytokines including TNF-α, GM-
CSF, IL-1β, IL-12 and IL-18 (Ashcroft et al., 2000; Bystrom et al., 2008; Fadok et al., 1998; Fadok 
and Henson, 1998). Moreover, macrophages that have ingested apoptotic cells also release pro-
resolving lipid mediators such as RvE1, protectin D1 and maresins that contribute to termination of 
the inflammatory process (Schwab et al., 2007; Serhan et al., 2012).  
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Transcriptomic analysis of murine resolution-phase macrophages (rM) shed light on their features 
during the resolution phase, revealing that they possess in vivo a hybrid phenotype of alternative 
activation, mannose receptor expression and IL-10 and arginase 1 synthesis (M2, anti-inflammatory) 
with high cyclooxygenase-2 (COX2) and iNOS expression (M1, pro-inflammatory) (Stables et al., 
2011). This study suggested a role of these cells in antigen processing/presentation, T- and B-
lymphocyte recruitment, clearance of inflammatory cells and subsequent restoration of tissue 
homeostasis, highlighting the naivety of trying to categorize such plastic cells in a dynamic 
environment (Stables et al., 2011). Resolving macrophages exhibit lower CD11b expression levels, 
enhanced ability to engulf apoptotic neutrophils, reduced responsiveness to microbial challenge 
(Schif-Zuck et al., 2011). Clearly, the latter two studies indicate heterogeneity of resolution-phase 
macrophages. 
 
1.4.5 Targeting resolution pathways 
 
Many aspects of the resolution cascade can be therapeutically targeted to alter the inflammatory 
profile without compromising the host’s immune tolerance. Modulation of any of these events along 
with supplementation of, or catabolic inhibition of, soluble pro-resolving mediators represents a 
strategy to invoke resolution and has dominated drug research for inflammatory diseases in the last 
decades (Buckley et al., 2014; Fullerton and Gilroy, 2016). An ideal immunoresolvent would limit 
continued neutrophil infiltration, counter-regulate pro-inflammatory mediators, enhance the 
efferocytosis of cell debris and apoptotic neutrophils, and promote restoration of tissue homeostasis 
(Ortega-Gomez et al., 2013). Pro-resolving mediators administered exogenously have proved 
efficacious at improving disease and inflammatory outcomes in a variety of experimental models, 
including periodontitis, colitis, myocardial infarction and reperfusion injury and allergic airway 
disease (Headland and Norling, 2015). 
 
Abrogation of continued leukocyte recruitment is essential to favor the return to tissue homeostasis. 
AnxA1 dampens neutrophil accumulation through several mechanisms including down-regulation of 
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trans-endothelial migration, promotion of neutrophil apoptosis and stimulation of their clearance by 
macrophages (Scannell et al., 2007). In addition, lipoxins and resolvins inhibit neutrophil influx and 
enhance efferocytosis without compromising host defence (Serhan, 2014) and RvD1, RvD5 and 
protectin D1 accelerate leukocyte-mediated killing of bacteria and enhance antibiotic efficacy (Chiang 
et al., 2012). There are several strategies for enhancing neutrophil apoptosis in vivo, including CDK 
inhibition (with roscovitine or AT7519) or inhibition of PI3K, ERK1/2 or NF-κB signaling pathways 
(Alessandri et al., 2013). For maximum benefit, this must be accompanied by enhanced and effective 
efferocytosis by macrophages, which can be augmented by melanocortins, glucocorticoids or annexin 
A1 (Poon et al., 2014). This can also be induced by lipid mediators such as PGJ2 and RvD1 and 
mimetics based on their mode of action through G protein-coupled receptors represent a very effective 
target for treating ongoing inflammation (Cash et al., 2014) 
 
Although induction of apoptosis in neutrophils and the resultant reprogramming of macrophages 
following efferocytosis may be beneficial against tissue injury, resolving inflammation before the 
tissue is fully immunologically and functionally restored opens a window of potential infectious 
opportunity (Fullerton and Gilroy, 2016; Grabiec and Hussell, 2016). It is shown that apoptotic cells 
suppress in vitro the phagocytosis and killing of bacteria by alveolar macrophages in a PGE2-, PGE2 
receptor EP2 subtype (PTGER2) and cAMP-mediated manner (Medeiros et al., 2009). Importantly, 
intrapulmonary administration of apoptotic thymocytes impaired lung recruitment of neutrophils as 
well as clearance of Streptococcus pneumoniae, also in a PGE2/PTGER2-dependent pathway. These 
results suggest that additionally to their beneficial homeostatic influence, anti-inflammatory/pro-
resolution programs initiated following acute tissue injury, at least in the lung, dampen antimicrobial 
responses and may lead to host’s susceptibility to secondary infections (Medeiros et al., 2009).  
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1.5 Mer Tyrosine Kinase (MerTK) receptor 
 
1.5.1 The TAM receptor Tyrosine Kinase family  
 
Receptor tyrosine kinases (RTKs) are surface transmembrane receptors possessing a regulated protein 
tyrosine kinase activity in their cytoplasmic domains. They act as sensors for extracellular ligands the 
binding of which triggers receptor dimerization and receptor’s kinase activation (Lemke and Rothlin, 
2008). This leads further to phosphorylation and activation of multiple downstream signaling 
pathways which affect cell physiology by controlling diverse processes, from cell differentiation to 
cell death. The TAM family of receptors (TAMs) is a relatively recently identified subfamily of RTKs 
with diverse biological roles (Lai and Lemke, 1991). Subsequent cloning of full-length cDNAs by 
different laboratories resulted in a plethora of different TAM names: Tyro3/Dtk/Brt/Sky/Tif/Rse, 
Tyro7/Axl/Ufo/Ark and Tyro12/v-Ryk/c-Eyk/Mer. However, Tyro3, Axl, and Mer are now being 
used according to the National Center for Biotechnology Information (NCBI) designations (Rothlin et 
al., 2015). 
 
TAM signaling pathway functions to restore homeostasis through different mechanisms: it negatively 
regulates inflammation by limiting the intensity and duration of the immune response (Lemke and 
Rothlin, 2008). TAMs also function in phagocytosis, specifically the phagocytic removal of apoptotic 
cells and debris; these receptors bind to phosphatidylserine (PtdSer) exposed on the plasma membrane 
of apoptotic cells, in association with their respective ligands, that enables the selective uptake and 
clearance of apoptotic cells (Scott et al., 2001). This action is necessary to prevent continuous 
inflammation and is a transitional signal from “attack the pathogen” to “tissue-repair/restore organ 
function” mode. TAMs are mainly expressed by cells of the immune, nervous, reproductive and 
vascular system (Rothlin et al., 2015). Axl is widely expressed in our body, MerTK is found in 
hematopoietic cells and in specialized epithelia, including retinal pigmental epithelium (RPE) and 
Sertoli cells and Tyro3 is strongly expressed in the central nervous system. Importantly, downstream 
signaling interacts with other growth factor pathways, thus TAMs can be proto-oncogenic and are 
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overexpressed in many human cancers (Graham et al., 2014). They do not play an essential role in 
embryonic development but rather function as regulators of cell and tissue homeostasis in fully 
differentiated organs that are under continuous renewal throughout adult life as discussed below. 
 
1.5.2 TAM receptor structure and signaling features 
 
TAM receptors share structural similarities: from the extracellular N-end to the cytosolic C-end, these 
receptors display two Ig-like domains, two fibronectin type III (FNIII) domains, a hydrophobic 
transmembrane domain, and a tyrosine kinase domain (Fig. 1.5) (Rothlin et al., 2015). The Ig-like 
domains are formed by 7-9 antiparallel β-strands and are involved in interactions with the TAM 
ligands, while FNIII domains are all β-strand structures with similarities to Ig folds. Three tyrosine 
autophosphorylation sites (Tyr749, Tyr753, and Tyr754) have been identified in MerTK (Ling et al., 
1996). These residues are conserved in Axl and Tyro3 and are frequently phosphorylated, yet their 
requirement for the receptor’s kinase activity remains to be examined (Hornbeck et al., 2012). Within 
their intracellular domains Axl and MerTK, but not Tyro3, carry a conserved ITIM (Immunoreceptor 
Tyrosine-based Inhibitory Motif, LLYSRL) (Staub et al., 2004). TAM signaling activation is coupled 
to downstream phosphoinositide 3 kinase (PI3K)/AKT pathway activation and most of this pathway is 
nucleated through a TAM autophosphorylated Grb2 binding site (Rothlin et al., 2015). Coupling to 
phospholipase C, ERK1/2, Ras, and MAP kinase activation have been described in many different 
cells (Keating et al., 2010; Ou et al., 2011).. Macrophages, dendritic cells and other immune cells also 
express cytokine receptors, such as type I interferon (IFN), that can be coupled to TAMs. Hence, the 
TAM-activated PI3K/AKT pathway is often dominated by a TAM-activated JAK/STAT pathway in 
these cells (Lemke and Rothlin, 2008; Rothlin et al., 2007). 
 
1.5.3 TAM ligand structure and receptor specificity 
 
Two ligands that bind and activate the TAM receptors have been identified: growth-arrest-specific 6 
(Gas6) and Protein S (Pros1) (Rothlin et al., 2015). Both ligands are large (~80 kD) proteins that are 
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~42 % identical in amino acid sequence and share the same multi-domain arrangement. Tyro3, Axl, 
and MerTK can all effectively signal as homodimeric receptors that bind just one ligand dimer 
(Rothlin et al., 2015). Gas6 and Protein S possess two structural features key to their activity (Fig. 
1.6). The first is a C-terminal “sex hormone binding globulin” (SHBG) domain that binds to the Ig-
like domains of the TAM receptors. The second is an N-terminal “GLA” domain. GLA domains bind 
in a Ca2+-dependent manner to exposed PtdSer on the surface of apoptotic cells, another crucial 
feature for TAM activation (Lemke and Rothlin, 2008). Of note, GLA domains are detected in several 
proteins of the coagulation cascade and Protein S also functions as an anticoagulant in a TAM-
independent mechanism (Dahlback, 2000).  
 
The extent to which TAM ligands contribute to TAM signaling has only begun to be dissected. 
Current evidence indicates that Gas6 is as a ligand for all three TAM receptors and is produced 
primarily in vascular smooth muscle and endothelial cells (Rothlin et al., 2015). Gas6 can bind and 
activate Axl without PtdSer, suggesting a function additonal to apoptotic cell clearance (Tsou et al., 
2014). During steady state, Gas6 serum concentrations are low (<0.2 nM) but increase dramatically 
during acute stress or tissue injury such as sepsis (Mukherjee et al., 2016). In contrast, Pros1 is a 
selective TAM ligand that binds and activates Tyro3 and MerTK (Lew et al., 2014; Tsou et al., 2014). 
Another difference between TAM ligands is their sites of expression.  Pros1 is abundant in the blood, 
being present at ~ 300 nM in the human circulation whereas Gas6 is nearly absent. Pros1 is produced 
by hepatocytes, endothelial cells and in tissues that use MerTK-mediated clearance of apoptotic cells 
(Rothlin et al., 2015). Galectin-3 is a another recently identified TAM ligand, the levels of which are 
elevated during tissue damage, such as acute and chronic liver injury (Mukherjee et al., 2016). It 
employs a number of downstream signaling pathways, and to date it’s only described to facilitate 




Figure 1.6 Domain organization of TAM receptors and their ligands. 
The TAM ligands Gas6 and Pros1 (red) carry an N-terminal GLA domain that binds to PtdSer (green) exposed on the 
plasma membrane of apoptotic cells. GLA domains are followed by four EGF-like repeats. At the C terminus, the TAM 
ligands carry two laminin G domains, of which domain 1 interacts with the Ig-like domains of the TAM RTKs to form a 
heterotetrameric complex. Ig-like domains are followed by two FNIII domains and an intracellular tyrosine kinase domain 
(blue).. The structure of the whole complex—including PtdSer, TAM ligands, and TAM receptors—remains unknown. 
Abbreviations: EGF, epidermal growth factor; FNIII, fibronectin type III; RTK, receptor tyrosine kinase; TAM, TYRO3, 
AXL, and MERTK [from: (Rothlin et al., 2015)]. 
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1.5.4 MerTK-mediated regulation of phagocytosis 
 
TAM signaling plays a critical role in the phagocytosis of apoptotic cells and cellular debris in mature 
tissues (Lemke and Burstyn-Cohen, 2010; Scott et al., 2001; Zagorska et al., 2014). During this 
process, TAM ligands serve as a “bridge” to link the TAM receptor, expressed on the surface of the 
phagocyte, to PtdSer exposed on the surface of the apoptotic cell that will be engulfed (Nagata et al., 
2010). Simultaneously, the ligand must activate the TAM receptor tyrosine kinase activity for the 
process of phagocytosis (Scott et al., 2001). Recent evidence show that “bridging” in the absence of 
TAM kinase activation and/or kinase activation in the absence of bridging, are insufficient to promote 
efferocytosis (Zagorska et al., 2014).  
 
The first phenotype described in TAM knockout mice (TAM–/–) was male infertility. TAM expression 
in Sertoli cells is required to clear apoptotic remnants of meiosis in the testes and TAM–/– male mice 
show inflammatory damage at seminiferous tubules and infertility (Sun et al., 2010; Zhang et al., 
2013). MerTK–/– mice show increased accumulation of apoptotic germ cells whereas Tyro3–/– and 
Axl–/– mice display no apoptotic cell accumulation (Lew et al., 2014). A similarly strong phenotype is 
detected in the eyes of MerTK–/– mutants which are born with normal retinae. Retinal pigment 
epithelium (RPE) cells in MerTK–/– mice differentiate normally but fail to clear apoptotic cells and 
debris. This leads to death of nearly all photoreceptors (PRs), pro-longed inflammation, fibrosis, and 
retinal degeneration (Duncan et al., 2003; Prasad et al., 2006). Within the central nervous system 
MerTK-lacking microglial cells are unable to clear ineffective synaptic connections, leading to 
impaired hippocampal development and neuronal damage (Ji et al., 2013).  
 
TAMs play important roles in the clearance of apoptotic cells by macrophages and other phagocytes 
(Scott et al., 2001). Axl and MerTK are the two most important receptors for the engulfment of 
apoptotic cells by macrophages and dendritic cells (Lemke and Burstyn-Cohen, 2010). Recent studies 
show that these two act in distinct environments with MerTK receptor mediating homeostatic 
phagocytosis in tolerogenic settings and Axl functioning in inflammatory microenvironments created 
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by infection or tissue damage (Zagorska et al., 2014). In those settings in which efferocytosis is Axl-
dependent it is also Gas6-dependent whereas Mer-dependent efferocytosis can be stimulated by both 
Gas6 and Protein S. Incomplete efferocytosis can lead to the accumulation of secondary necrotic cells 
which constitute a major source of auto-antigens, thus defects in phagocytosis are associated with the 
development of autoimmune diseases and is a prominent feature of the phenotypes of TAM mutants 
(Rothlin and Lemke, 2010).  
 
 
1.5.5 MerTK signaling in immune regulation 
 
TAM receptors and their ligands are essential regulators of the immune system and function at the 
interface of innate and adaptive immunity, as demonstrated by studies on macrophages and DCs 
(Rothlin et al., 2007). These cells use pattern recognition receptors (PRRs), such as Toll-like receptors 
(TLRs), to detect molecular patterns, such as lipopolysaccharide and double-stranded RNA, that are 
associated with bacteria and other pathogens (Chung et al., 2012). Activation of PRRs leads to the 
production of pro-inflammatory cytokines, for example type I interferons. However, these cytokines 
must be tightly controlled after the innate immune response is mobilized because unrestrained 
cytokine signaling results in chronic inflammation (Rothlin et al., 2015).  
 
Studies using experimental models of sterile and pathogen-induced inflammation have demonstrated 
that TAM receptor loss can result in exaggerated activation and ineffective resolution, thus leading to 
excessive inflammatory tissue damage (Mukherjee et al., 2016). In a model of endotoxemia, MerTK-
deficient mice almost uniformly succumbed to septic shock and died as a result of tissue damage 
mediated by excessive levels of TNF-α and IL-1 (Camenisch et al., 1999). Bleomycin-induced lung 
injury was significantly reduced when MerTK macrophage expression was enhanced in mice, that 
were also typified by increased anti-inflammatory mediators, such as TGF-β and hepatocyte growth 
factor (HGF) and reduced TNF-α and IL-1 expression levels (Lee et al., 2012c). 
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TAMs regulate the innate immune responses through the modulation of cytokine secretion (Rothlin et 
al., 2015). There is direct evidence that TAMs are significantly upregulated in murine DCs following 
TLR engagement and that TLR-induced pro-inflammatory cytokine production is attenuated by both 
MerTK and Axl signaling (Rothlin et al., 2007). The mechanism of TAM action involves the 
suppressor of cytokine signaling proteins SOCS-1/3 which act as inhibitory proteins at various points 
in the TLR cascade. Increased SOCS-1/3 expression occurs downstream of TAM signaling and a 
dynamic feedback loop exists, in which the initial burst of cytokines as products of TLR pathway bind 
to their respective receptors and activate the transcription factor STAT1. In addition to promoting 
further the pro-inflammatory cytokine production, STAT1 induces Axl expression. In association with 
its ligands, Axl interacts with the cytokine receptor interferon (IFN)-associated receptor and this 
protein complex appears to differentially activate STAT1, redirecting its downstream genetic targets 
toward SOCS-1/3 and crucially acting as a brake for TLR-evoked cytokine production by pathogens 
(Rothlin et al., 2007).  Hence, this braking mechanism is not available at the onset of inflammation, 
but manifests only following initiation and propagation of the immune response.  
 
MerTK signaling in macrophages also skews their cytokine secretion profile following efferocytosis 
to promote tissue-repair and wound healing processes. MerTK-mediated efferocytosis promotes anti-
inflammatory cytokine productions (IL-4, IL-10, and TGF-β) that promote tissue-repair and resolution 
of inflammation (Filardy et al., 2010), and this depends upon inhibition of nuclear factor (NF)-kB 
signaling and activation of the phosphatidylinositol 3-kinase pathway (Sen et al., 2007). In addition, 
IL-10 further acts in an autocrine manner on macrophages by inducing MerTK expression and 
propagating an anti-inflammatory response to tissue damage (Zizzo et al., 2012). Gas6 and Protein S 
are also secreted in an autocrine manner by macrophages and DCs, following activation of both 
MerTK and Axl, thus further amplify TAM signaling at sites of tissue inflammation (Rothlin et al., 
2007). Recent work proposed that differential TAM receptor expression by different immune cells 
may indicate specificity in biological function (Zagorska et al., 2014). Axl is more abundant in murine 
DCs whereas MerTK is predominantly expressed in macrophages. Axl expression is increased in 
response to TLR ligands lipopolysaccharide (LPS) and poly(I:C) whilst MerTK expression is induced 
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following the uptake of apoptotic cells and IL-10 (Zizzo et al., 2012). These findings support that 
MerTK enables phagocytic clearance in homeostatic settings and Axl functions in antigen-presenting 
cells in response to acute inflammatory tissue damage (Zagorska et al., 2014) 
 
1.5.6 MerTK signaling and human disease 
 
1.5.6.1 MerTK in autoimmunity 
 
 
Autoimmune diseases such as systemic lupus erythematosus (SLE) are linked with accumulation of 
apoptotic cell debris (Rothlin and Lemke, 2010). Not surprisingly, the delayed efferocytosis of 
apoptotic cells and loss of the regulation of the inflammatory response are associated with the 
development of a lupus-like syndrome in TAM triple knock out (TKO) mice (Cohen et al., 2002; Lu 
and Lemke, 2001). These TKO mice are show elevated titers of circulating auto-antibodies (anti-
chromatin and anti-double and single stranded DNA antibodies), uncontrolled B and T cell 
proliferation and accumulation of lymphocytes in secondary lymphoid organs (Cohen et al., 2002; Lu 
and Lemke, 2001). This phenotype appears to be cell non-autonomous with respect to lymphocytes, 
since T and resting B cells and do not express TAMs. In humans SLE, there is defective clearance of 
autoreactive lymphocytes in germinal centers of lymph nodes by tingible body macrophages that 
express MerTK (Gaipl et al., 2006; Rahman et al., 2010). Genetic studies also showed polymorphisms 
in the MerTK gene, that are tied to SLE and development of multiple sclerosis (Cheong et al., 2007; 
Ma et al., 2011). Furthermore, deficiencies in the TAM ligand Pros1 have also been frequently 
detected in SLE patients, suggesting a role for impaired TAM signaling in its pathogenesis (Song et 
al., 2000), and recent evidence has highlighted a further role for MerTK in innate and adaptive 
immunity. Cytotoxic T lymphocytes in mice produce Pros1 and externalize patches of PtdSer, thereby 
activate MerTK on antigen-presenting cells, dampening pro-inflammatory cytokines and antigen-




1.5.6.2 MerTK in viral infection 
 
 
TAM receptors and their ligands have been described on affecting viral infectivity. TAMs function as 
entry factors for the Ebola/Marburg family of hemorrhagic fever filoviruses (Rothlin et al., 2015). 
Similar results are obtained following cell infection with lentiviral vectors pseudotyped with Sindbis 
virus, vesicular stomatitis virus, Ebola, and Marburg virus glycoproteins and for infection by the 
flaviviruses Dengue virus and West Nile virus (Rothlin et al., 2015). Enveloped viruses, mentioned 
above, employ a strategy to evade the immune system, known as “apoptotic mimicry”, where they 
expose PtdSer on their surface (Mercer and Helenius, 2010). This allows them to use TAM ligands as 
“bridging molecules” and link themselves to TAMs expressed on target cells. It is shown that Gas6 
and Pros1 as well as their binding to exposed PtdSer is required for TAM-mediated viral infection  
(Bhattacharyya et al., 2013; Morizono et al., 2011). The expression of kinase dead receptors or the 
addition of a TAM inhibitor to the cell culture reduced the capacity of TAMs to favor viral infection 
in vitro (Meertens et al., 2012).  
 
Most studies have examined the ability of TAMs to promote viral replication in vitro, however their 
role in vivo remains controversial. Axl−/− mice are more susceptible to herpes simplex virus (HSV)-1 
infection maybe due to reduced capacity of Axl−/− DCs to cross-present viral antigen (Subramanian et 
al., 2014). In contrast, systemic administration of an anti-Axl antibody to WT mice infected with a 
lethal dose of PR8 influenza virus strain led to reduced mice mortality (Shibata et al., 2014). 
Similarly, administration of anti-Axl antibody reduced the lung pathology upon respiratory syncytial 
virus infection in mice (Shibata et al., 2014). Moreover, no significant differences were detected in 
the response to lymphocytic choriomeningitis virus infection between WT and Axl−/− mice (Sullivan 




1.5.6.3 MerTK in cancer 
 
TAM-mediated regulation of immune responses is implicated in antitumor immunity with existing 
literature focused on TAM function in tumor cells and tumor-associated immune cells, describing 
both pro-oncogenic and anti-oncogenic roles (Linger et al., 2010; Rothlin et al., 2015). Tumor-
associated macrophages secrete higher Gas6 levels compared to their splenic counterparts while 
mediators (i.e, IL-10 and M-CSF) enriched in the tumor microenvironment may further upregulate 
their Gas6 production (Loges et al., 2010). Of note, Gas6 levels are elevated in a number of different 
solid tumors (Graham et al., 2014). TAMs also possess non–tumor cell autonomous roles; MerTK 
ablation in a model of breast cancer, or syngeneic transplantation of melanoma and colon cancer cells 
in MerTK−/− mice, led to reduced tumor burden and fewer metastases (Cook et al., 2013) and in vivo 
administration of a  TAM inhibitor reduced both tumor and metastatic burden, as result of enhanced 
NK cell activation and anti-tumor activity (Paolino et al., 2014). In contrast, an anti-inflammatory and 
anti-tumor TAM function is supported in colorectal cancers. Gas6−/− mice showed increased 
susceptibility to inflammation-induced colon carcinogenesis, as a result of azoxymethane (AOM) and 
dextran sodium sulfate (DSS) treatment, characterized by a greater number of PCNA/c-Myc-positive 
polyps, higher TNF-α levels, increased NF-κB activation and reduced survival (Akitake-Kawano et 
al., 2013). Accordingly, Axl−/− Mer−/− mice post AOM-DSS treatment had more and larger polyps, 
increased tumor score and their colons exhibited increased number of apoptotic Ly6G+ neutrophils 
and increased IFN-γ and TNF-α production, compared to WT (Bosurgi et al., 2013).  
 
 
1.5.6.4 MerTK in liver disease 
 
 
TAM-mediated immune regulation in the liver is vital for maintaining hepatic immune tolerance. The 
liver is a central immunological organ with high exposure to circulating antigens and endotoxins 
derived from the gut, hence several mechanisms during homeostasis ensure suppression of hepatic 
immune responses, resulting in tolerance (Heymann and Tacke, 2016). This important function is 
orchestrated by the resident population of antigen-presenting cells, adapted epithelial cells and an 
enriched NK cell population (Kubes and Mehal, 2012). Importantly, all TAM receptors have been 
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identified in the livers of mice: MerTK is expressed in liver-resident KCs and sinusoidal endothelial 
cells, but not in hepatocytes, Axl is expressed by all three cell types whereas Tyro3 is restricted to 
macrophages (Qi et al., 2013; Rothlin et al., 2015). TAM TKO mice develop autoimmune hepatitis, 
by six months of age, with elevated transaminases and titers of autoantibodies (Qi et al., 2013). 
Histological analysis reveals a rich infiltrate of autoreactive CD4 T cells and circulatory macrophages, 
while hepatocytes show elevated pro-inflammatory cytokines such as IL-6, IL-1β, TNF-α, and IFNs 
through NF-κB and IFN regulatory factor 3 upregulation. Ηowever, this phenotype was not observed 
when the bone marrow of TAM TKO mice was transplanted with WT stem cells (Qi et al., 2013).  
 
TAM signaling is also studied in chronic and acute liver inflammation. A genome-wide association 
study in patients with chronic hepatitis C virus (HCV) infection identified several susceptibility loci 
for severity and progression of liver fibrosis (Patin et al., 2012). The strongest was homozygosity for 
rs4374383 G>A single nucleotide polymorphism, a non-coding variant in the MerTK locus, that was 
associated with the protection against fibrosis progression in HCV (Patin et al., 2012). Another study 
found that the MerTK rs4374383 AA genotype, associated with lower hepatic MerTK expression, is 
protective against stage F2-F4 fibrosis in patients with NAFLD (Petta et al., 2016). MerTK was 
overexpressed in in vivo models of fibrogenesis whereas exposure of cultured human HSCs to the 
MerTK ligand Gas6, increased cell migration and induced	procollagen expression, effects that were 
counteracted by MerTK inhibition and resulted in apoptotic HSC death, thus proposing a MerTK-
dependent modulation of HSC activation (Petta et al., 2016). In a murine model of hepatic ischemia, 
serum Gas6 levels rose shortly after arterial ligation and western blot analyses after ischemic insult 
revealed an increase in hepatic phosphorylated MerTK over Axl levels, indicating a preferential 
activation of MerTK signaling (Llacuna et al., 2010). Compared to WT, Gas6-/- animals had higher 
mRNA levels of pro-inflammatory cytokines (IL-1α and TNF-α) and more frequently succumbed to 
fulminant hepatic failure after only partial ischemic insult. Recombinant Gas6 administration 
protected these mice from fulminant disease, however it is unclear if this was due to TAM signaling 
in liver immune cells or parenchyma (Llacuna et al., 2010).  
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Recently, MerTK signaling was also studied in human acute-on-chronic liver failure (AoCLF). There 
is an expansion of MerTK+ monocytes in AoCLF patients, compared to healthy and cirrhotic 
controls, with a concomitant increase in all TAM ligands as well as phosphorylated MerTK levels, 
that indicate an active TAM signaling (Bernsmeier et al., 2015). Monocytes in AoCLF exhibited an 
attenuated response to microbial challenge while blocking MerTK with a small molecule inhibitor 
restored their TNF-α and IL-6 secretion. The authors also showed that MerTK+ monocytes have 
enhanced migration abilities across hepatic endothelium, thus they proposed a dynamic model in 
which monocytes are recruited to the inflamed liver, resulting in increased MerTK expression in 
response to liver tissue damage. However, in the setting of a systemic inflammatory response, 
endothelial dysfunction enables their reverse transmigration back into the circulation and local lymph 
nodes, potentially contributing to immuneparesis and susceptibility to sepsis (Bernsmeier et al., 2015). 
 
Although TAM signaling is beneficial during liver homeostasis and perhaps in response to acute liver 
injury, research on chronic liver disease suggests it is potentially deleterious. HSC activation is 
pivotal in progression of chronic liver injury by promoting fibrogenesis and cirrhotic transformation 
(Tacke and Zimmermann, 2014). In a murine model of CCL4-induced chronic liver injury, HSC 
activation was shown to rely upon Gas6-mediated Axl activation that leads to upregulation of 
signaling via protein kinase B and NF-kΒ. There was increased Axl transcription and translation as 
well as activation of the downstream signaling in both hepatic macrophages and stellate cells 
(Barcena et al., 2015; Fourcot et al., 2011). In another model where mice develop steatohepatitis, 
following a choline-deplete ethionine-supplemented diet, Gas6-/- mice exhibited a reduction in HSC 
activation and TGF-β expression and their onset of necroinflammation and steatosis was delayed, 
compared with WT mice (Fourcot et al., 2011). 
 
TAM function, in particular Axl, is studied in chronic HCV infection where Axl is shown to regulate 
IFN signaling and IFN-stimulated gene (ISG) expression. Of note, chronically infected HCV patients, 
characterized by prolonged activation of type I/III IFN signaling and high expression of ISGs before 
treatment, are less likely to achieve sustained virological response (Read et al., 2015a; Read et al., 
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2015b). Using in vitro and in vivo models, Read et al. showed that Axl expression was upregulated in 
chronically HCV infected hepatocytes; in particular, hepatocytes from “non-responder” patients 
showed higher Axl levels than hepatocytes from “responders” (Read et al., 2015a; Read et al., 2015b). 
Axl overexpression in hepatocytes in vitro resulted in reduced phosphorylation of STAT1 and 
subsequent ISG expression. Together, these results propose that IFN-induced Axl expression mediates 
a negative feedback loop, down-regulating IFN signaling, in a similar manner to that previously 
shown in DCs (Rothlin et al., 2007). This does not appear to be via SOCS-1/3 in hepatocytes but may 
be an effect of Axl on IFN signaling pathways (Read et al., 2015a; Read et al., 2015b).  
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1.6 Secretory leukocyte protease inhibitor (SLPI) 
 
1.6.1 Structure and expression of SLPI 
 
Secretory leukocyte protease inhibitor (SLPI) is a 107-amino acid-long protein with two homologous 
whey acidic protein (WAP) domains (Fig. 1.7). Each one is characterized by eight cysteine residues 
that form four characteristic intramolecular disulfide bonds. The WAP II (C-terminal) domain is 
mainly responsible for SLPI’s inhibitory function against proteases and the protease-inhibiting region 
is localized between residues 67–74 (Majchrzak-Gorecka et al., 2016). The biological function of the 
WAP I (N-terminal) domain is less understood, although SLPI’s antimicrobial activity is thought to 
reside in it (Scott et al., 2011a). SLPI is secreted by epithelial cells, including those cells lining the 
respiratory, digestive or reproductive tracts, as well as those cells of the breast, kidney and skin where 
it is thought to have homeostatic and protective functions. It is also produced by host-defense myeloid 
cells, constitutively or transiently, such as macrophages, granulocytes, dendritic cells (DCs) and 
platelets, as well as in neurons, and skeletal muscle cells (Sallenave, 2010; Scott et al., 2011a).  
 
1.6.2 Regulation of SLPI expression 
 
A variety of pro-inflammatory stimuli that trigger cell responses by binding to pattern recognition 
receptors, for example TLRs, increase SLPI expression. These include bacteria and bacterial cell wall 
components [LPS and lipoteichoic acid (LTA)], viral RNA analogs and pathogenic parasites 
(Majchrzak-Gorecka et al., 2016). Likewise, SLPI expression can be controlled by pro-inflammatory 
cytokine signals (TNF-α and IL-1β) and thymic stromal lymphopoietin (TSLP) while neutrophil 
elastase (NE) which is a target of SLPI also increases its secretion during granulopoiesis (Klimenkova 
et al., 2014). In addition, macrophages secrete SLPI following phagocytosis of apoptotic cells and in 
response to anti-inflammatory cues (IL-6 and IL-10) (Ashcroft et al., 2000). On the contrary, the pro-
inflammatory stimuli IFN-γ inhibits both basal and LPS-induced SLPI secretion by macrophages and 
may account for the low SLPI levels detected in severe asthma patients  (Jin et al., 1997; Raundhal et 
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al., 2015).  Regulation of SLPI at transcriptional and post-transcriptional level is discussed in more 
detail elsewhere (Majchrzak-Gorecka et al., 2016; Scott et al., 2011a).  
 
1.6.3 Multiple functions of SLPI 
 
1.6.3.1 SLPI as an anti-protease 
 
 
The most well-documented role of SLPI is the reversible inhibition of neutrophil elastase (NE). SLPI 
inhibits the enzymatic activity of other serine proteases, albeit with lesser efficiency, such as 
chymotrypsin, chymase, cathepsin G and trypsin (Wright et al., 1999). SLPI also interferes with the 
synthesis of proteases; for example, SLPI suppresses the MMP1 and MMP9 expression in monocytes 
and plays a role in the conversion of protease zymogen form (e.g. serine protease plasmin) where it is 
shown to block plasminogen activation through its interaction with annexin A2 at the surface of 
macrophages (Wen et al., 2011; Zhang et al., 1997).  
 
1.6.3.2 SLPI as an inhibitor of NF-kB activity 
 
 
SLPI possesses a wide functional repertoire such as antimicrobial and immune-modulatory activities, 
due to its ability to regulate the NF-κB pathway in immune cells. SLPI inhibits the LPS and LTA 
induced NF-κB activation of human monocytes (Lentsch et al., 1999) while others using anti-protease 
active-site mutated or truncated SLPI reveal it suppresses macrophage-like cell responses to LPS 
(Yang et al., 2005). These results suggest that the LPS-antagonizing action of SLPI is independent of 
its anti-protease effect. SLPI attenuates monocyte/macrophage responses via both intracellular and 
extracellular mechanisms. Outside the cell, SLPI can bind to and neutralize LPS, thereby can prevent 
TLR activation (Ding et al., 1999), whereas inside the cell SLPI prevents the degradation of NF-kB 
inhibitory components (IkBα and IkBβ) (Taggart et al., 2002) or competes with the NF-kB component 
p65 for binding to the NF-kB sites in the promoter regions of the pro-inflammatory genes TNF-α and 
CXCL8 (Taggart et al., 2005). The immune-modulatory activity of SLPI is also demonstrated in vivo, 
for example SLPI knockout mice are more susceptible to LPS-induced endotoxin shock and exhibit 
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higher mortality compared to WT mice (Nakamura et al., 2003). Human experimental and murine 
studies on acute tissue injury and wound healing, show that SLPI is a key anti-inflammatory mediator 
in the local micro-environment by directly inhibiting macrophage NF-κB dependent pro-inflammatory 
responses (Ashcroft et al., 2000; Odaka et al., 2003b; Sano et al., 2000; Sano et al., 2003).  
 
1.6.3.3 Αntimicrobial and antiviral actions of SLPI 
 
 
SLPI is shown to inhibit bacteria/fungal growth and to restrain viral infections. It exerts bactericidal 
activity against Gram-positive/negative bacteria (Majchrzak-Gorecka et al., 2016); many skin-
associated bacteria including E. coli, Staphylococcus aureus, P. aeruginosa and Staphylococcus 
epidermidis are affected by SLPI in vitro suggesting it controls the skin microbial burden in the skin 
(Hiemstra et al., 1996). SLPI also possesses antifungal properties against Candida albicans and 
metabolically active Aspergillus fumigatus (Sallenave, 2010; Scott et al., 2011a) and its antimicrobial 
activity is attributed mainly to its N-terminal (WAP I) domain, as discussed above (Majchrzak-
Gorecka et al., 2016; Verma et al., 2007). Another important antimicrobial activity is described by 
McNeely et al. who found that SLPI inhibited the ability of HIV-1 to infect macrophages (McNeely et 
al., 1995) since it competitively binds to annexin II, an important cellular co-factor that facilitates 





Figure 1.7 Amino acid sequence of human SLPI. 
 (a) Amino acid sequences of two WAP domains are shown in yellow and green background. Cysteine residues (red) make 
intradomain disulfide bridges (black lines). The fragment of the WAP II sequence spanning residues from 67 to 74 (blue) 
corresponds to the protein region involved in interactions with proteases as determined by structural studies. (b) Two 
orthogonal views of the 3D structure of the WAP II domain are shown. Three b-strands and a short a helix are shown in 
yellow and red, respectively. Four disulfide bridges are shown as yellow sticks. Alpha carbon atoms of a loop ranging from 
T67 to N75 are shown as small spheres with appropriate labeling of consecutive amino acid residues. [from: (Majchrzak-
Gorecka et al., 2016)]. 
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1.6.4 SLPI in pathological inflammatory responses 
 
1.6.4.1 SLPI in infectious and allergic diseases 
 
 
The levels and activity of SLPI are altered in numerous inflammatory, infectious, allergic and 
autoimmune diseases. SLPI is expressed at portals of pathogens where it regulates the epithelial 
activation threshold in order to protect against microbial signals (Menckeberg et al., 2015). Another 
homeostatic function at body barriers involves the in situ regulation of class switching and antibody 
production in B cells, that are induced by epithelial cell-derived factors (Xu et al., 2007). SLPI is also 
crucial in controlling host susceptibility to bacterial infection; serum SLPI levels are elevated in 
experimental LPS-induced endotoxemia and in patients with sepsis (Grobmyer et al., 2000). SLPI-/-  
mice were more susceptible to LPS-induced endotoxin shock and sepsis, caused by cecal ligation and 
puncture and developed more inflammation (Nakamura et al., 2003). In a model of pulmonary 
infection with M. tuberculosis, SLPI-/- mice were less capable of clearing the infection, having high 
bacterial loads in the lung and spleen and reduced survival (Nishimura et al., 2008). SLPI also mounts 
an effective immune response to the protozoan parasite L. major. SLPI-/- mice did not control the 
infection, however adenoviral delivery of SLPI to the infected SLPI-/- animals significantly restored 
their infection resistance (McCartney-Francis et al., 2014).  
 
There is also emerging evidence that SLPI is a negative regulator of inflammation in non-infectious 
conditions such as allergic asthma. Increased levels of SLPI are detected in sputum and nasal lavage 
specimens from individuals with allergic asthma and allergic rhinitis. SLPI mRNA expression was 
lower in epithelial cells from patients with severe asthma (SA), compared to mild-moderate asthma 
(MMA) patients (Raundhal et al., 2015). Insufficient SLPI levels may lead to loss of tolerance to an 
allergen and persistent airway inflammation and/or airway hyperresponsiveness (AHR). Accordingly, 
SLPI-/- mice failed to maintain unresponsiveness to ovalbumin (OVA) protein and this brake in 
tolerance was attributed to enhanced DC activation in the draining lymph nodes (Samsom et al., 
2007). In a mouse model of OVA-induced allergic asthma, researchers using gain-of-function and 
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loss-of-function approaches demonstrated that SLPI exerts a protective effect against allergic asthma 
(Marino et al., 2011). A recent study in SA pointed SLPI as a negative regulator of asthma related 
inflammation; SA is characterized by Th1-dominated responses whereas MMA by Th2-dominated 
responses. Compared to WT, IFN-γ–/– mice subjected to SA failed to mount AHR without an effect on 
airway inflammation and AHR was unaltered in IL-17ra–/– mice, although airway inflammation was 
lower (Raundhal et al., 2015). Computer-based analysis tools linked IFN-γ to SLPI, the levels of 
which inversely correlated in SA patients. In mice with SA, induced SLPI expression decreased AHR 
in absence of corticosteroids and it was further reduced when SLPI was combined with corticosteroids 
(Raundhal et al., 2015). 
 
1.6.4.2 SLPI in autoimmunity 
 
 
SLPI exerts crucial immune-modulatory activities during a variety of autoimmune diseases by 
contributing to the host’s responses to “self-antigens” through DC activation and inhibition of NET 
formation. In a rodent model of experimental autoimmune encephalomyelitis, analysis of the spinal 
cord transcriptome revealed significantly up-regulated SLPI levels, suggesting it as an endogenous 
factor for disease outcome progression (Mueller et al., 2008). In another model of streptococcal cell 
wall-induced arthritis increased SLPI levels were found in affected joints of rats, during the early 
acute and the chronic destructive phase, although its expression was barely detected in the interval 
preceding chronic destructive disease (Song et al., 1999). Others have also linked SLPI with skin 
psoriasis, suggesting it contributes to the host response to “self-antigens” by enabling DCs to sense 
extracellular DNA, which is typically not immunogenic, and controlling deposition of this potentially 
harmful stimulus (Skrzeczynska-Moncznik et al., 2013; Skrzeczynska-Moncznik et al., 2012). SLPI 
expression is elevated in psoriatic skin, mostly in keratinocytes, and found to localizes in NETs, thus 
proposed to trigger the DNA-mediated activation of plasmacytoid DCs (Skrzeczynska-Moncznik et 
al., 2013; Skrzeczynska-Moncznik et al., 2012; Wingens et al., 1998). Importantly, SLPI inhibits NET 
formation, a process that requires chromatin de-condensation during which NE, a SLPI’s target, plays 
a key role (Sorensen and Borregaard, 2016). SLPI detected in the granules and cytoplasm of resting 
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neutrophils can translocate to the nucleus upon neutrophil activation and restrain NET release; this 
inhibitory function is partially attributed to SLPI's anti-NE activity (Zabieglo et al., 2015b). SLPI also 
inhibited NET formation (NETosis) in vitro, in human neutrophils and SLPI-/- murine bone marrow-
derived neutrophils while a similar effect of SLPI was observed in vivo in an experimental model of 
psoriasis in which more neutrophils producing NETs were detected in the affected skin of SLPI-/-  
mice compared to WT animals (Zabieglo et al., 2015b). 
 
1.6.4.3 SLPI in wound healing and tissue repair 
 
Numerous studies underline the important role of SLPI in wound healing with contributions at all of 
its phases starting as early as coagulation, since SLPI-/- mice have significantly prolonged plasma 
clotting time (Schulze et al., 2004). SLPI-/- mice subjected to cutaneous injury exhibit delayed skin 
wound healing that is reversible by SLPI administration to cutaneous wounds (Ashcroft et al., 2000). 
Use of anti-TGF-β and anti-TNF-α neutralizing antibodies in vivo largely reversed this impaired 
healing, thus suggesting a SLPI-mediated control of TGF-β and TNF-α levels is required for 
cutaneous wound healing (Ashcroft et al., 2012; Ashcroft et al., 2000). Also, SLPI is involved in the 
growth phase of the healing cascade following dermal injury where it is likely to protect growth 
factors from protease cleavage. Such a mechanism is proposed for NE, SLPI and proepithelin which 
at its intact form is a growth factor for epithelial cells that also inhibits neutrophil activation (Zhu et 
al., 2002). Similarly, TSLP-deficient mice have reduced SLPI levels in the colon and fail to recover 
from colon damage when challenged with dextran sulfate sodium (DSS). This may be due to 
increased NE activity during the recovery phase and an imbalance in proepithelin/epithelin conversion 
(Reardon et al., 2011). Moreover, SLPI is implicated in controlling the inflammation associated with 
axonal damage and promoting axonal regeneration following injury in the central nervous system 





1.6.4.4 SLPI in regulating various aspects of cell biology  
 
 
SLPI may also influence various aspects of cell biology. Several studies propose a role for SLPI in 
controlling cell growth, however opposing results are reported, exemplified by its effects on cancer 
cells where it can support and antagonize tumor growth (Bouchard et al., 2006). SLPI supports the 
growth of different epithelial cell types, hematopoietic cell precursors or B cells while it impacts on 
the differentiation, proliferation and survival of neural stem cells and early granulocytes (Klimenkova 
et al., 2014; Mueller et al., 2008; Nakamura et al., 2003). Emerging evidence suggest a regulatory role 
of SLPI in granulocytic differentiation. Low levels of NE and SLPI are found in myeloid cells and 
plasma of severe congenital neutropenia patients where SLPI is shown to control myeloid 
differentiation through regulation of NFkB, ERK1/2:LEF-1, and c-myc activation (Klimenkova et al., 
2014). SLPI is also shown to regulate apoptosis in mature granulocytes and monocytic cells, in an 
antiprotease-independent manner, however the mechanisms remain largely obscure (McGarry et al., 




1.7 Summary and aims 
 
ALF is a clinical syndrome characterized by overwhelming hepatocyte death. Drug-induced liver 
injury, particularly AALF, is the commonest cause of ALF (Bernal et al., 2015), with a high mortality 
rate, due to activation of SIRS and its attendant complications of multi-organ failure and recurrent 
infection, generated by uncontrolled immune-mediated liver injury (Antoniades et al., 2008; Vaquero 
et al., 2003). Central to the pathogenesis of ALF is liver inflammation, where infiltration of myeloid 
cells in areas of necrosis is contrasted by immune cell depletion and dysregulation in the systemic 
circulation (Antoniades et al., 2012). At steady state monocytes traffic to the liver, augmenting the 
local macrophage pool, a process that is markedly increased during ALF (Holt et al., 2008; Zigmond 
et al., 2014). ALF patients have an expansion of hepatic macrophages, localized in areas of necrosis, 
that is through chemokine-dependent recruitment of MoMFs and proliferation of resident KCs 
(Antoniades et al., 2012; Choi et al., 2015a; Dambach et al., 2002; Holt et al., 2008; Mossanen et al., 
2016; Zigmond et al., 2014). Studies in humans and mice show that hepatic macrophages orchestrate 
both tissue-destructive and resolution/repair responses following acute liver injury (Antoniades et al., 
2014; Antoniades et al., 2012; Mossanen et al., 2016; Zigmond et al., 2014).  
 
MerTK, expressed predominantly by macrophages, dampens innate immune responses and promotes 
the clearance of apoptotic cells (efferocytosis) following acute tissue injury (Rothlin et al., 2015). 
Engagement and activation of MerTK inhibits signaling pathways triggered by cytokines toll-like 
receptor ligands (Lemke and Rothlin, 2008). MerTK recognizes the exposed phosphatidylserine on 
the surface of apoptotic cells, in association with its ligands, while their efferocytosis induces a 
macrophage functional switch towards resolution/tissue-repair responses (Zagorska et al., 2014). 
SLPI, secreted by epithelial and myeloid cells, suppresses monocyte/macrophage pro-inflammatory 
responses through inhibition of NF-κB signaling (Ashcroft et al., 2000; Nakamura et al., 2003; 
Sallenave, 2010; Scott et al., 2011b). SLPI is shown to exert immune-modulatory activities during 
tissue inflammation in a variety of diseases, such as sepsis, asthma and cancer (Majchrzak-Gorecka et 
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al., 2016) while it was recently identified that SLPI, secreted in the liver by biliary epithelial cells and 
hepatic macrophages, is a key modulator of circulating monocyte function in human ALF (Antoniades 
et al., 2014).  
 
The aim of the research described in this thesis is to investigate, using a combination of human and 
murine experimental models, the role of MerTK during resolution of inflammation following acute 
liver injury and examine how SLPI, as a pro-resolving mediator, governs this immunological response 
between macrophages and neutrophils. Hence, I aimed to examine the: 
§ Phenotypic/functional profile, migratory characteristics and tissue topography of monocytes 
and hepatic macrophages in ALF patients. 
§ Phenotype of hepatic macrophages in WT mice following APAP-induced acute liver injury 
and the biological relevance of MerTK+ cells for resolution of hepatic inflammation using 
WT and MerTK-deficient mice. 
§ Effects of micro-environmental triggers including biliary epithelial cells, apoptotic cell debris 
and SLPI, detected in the inflamed ALF liver, on skewing monocytes/macrophages towards a 
MerTKhigh resolution-like type. 
§ Direct and indirect effects of SLPI on the innate immune function and survival of neutrophils. 
§ Effects of SLPI administration in WT mice, with APAP-induced acute liver injury, on the 
hepatic macrophage phenotype and the activation/apoptosis state of neutrophils.  
§ Examine the circulating and hepatic micro-environmental milieu and characterize the hepatic 



























2. PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF 
MONOCYTES AND MACROPHAGES IN PATIENTS WITH ACUTE 
LIVER FAILURE 
 
2.1 Background and aims 
 
Central to the pathogenesis of ALF is liver inflammation where the infiltration of myeloid cells in 
areas of hepatic necrosis is contrasted by immune cell depletion and dysregulation in the circulation 
(Antoniades et al., 2006; Antoniades et al., 2008). During steady state, monocytes traffic to the liver 
augmenting the local macrophage pool, a process that is markedly increased during experimental ALF 
(Holt et al., 2008; Zigmond et al., 2014). Consistently, ALF patients show an expansion of hepatic 
macrophages, due to the chemokine-dependent recruitment of monocytes and proliferation of resident 
KCs (Antoniades et al., 2012; Choi et al., 2015a; Dambach et al., 2002; Holt et al., 2008; Mossanen et 
al., 2016; Zigmond et al., 2014). Several studies suggest that hepatic macrophages orchestrate both 
tissue-destructive and resolution responses following acute liver injury (Antoniades et al., 2014; 
Antoniades et al., 2012; Mossanen et al., 2016; Zigmond et al., 2014).  
 
In the past decade, research in human ALF started to explore the role of monocytes and macrophages 
in the pathophysiology of the disease (Possamai et al., 2014b). Compared to healthy controls (HC) 
and chronic liver disease (CLD) patients, monocytes and hepatic macrophages in ALF have an anti-
inflammatory CD163highHLA-DRlow phenotype and functional characteristics, typified by reductions 
in NF-κΒp65, TNF-α and IL-6 levels and preserved IL-10 secretion following microbial challenge 
(Antoniades et al., 2006; Antoniades et al., 2014; Antoniades et al., 2012). These data implicated 
monocytes/macrophages in the resolution and tissue-repair processes during human ALF (Antoniades 
et al., 2014; Antoniades et al., 2012).  
 
MerTK, expressed predominantly by tissue macrophages, dampens innate immune responses and 
promotes clearance of apoptotic cells following acute tissue injury (Rothlin et al., 2015). Recently, a 
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study on acute-on-chronic liver failure (AoCLF) patients revealed that these patients are characterized  
by monocyte dysfunction and attenuated pro-inflammatory responses to microbial challenge, similar 
to ALF patients (Bernsmeier et al., 2015). In particular, it described increased numbers of MerTK+ 
monocytes/macrophages, showing that these cells contribute to down-regulation of innate immune 
responses in AoCLF. This immune-regulatory subset was detected in both circulatory and tissue (liver 
and lymph-node) compartments of AoCLF patients, exhibited an anti-inflammatory CD163highHLA-
DRlow phenotype, echoing the one observed in ALF (Antoniades et al., 2014; Antoniades et al., 2012). 
Interestingly, this MerTK+ monocyte subset was also detected, remarkably at higher levels than the 
AoCLF study group, in the circulation of ALF patients (Bernsmeier et al., 2015). 
 
Hypothesis and aims: 
Given the previous and new findings on circulating monocytes and hepatic macrophages in human 
ALF, I hypothesized that this MerTK+ immune-regulatory subset is expanded in ALF, and is detected 
at both circulatory and tissue compartments of these patients. In addition, these cells fundamentally 
contribute to the resolution of hepatic inflammation processes following acute liver injury. Hence, in 
this chapter I aimed to: 
§ Examine the phenotypic/functional profile of circulating monocytes and liver-derived hepatic 
macrophages isolated from ALF patients, healthy and disease controls. 
§ Assess the migratory characteristics across hepatic endothelium of monocytes in healthy 
controls and ALF. 
§ Determine the topography and phenotypic profile of monocytes/macrophages in liver and 
mesenteric lymph-node tissue derived from pathological controls and ALF patients. 
  
 85 
2.2 Materials and methods 
 
2.2.1 Patient recruitment 
 
Acetaminophen-induced ALF (AALF, n=23) and non-acetaminophen-induced ALF (NAALF, n=9) 
patients, as detailed in (Table 2.1), were recruited into the study within 24 hours following admission 
to the Liver Intensive Care Unit at King’s College Hospital (London, UK). Chronic liver disease 
(CLD, n=10) inpatients, none with acute-on-chronic liver failure (Table 2.1), and healthy volunteers 
(HC, n=15) served as pathological and healthy controls, respectively. Exclusion criteria were age <18 
or >65 years, neoplasia and immunosuppressive therapy. AALF patients were identified for 
transplantation according to the King’s College Hospital  criteria (Bernal et al., 2002).  
The study was approved by the NRES Health Research Authority (12/LO/0167). Assent was obtained 
by the patients’nominated next of kin if they were unable to give informed consent themselves. All 
human diseased (06/Q2708/11) and normal donor (06/Q2702/61) liver tissue and blood samples 
(04/Q2708/41) obtained through the Liver Unit at the Queen Elizabeth Hospital (Birmingham, UK) 
were collected with local research ethics committee approval and patient consent. Clinical, 
hematological and biochemical parameters were determined in patients using a hematology analyzer 
(Siemens Advia 2120, Berks, UK). 
2.2.2 Isolation of peripheral blood mononuclear cells, monocytes and neutrophils 
 
Whole blood was obtained from healthy volunteers and ALF patients, recruited at King’s College 
Hospital, in order to isolate peripheral blood mononuclear cells (PBMCs) using Ficoll-Paque Plus 
(GE Healthcare) and neutrophils using Polymorphprep (Axis-Shield, Norway), as recommended by 
the manufacturers. Cell viability was >95% according to trypan blue staining. CD14+ cells were 
isolated from healthy PBMCs using CD14 magnetic beads (Miltenyi Biotec, UK). In addition, purity 
of monocytes and neutrophils was assessed by flow cytometry (90-95%) by using monoclonal 
antibodies against CD14 and CD66b, respectively (BD Biosciences, UK). After isolation, PBMCs, 
monocytes and neutrophils were washed in PBS (Life Technologies, UK). 
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2.2.3 Isolation of hepatic mononuclear cells 
 
Hepatic mononuclear cells (HMCs) were isolated from approximately 120-150 g of human liver 
tissue, as previously described (Liaskou et al., 2013). The tissue was washed in cold sterile phosphate-
buffered saline and was cut into small pieces in order to be mechanically digested in RPMI-1640 
medium using a Stomacher400 Circulator (Cole-Parmer Instrument, United Kingdom) for 5 min at 
260 speed. The tissue homogenate was then filtered and HMCs were purified further by density 
gradient centrifugation using Lympholyte (Cedarlane Laboratories, Canada) for 20 min at 550xg. 
HMCs were washed in phosphate-buffered saline and were further examined for their phenotype and 
function or cultured. 
 
2.2.4 Flow cytometry of immune cells 
 
Human PBMCs and HMCs were incubated with mouse anti-human monoclonal antibodies [CD14-
PE-Cy7, CD16-APCH7, CD163-PE, CCR2-AF647, CCR5-FITC, CCR7-FITC (BD Biosciences, 
UK); HLA-DR-PerCP (eBioscience, UK); MerTK-APC, Tie-2-PE (R&D Systems, UK)] for 20 min 
at room temperature in the dark and then assessed by flow cytometry for surface marker expression. 
Cells were washed and re-suspended in phosphate-buffered saline supplemented with 1% fetal bovine 
serum. Cells were fixed and permeabilized for intracellular cytokine staining (BD Biosciences, UK). 
Also, TNF-α and IL-6 levels (BD Biosciences, UK) were determined by flow cytometry using 
intracellular cytokine staining (BD Biosciences, UK) following 6h LPS (100 ng/ml) stimulation 
(Sigma-Aldrich, UK).  
 
2.2.5 Gene expression analysis 
 
Gene expression analysis was performed using the NanoString nCounter® GX Human Immunology 
V2 assay (NanoString Technologies, Inc., Seattle, WA) profiling 594 immunology-related genes. 
FACS-separated cells from HC and ALF patients (n=3 each) were lysed in RLT lysis buffer (Qiagen, 
 87 
Dusseldorf, Germany) (max 50.000 cells / 2µl) and were stored at -80°C. The cell lysates were 
incubated with reporter and capture probe sets overnight and afterwards were immobilized on a 
cartridge using the nCounter® Prep Station (NanoString Technologies, Inc., Seattle, WA). Cartridges 
were scanned on the nCounter® Digital Analyzer at 600 fields of view at the UCL Nanostring Facility 
(University College London, UK). The differential gene expression was calculated and plotted as 
heatmap using the nSolver™ Analysis Software 3.0 (NanoString Technologies, Inc., Seattle, WA). 
Statistically relevant results are considered with P < .05 and a fold-change of 50% higher or lower. 
 
2.2.6 Measurement of inflammatory mediator and cytokine levels 
 
Human quantikine ELISA was used to measure SLPI levels (R&D Systems, UK) in PBMC culture 
supernatants from ALF patients and HC, following 6h LPS (100 ng/ml) stimulation (Sigma-Aldrich, 
UK). The MSD Human Pro-inflammatory 10-plex panel was also used to assess (IFN-γ, IL-1β, IL-2, 
IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-α) cytokine levels in culture supernatants. ELISA 
microplates were read using the SoftMax® Pro software (Molecular Devices, USA). MSD plates were 
read on the Sector Imager 2400 apparatus (Gaithersburg, MD). All experiments were performed in 
duplicates and according to the manufacturer's instructions. 
 
2.2.7 Tissue sampling, immunohistochemistry and imaging 
 
Human liver tissue was obtained from ALF patients undergoing orthotopic liver transplantation 
(OLT), diseased liver tissue from CLD patients while normal liver tissue was derived from hepatic 
resection margins of colorectal malignancies. For phenotypic characterization of liver-derived 
macrophages, HMCs were isolated from fresh ALF (n=8), CLD (n=10) and NL (n=6) explant liver 
tissue. For immunohistochemistry (IHC), liver and mesenteric lymph node (LN) tissue was obtained 
from ALF (n=6) and hepatic resections, serving as pathological controls (PC, n=4).  
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Single-epitope enzymatic immunohistochemistry for detection of MerTK, CD163, and HLA-DR 
expressing cells. FFPE tissue was cut at 4 µm using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-L-lysine coated slides which were manually stained using a) 
rabbit monoclonal anti-MerTK primary antibody (# ab52968, Abcam, UK; dilution 1:500), b) mouse 
monoclonal anti-HLA-DR antibody (# M0746, Dako, UK; dilution 1:100), c) mouse monoclonal anti-
CD163 primary antibody (# NCL-L-CD163, Leica Biosystems, UK; dilution 1:100) d) rabbit 
polyclonal anti-MPO primary antibody (# ab9535, Abcam, UK; dilution 1:50). All slides were 
dewaxed in xylene, rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium 
citrate buffer, pH 6, for 20 min, and allowed to cool, followed by one incubation at room temperature 
with the primary antibody. The signal was detected using EnVisionTM G/2 Doublestain System, 
Rabbit/Mouse (DAB+/Permanent Red) (# K536111-2, Dako, UK), and visualized with the Vector 
VIP peroxidase kit (# SH-600, Vector Laboratories, UK). The slides were then dehydrated with 
alcohol, cleared with xylene and cover slipped with DPX (Leica Biosystems, UK) after hematoxylin 
counterstaining. Images were captured with a Nikon Eclipse E600 microscope using the Nuance™ 
3.0.2 (PerkinElmer, UK) multispectral imaging technology. 
 
Double-epitope enzymatic immnohistochemistry for detection of MerTK/CD163 and MerTK/HLA-DR 
expressing cells. FFPE tissue was cut at 4 µm using a Leica RM2235 rotary microtome (Leica 
Biosystems, UK) and picked up on poly-L-lysine coated slides which were manually stained using a) 
rabbit monoclonal anti-MerTK primary antibody (# ab52968, Abcam, UK; dilution 1:300) and mouse 
monoclonal anti-CD163 primary antibody (# NCL-L-CD163, Leica Biosystems, UK; dilution 1:100), 
b) rabbit monoclonal anti-MerTK primary antibody (# ab52968, Abcam, UK; dilution 1:300) and 
mouse monoclonal anti-HLA-DR antibody (# M0746, Dako, UK; dilution 1:100). Slides were 
dewaxed in xylene, rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium 
citrate buffer, pH 6, for 20 min, and allowed to cool, followed by 1 MerTK incubation at room 
temperature with either the anti-HLA-DR or anti-CD163 antibody. The signal was detected using the 
EnVisionTM G/2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) (# K536111-2, Dako, 
UK), with Permanent Red for visualization. The slides were then incubated for 1 MerTK at room 
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temperature with the anti-MerTK antibody, and the second signal was detected using the same 
detection kit but with the Vector VIP peroxidase kit (# SH-600, Vector Laboratories, UK) for 
visualization. Slides were then dehydrated with alcohol, cleared with xylene and cover slipped with 
DPX (Leica Biosystems, UK) after hematoxylin counterstaining.  
 
MerTK/CD163 and MerTK/HLA-DR double epitope fluorescent immunostaining. FFPE tissue cut at 4 
µm using a Leica RM2235 rotary microtome (Leica Biosystems, UK) was picked up on poly-L-lysine 
coated slides which were manually stained using a) rabbit monoclonal anti-MerTK primary antibody 
(# ab52968, Abcam, UK; dilution 1:250) and a mouse monoclonal anti-CD163 antibody (# NCL-L-
CD163, Leica Biosystems, UK; dilution 1:100) or b) rabbit monoclonal anti-MerTK primary antibody 
(# ab52968, Abcam, UK; dilution 1:250) and a mouse monoclonal anti-HLA-DR antibody (# M0746, 
Dako, UK; dilution 1:100). Slides were dewaxed in xylene, rehydrated, subjected to heat-induced 
epitope retrieval (HIER) using sodium citrate buffer, pH 6, for 20 min, and allowed to cool, followed 
by 15 mins avidin and biotin blocking steps using an avidin/biotin blocking kit (# SP-2001, Vector 
Laboratories, US), and a 1h incubation with 3% skimmed milk in PBS. Slides were first incubated for 
MerTK at room temperature with the anti-MerTK antibody, followed by an incubation in the same 
conditions with a biotinylated goat-anti-rabbit secondary antibody (# E043201-8, Dako, UK; dilution 
1:200), and another incubation with Alexa Fluor 488-conjugated streptavidin (# S32354, Life 
Technologies, UK; dilution 1:200). The second primary antibody was then applied (1.5 MerTK at 
room temperature) followed by an incubation in the same conditions with an Alexa Fluor 594-
conjugated goat anti-mouse antibody (# A11032, Life Technologies, UK; dilution 1:200). All slides 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (# D1306, Life Technologies, UK), 
cover slipped using a fluorescence mounting medium (# S302380-2, Life Technologies, UK) and 
imaged using a Zeiss LSM800 confocal microscope (Zeiss, UK). 
 
Assessing MerTK/HLA-DR and MerTK/CD163 expression - multispectral imaging and confocal 
microscopy. Double-epitope enzymatic immunohistochemistry (MerTK/CD163, MerTK/HLA-DR, 
MPO/TUNEL) was used to assess co-localization. Distinguishing between red and purple and 
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unmixing these co-localized chromagens is not feasible with an RGB camera as it only uses 3 
channels, so a multispectral approach was used. Nuance camera takes several images over different 
wavelengths, thus identifying the ‘individual spectral signature’ of each chromagen, saving and 
unmixing it from adjacent colours. Once unmixed, images are re-coloured, enabling distinction of 
chromogens and inverting to a pseudo-fluorescence image. In addition, confocal examination of 
double epitope fluorescent immunostains was used to confirm MerTK/HLA-DR, MerTK/CD163 and 
MPO/TUNEL cells co-expression, to overcome a few obstacles such as the thickness of the 
histological sections which allowed for the overlapping of signals. 
 
2.2.8 Monocyte migration across hepatic endothelium  
 
Trans-endothelial migration of ALF and HC monocytes across stimulated hepatic endothelium were 
assessed using a recently established in vitro migration assay (Bernsmeier et al., 2015; Zimmermann 
et al., 2015). Collagen plugs were formed in cell culture inserts (Merck Millipore, Germany) placed in 
24-well plates (Corning, USA). Human hepatic sinusoidal endothelial cells (HSECs) (5×104) were 
added/grown on the plugs and then were stimulated with TNF-α and IFN-γ (both 10 ng/ml) (R&D 
Systems, UK) (37oC in 5% CO2). CD14-isolated monocytes (2x106) were added on top of the 
collagen matrix and after 1.5h incubation non-migrated monocytes were harvested. Sub-endothelial 
monocytes were recovered from the HSEC/collagen matrix after 24h, following incubation with 
collagenase solution. Monocyte phenotype was determined and cells (cells/µl) were quantified using 
Count Bright Absolute Counting Beads by flow cytometry (Life Technologies, UK). 
 
2.2.9 Efferocytosis, phagocytosis and oxidative burst 
 
Human neutrophils were isolated as described above (2.2.2) and were re-suspended at 106 cells/ml in 
complete medium, labeled with CellTracker Green CMFDA (Life Technologies, UK) (5 µM in 
serum-free medium, 45 min, dark) and incubated for 20h (37 ̊C in 5% CO2) in 24-well plates 
(Corning, USA). Annexin V kit (BD Biosciences, UK) was used to determine the percentage of 
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cultured neutrophils that are actively undergoing apoptosis which was over 70% apoptotic cells. Next, 
PBMCs from HC or ALF patients were re-suspended and co-incubated in 1:2 ratio for 4 hours with 
CMFDA-labeled apoptotic neutrophils and flow cytometry was used to quantify the percentage of 
CD14-labeled monocytes that phagocytosed apoptotic cells. In addition, neutrophil oxidative burst 
was assessed using the Phagoburst kit (Glycotrope, Germany) and monocyte phagocytosis of bacteria 
bioparticles using the pHRodo kit (ThermoFisher Scientific, UK) by flow cytometry, according to the 
manufacturer's instructions. 
 
2.2.10 Statistical analysis  
 
Analysis and graphing of data were performed using GraphPad Prism 6 software (GraphPad Software, 
La Jolla California, USA). Statistical significance was assessed with non-parametric analysis for data 
not normally distributed, unless otherwise specified in figure legends. Results are presented as median 





2.3.1. Patient characteristics 
 
No significant differences were detected in ages between acute liver failure (ALF) patients and 
healthy controls (HC). Patients with chronic liver disease (CLD) were significantly older compared to 
both ALF and HC groups [52 (44-65) vs 35 (28-45)/29 (26-45); p< 0.01] (Table 2.1). Patients with 
ALF showed significantly higher biochemical and physiological indices of liver injury including 
international normalized ratio (INR) and creatinine, bilirubin and AST levels, when compared to CLD 
patients (Table 2.1). 
 
2.3.2. Circulating monocytes exhibit a resolution-like MerTK+ phenotype in ALF  
 
 The immune-phenotype of circulating monocytes isolated from patients with CLD (n=10), ALF 
(n=15) and HC (n=15) was assessed using flow cytometry. Monocytes were identified following a 
previously established gating strategy (Abeles et al., 2012; Antoniades et al., 2014) based upon CD14, 
CD16 and HLA-DR expression (positive selection) (Fig. 2.1A). The expression levels of different 
surface markers were determined in the total monocyte population and the three monocyte subsets, 
that exist in human blood and liver: “classical” (CD14+CD16-), “intermediate” (CD14++CD16+) and 
“non-classical” (CD14lowCD16+) monocytes (Antoniades et al., 2014; Liaskou et al., 2013). 
 
The immune profiling revealed a significantly increased proportion of MerTK-expressing (MerTK+) 
circulating monocytes in ALF patients, compared to HC and CLD patients (48.3 vs 8.7/9.3 %, both p< 
0.0001) (Fig. 2.1B). Compared to classical and non-classical monocytes, MerTK expression in ALF 
was much higher in the intermediate subset (41.0/25.8 vs 70.9 %, both p< 0.01) (Fig. 2.1B) that is 
expanded in ALF (Abeles et al., 2012). Moreover, patients with AALF have a higher proportion of 
MerTK+ monocytes compared to non-acetaminophen induced ALF (NAALF) cases (51.5 vs 36.0 %; 
p< 0.01) (Table 2.2). Also, I found that monocyte MerTK expression in ALF patients correlated 
positively with SIRS score (r=0.6217; p=0.0004), INR (r=0.5523; p=0.0023) and negatively with 
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bilirubin (r=-0.4399; p=0.0192) and monocyte count (r=-0.4117; p=0.0295) (Fig. 2.1-C). In contrast 
with HC and CLD, I show that monocytes in ALF are characterized by a resolution-like (HLA-
DRlowCD163highTie-2high) phenotype with enhanced tissue homing (CCR2highCCR5highCCR7high) 
properties (Fig. 2.1D-E). These results confirm and extend recent findings in patients with 
acetaminophen-induced ALF (AALF) and acute-on-chronic liver failure (AoCLF) (Antoniades et al., 
2014; Bernsmeier et al., 2015).  
Functional in vitro analyses revealed that, compared to HC cells, monocytes isolated from ALF 
patients exhibit enhanced efferocytosis of CMFDA-labelled apoptotic neutrophils (42.4 vs 72.6 %; p< 
0.01) (Fig. 2.2A), and their MerTK expression strongly correlated with their efferocytosis index 
(r=0.78; p<0.01). Compared to HC, MerTKhigh monocytes in ALF secrete comparable (e.g. IL-10) or 
elevated levels (SLPI, 46 vs 278 pg/ml, p< 0.05) of anti-inflammatory mediators and reduced levels of 
pro-inflammatory mediators [IFN-γ (703 vs 4), p< 0.05; TNF-α (3110 vs 346), p< 0.0001; IL-6 (2.544 
vs 308), p< 0.001; all pg/ml] following microbial challenge (Fig. 2.2B-C). Furthermore, using flow 
cytometry based (CD14+) monocyte intracellular cytokine staining I reveal that compared to MerTK-, 
MerTK+ monocytes secrete significantly reduced TNF-α levels, with an inverse correlation between 
monocyte MerTK expression and TNF-α secretion (r=-0.57; p<0.05).  
It is also proposed that monocyte MerTK expression may be modulated through activation of cytokine 
receptors and their ligands (e.g. IL-10) (Lemke and Rothlin, 2008; Zizzo et al., 2012), thus the 
systemic inflammatory milieu is likely to induce MerTK expression in monocytes. In order to assess 
those effects on monocyte phenotype, I conditioned healthy monocytes in plasma derived from ALF 
patients and HC (Fig. 2.2D). Compared to monocytes cultured in HC plasma, I found that monocyte 
culture in ALF plasma induced the distinct HLA-DRlowCD163highTie-2high immune-phenotype (Fig. 
2.2D) with increased tissue/lymph-node homing (CCR2highCCR5+CCR7high) marker expression, 




Table 2-1. Clinical and physiological characteristics of patients with ALF in comparison to CLD 





Abbreviations: INR: international normalized ratio; AST: aspartate aminotransferase; MELD: Model for End stage Liver 
Disease; SOFA: sequential organ failure assessment; WCC: white (leukocyte) cell count; ALD: alcoholic liver disease; 
NAFLD: non-alcoholic fatty liver disease; HFE: haemochromatosis; PSC: primary sclerosing cholangitis; PBC: primary 
biliary cholangitis. *p=0.006; **p=0.001; ***p<0.0001, compared to CLD group. 
 
 
Parameter ALF CLD HC 
Number of 
patients 







Sex (M/F) 15:17 6:4 6:9 
Aetiology Drug-induced:  
Acetaminophen [23] 




Hepatitis B [1] 



































































Figure 2.1. Phenotypic characterization of resolution-like MerTK+ monocytes in ALF. 
Circulating monocytes were isolated from ALF (n=15), CLD (n=10) patients and HC (n=15) and were phenotypically 
characterized using flow cytometry. (A) Representative flow cytometry analysis and gating strategy used to determine 
MerTK expression in total circulating monocytes and their subsets [classical (CD14+CD16-), intermediate (CD14++CD16+) 
and non-classical (CD14lowCD16+)]. (B) Data show monocyte MerTK expression levels in different study groups. (C) 
Correlations of monocyte MerTK expression with different clinical parameters of ALF patients. Data show the percentage of 
surface expression of (D) activation (HLA-DR), pro-resolution (CD163), pro-angiogenesis (Tie-2) and (E) tissue 
(CCR2/CCR5) and lymph-node (CCR7) homing markers in monocyte subsets in all study groups. Non-parametric (Mann-
Whitney) statistical analysis was used. Data presented as median values with interquartile range (IQR). * p< .05, ** p< 0.01, 
*** p< .001, **** p< .0001. SSC: side scatter, FSC: forward scatter. 
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Table 2-2. Clinical and physiological parameters of acetaminophen-induced ALF (AALF) and 





































Abbreviations: INR: international normalized ratio; AST: aspartate aminotransferase; MELD: Model for End stage Liver 
Disease; WCC: white (leucocyte) cell count; APACHE II: acute physiology and chronic health evaluation II score; SOFA: 
Sequential organ failure assessment score; SIRS: systemic inflammatory response syndrome. * p<0.05 and ** p<0.01, 
compared to NAALF group 
  
Parameter AALF NAALF 
Number of patients 23 9 
#patients transplanted/died 8/23 4/9 







































































Figure 2.2. Functional characterization of monocytes and effects of the systemic inflammatory 
microenvironment in ALF. 
PBMCs from healthy controls (HC) and ALF patients were co-cultured (4h) with CMFDA-labeled apoptotic neutrophils. (A) 
Representative flow cytometry analysis and data showing the percentage (%) of CMFDA-labeled neutrophils that were 
phagocytosed by CD14+ monocytes (n=5 each). (B) Data show the proportion of MerTK+ vs MerTK- monocytes that 
phagocytosed CMFDA-labeled neutrophils and that were stained positive for intracellular TNF-α following microbial 
challenge (LPS 100ng/ml, 6h). (C) Inflammatory cytokine secretion in HC and ALF PBMC supernatants (n=5 each) after 
microbial challenge (LPS 100ng/ml, 6h), as determined by ELISA. (D) Healthy CD14-isolated monocytes were cultured in 
medium containing (25%) plasma from ALF patients compared with HC (n=10 each) for 48 hours. Data show the 
percentage of surface expression of activation (HLA-DR), pro-resolution (MerTK/CD163), pro-angiogenesis (Tie-2) and 
tissue (CCR2/CCR5) and lymph-node (CCR7) homing markers, after conditioning monocytes in different plasma, as was 
assessed by flow cytometry. Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed as median 





2.3.3. Gene expression profile of MerTK+ monocytes in ALF 
 
To fully characterize the MerTK+ population in ALF, I performed FACS-sorting of MerTK± 
monocytes from HC and ALF patients (Fig. 2.3A) and subjected these cells to a quantitative gene 
expression array. Compared to MerTK-, MerTK+ monocytes at steady state (Fig. 2.3B-C), and in 
ALF patients (Fig. 2.4A-B), have a transcriptional profile consistent with a more differentiated 
“tissue-like” phenotype, characterized by a significant up-regulation of genes responsible for adhesion 
(e.g. ICAM2, ITGA4, ITGB1), phagocytosis/pattern-recognition (FCGR2A/C, FCGR3A/B, MSR1, 
C1q), cell proliferation/survival (e.g C81, LAIR1, SRC), antigen presentation (HLA-DPA1, HLA-
DPB1, HLA-DRA) and macrophage M2-like polarization (LGALS3, MARCO, MRC1, CMKLR1, 
CSF1R) (Fig. 2.3B-C and 2.4A-B). 
 
Comparison of the transcriptional profile between MerTK+ monocytes in ALF patients and HC (Fig. 
2.5A-B) revealed striking differences in line with the phenotypic and functional readouts (Fig. 2.1A-E 
and 2.2A-D). MerTK+ monocytes in ALF exhibit a marked reduction in a number of regulatory 
pathways, notably in antigen processing MHC class II associated transcripts (HLA-DMA, HLA-
DPA1, HLA-DPB1, HLA-DRA), TLR/NF-kB-dependent pro-inflammatory pathway (NFKBIA, 
NFKBIZ, TICAM1, TLR4, TLR8), phagocytosis/pattern-recognition (FCGR2A/C, FCGR3A/B) and 
cytokines/chemokines (CCL5, PTGS2, TNF) (Fig. 2.5A-B). Moreover, these cells maintain an M2-
like skewed profile (e.g. CD163, MARCO, MRC1), activation of the downstream MerTK/cytokine 
signaling pathway (IRF3, JAK3) with a concomitant down-regulation in genes linked with cell 







Figure 2.3. Gene expression pattern of MerTK+ versus MerTK- monocytes in healthy controls. 
MerTK+ and MerTK- monocytes were FACS-sorted in HC and ALF patients (n=3 each) with a gating strategy displayed by 
representative flow cytometry plots in (A). Highly pure isolates of the MerTK± subsets were subjected to quantitative 
microarray gene expression analysis (nCounter® GX Human Immunology V2 kit, profiling 594 immunology-related human 
genes; NanoString Technologies, Inc., Seattle, WA). (B-C) Data show the Log2 fold-change of expression and 
agglomerative cluster (heatmap, z-Score; green=min/red=max magnitude of expression) of differentially expressed genes, 





Figure 2.4. Gene expression pattern of MerTK+ versus MerTK- monocytes in ALF. 
MerTK+ and MerTK- monocytes were FACS-sorted in HC and ALF patients (n=3 each). Highly pure isolates of the 
MerTK± subsets were subjected to quantitative microarray gene expression analysis (nCounter® GX Human Immunology 
V2 kit, profiling 594 immunology-related human genes; NanoString Technologies, Inc., Seattle, WA). (A-B) Data show the 
Log2 fold-change of expression and agglomerative cluster (heatmap, z-Score; green=min/red=max magnitude of expression) 






Figure 2.5. Gene expression pattern of MerTK+ monocytes in ALF versus healthy controls.  
MerTK+ and MerTK- monocytes were FACS-sorted in HC and ALF patients (n=3 each). Highly pure isolates of the 
MerTK± subsets were subjected to quantitative microarray gene expression analysis (nCounter® GX Human Immunology 
V2 kit, profiling 594 immunology-related human genes; NanoString Technologies, Inc., Seattle, WA). (A-B) Data show the 
Log2 fold-change of expression and agglomerative cluster (heatmap, z-Score; green=min/red=max magnitude of expression) 





2.3.4. Characterization of MerTK+HLA-DRhigh and MerTK+HLA-DRlow subsets 
 
Using flow cytometry, I further characterized the MerTK+ circulating monocytes based upon their 
HLA-DR expression levels (Fig. 2.6A). Interestingly, the analyses identified key differences in the 
functional profile of these cells. Importantly, peak levels of MerTK+HLA-DRhigh cells are detected on 
patients’ admission to the Liver Intensive Care Unit and subsequently decline to levels (33.6 vs 17.5 
%; p<0.05) similar to HC by day 3-5 (Fig. 2.6B). In contrast to HC and CLD groups, MerTK+HLA-
DRlow cells are detected and significantly elevated in the circulation of ALF patients (1.3/0.5 vs 11.3 
%; both p< 0.001), and remain persistently elevated following their admission (Fig. 2.6B).  
I demonstrate that compared to HC and MerTK+HLA-DRlow cells, MerTK+HLA-DRhigh monocytes in 
ALF exhibit enhanced clearance of apoptotic (CMFDA+ Annexin-Vhigh neutrophils) and infective 
(pHrodoâ E. coli BioParticles) material, with attenuated secretion of pro-inflammatory (e.g. TNF-α) 
mediators following microbial challenge (Fig. 2.6C). Compared to HC and CLD, both MerTK+HLA-
DRlow and MerTK+HLA-DRhigh cells in ALF have a CD163highTie-2highCCR2highCCR5highCCR7high 
phenotype (Fig. 2.6D). Taken together, I identify that circulating monocytes in ALF patients exhibit a 
prorestorative phenotype, characterized by suppressed innate immune responses and enhanced 
efferocytic and phagocytic capabilities (Antoniades et al., 2006; Antoniades et al., 2012; Bernsmeier 
et al., 2015). 
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Figure 2.6. Functional characterization of MerTK+HLA-DRhigh and MerTK+HLA-DRlow 
monocyte subsets in ALF. 
Circulating monocytes were isolated from ALF (n=15), CLD (n=10) patients and HC (n=15) and were phenotypically 
characterized using flow cytometry. (A) Representative flow cytometry analysis and gating strategy used to identify 
MerTK+HLA-DRhigh and MerTK+HLA-DRlow monocyte subsets. (B) MerTK+HLA-DRhigh and MerTK+HLA-DRlow subsets 
as proportion (%) of total circulating monocytes in HC, CLD and ALF patients on admission (n=15) and days 3-5 following 
their admission (n=8). (C) Proportion of MerTK+HLA-DRhigh and MerTK+HLA-DRlow monocytes that efferocytosed 
apoptotic neutrophils, phagocytosed E. coli bioparticles and intracellularly produced TNF-α after microbial challenge in HC 
and ALF (n=5 each). (D) Representative histograms and expression levels (%) of different monocyte surface markers in 
MerTK+HLA-DRhigh and MerTK+HLA-DRlow subsets in all study groups. Non-parametric (Mann-Whitney) statistical 
analysis was used. Data presented as median values with interquartile range (IQR). * p< .05, ** p< 0.01, *** p< .001, SSC: 




2.3.5. MerTK+ monocytes readily migrate across hepatic endothelium in ALF 
 
During steady state and inflammation, circulating monocytes migrate into tissue compartments, where 
they differentiate into macrophages and promote anti-microbial responses (Gordon and Taylor, 2005), 
and may subsequently home either to regional lymph nodes or return to the circulatory pool (Gray and 
Cyster, 2012; Kastenmuller et al., 2012). In addition, human and experimental studies in ALF show 
that the hepatic macrophage pool is expanded not only due to the proliferation of the resident KCs but 
also through chemokine-recruited monocytes that give rise to MoMFs (Antoniades et al., 2012; Choi 
et al., 2015a; Dambach et al., 2002; Zigmond et al., 2014).  
 
Given the evidence above showing that ALF monocytes (Fig. 2.1E), as also shown for the MerTK+ 
subset (Fig. 2.6D), highly express tissue (CCR2/CCR5) and lymph node (CCR7) homing receptors, I 
sought to evaluate their migratory characteristics across cytokine-stimulated hepatic endothelium 
(Fig. 2.7). I employed a novel in vitro migration model (Bernsmeier et al., 2015; Zimmermann et al., 
2015) where using flow cytometry I assessed the immune-phenotype and kinetics of non-migrated 
cells, cells entering the sub-endothelial space and cells reverse-migrating back across the endothelial 
monolayer (Fig. 2.7A). Reverse migration is a pivotal in vivo process that allows the passage of 
immune cells out of tissue sites, trafficking either to regional lymph nodes to elicit immune responses, 
or to re-join the circulatory pool (Gray and Cyster, 2012; Kastenmuller et al., 2012). 
 
The immune profiling of monocytes in ALF showed they were characterized, in all migratory 
compartments, by the typical MerTKhighCD163high phenotype (Fig. 2.7A), as observed ex vivo in 
patients (Fig. 2.1B-E). Both HC and ALF monocytes preserved their tissue and lymph-node homing 
marker repertoire (CCR2+CCR5+CCR7+) (Fig. 2.7A). Using flow cytometry based cell-counting 
beads, I detected no differences between HC and ALF in the number of total (CD14+) cells migrating 
across the endothelium (Fig. 2.7B). However, compared to HC cells, I found a significantly lower 
number of sub-endothelial monocytes (75 vs 47 cells/ul; p<0.001) and increased number of reverse 
migrated monocytes in ALF (9 vs 18 cells/ul; p<0.001) (Fig. 2.7B). Furthermore, analysis of (CD14+) 
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monocytes based upon their MerTK expression revealed that whilst the number of MerTK+ cells 
entering into the sub-endothelial compartment was similar between study groups, a significantly 
higher proportion of MerTK+ cells underwent reverse migration in ALF (4 vs 16 cells/ul; p<0.01) 
(Fig. 2.7C). These findings support the hypothesis that in ALF there is an increased proportion of 
MerTK+ monocytes undergoing trans-endothelial migration from the circulatory compartment and 
home to sites of acute liver injury.  
 
 
2.3.6. Liver-derived hepatic macrophages exhibit a resolution-like phenotype in ALF 
 
Using flow cytometry, I assessed the phenotype of liver-derived hepatic macrophages, freshly isolated 
from explant tissue of patients with ALF (n=8), CLD (n=10) and normal liver (NL, n=6) tissue 
extracted from hepatic resections (Fig. 2.8). Compared to the NL and CLD study groups, I report a 
significantly increased frequency of CD14++CD16+ hepatic macrophages in the liver of ALF patients 
(34.6/39.6 vs 44.7 %; p< 0.05) with a reciprocal reduction in the CD14+CD16- subset (63.1/57.6 vs 
50.9 %; p< 0.05) (Fig. 2.8A-B). These findings are in accordance with previous studies showing  an 
expansion of the CD14++CD16+ monocyte subset in the circulation of ALF patients (Abeles et al., 
2012) and in the inflamed human liver (Liaskou et al., 2013). The phenotypic analysis revealed that 
liver-derived macrophages in ALF exhibit a resolution-like (MerTKhighCD163highTie-2highHLA-DRlow) 
phenotype, having augmented tissue/lymph-node homing (CCR2+CCR5highCCR7high) characteristics, 
that was different from macrophages isolated from CLD and NL specimens (Fig. 2.8C-D). This 
macrophage phenotype is similar to that described in circulatory (Fig. 2.1D-E) and sub-endothelial 





Figure 2.7. Migratory characteristics of circulating monocytes in ALF. 
Trans-endothelial migration of ALF (n=12) and HC (n=6) monocytes across hepatic endothelium was determined in vitro 
(n=3). (A) Schematic describing the assay: CD14-isolated monocytes are added on top of a cytokine stimulated (TNF-α/IFN-
γ) hepatic endothelium monolayer; non-migrated monocytes are harvested 1.5 hours after while sub-endothelial and reverse-
migrated monocytes are obtained 24h later. Data show expression levels (percentage, %) of pro-resolution (MerTK, CD163), 
activation (HLA-DR), tissue (CCR2/CCR5) and lymph-node (CCR7) homing markers of (left panel) non-migrated, (middle 
panel) sub-endothelial and reverse migrated (right panel) monocytes, as dtermined by flow cytometry. (B) Data show the 
number of monocytes (cells/ul), determined using flow cytometry based cell counting beads, that did not migrate, migrated 
sub-endothelially migrated and reverse migrated on top of the monolayer. Results are shown for total CD14+ monocytes and 
monocyte subsets. (C) Data show the number of MerTK+ monocytes (cells/ul) at different migratory compartments. Non-
parametric (Mann-Whitney) statistical analysis was used. Data are expressed as median values with interquartile range 




Figure 2.8. Phenotypic characterization of liver-derived hepatic macrophages in ALF 
Hepatic macrophages were freshly isolated from human explant liver tissue of ALF (n=8), CLD (n=10) patients and normal 
liver (NL, n=6) from hepatic resections and were phenotypically characterized using flow cytometry. (A) Representative 
flow cytometry analysis and gating strategy used to identify macrophages and their subsets [classical (CD14+CD16-), 
intermediate (CD14++CD16+) and non-classical (CD14lowCD16+)]. (B) Data show the proportion (%) of macrophage 
subsets (classical, intermediate and non-classical) in different study groups. (C-D) Data show the percentage (%) of surface 
expression of MerTK and activation (HLA-DR), pro-resolution (CD163), pro-angiogenesis (Tie-2), tissue (CCR2/CCR5) 
and lymph-node (CCR7) homing markers of different macrophage subsets in all study groups. Non-parametric (Mann-
Whitney) statistical analysis was used. Data presented as median values with interquartile range (IQR). * p< .05, ** p< 0.01, 
*** p< .001, **** p< .0001. SSC: side scatter, FSC: forward scatter. 
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2.3.7. MerTK+ hepatic macrophages localize in areas of necrosis in the ALF liver 
 
Having demonstrated an increased proportion of MerTK+ monocytes/macrophages in ALF patients, I 
used immunohistochemistry, multispectral and confocal imaging in order to delineate the topography 
and phenotype of these cells in human explant liver tissue, in ALF and pathological controls (PC) 
(Fig. 2.9). Compared to the non-acutely inflamed PC liver tissue, I confirm a numerical increase of 
MerTK+ intrahepatic cells, of monocyte/macrophage lineage (CD163+), that localize in areas of 
centrilobular necrosis in ALF (7 vs 35 cells/HPF; p<.0.0001) (Fig. 2.9A-B), in keeping with the data 
on freshly liver-derived hepatic macrophages (Fig. 2.8C). Also, the proportion of MerTK+ cells that 
were derived from infiltrating monocytes (Antoniades et al., 2012), MAC387+MerTK+, was less than 
39% in PC liver tissue and similar to circulation-derived cells examined in ALF liver (Fig. 2.10A). 
 
Similar to other models of sterile acute liver injury (Dal-Secco et al., 2015; Mori et al., 2009), I 
demonstrate that hepatic macrophages in ALF form ring-like structures around areas of necrosis (Fig. 
2.9A). I detected that macrophages populating the outer rim of necrosis show a distinct MerTK+HLA-
DRhigh expression profile that resembles the avidly phagocytic subset described ex vivo in ALF 
patients (Fig. 2.6C) whereas cells located in more central and perivenular areas are predominately 
MerTK+HLA-DRlow (Fig. 2.9A-B). Enumeration of MerTK+ cells based upon their HLA-DR 
expression levels, revealed a significant increase in both MerTK+HLA-DR+ and MerTK+HLA-DR- 
subsets in ALF patients, compared to PC liver tissue (Fig. 2.9B). These data are in consistency with 
the extensively characterized MerTKhighCD163highHLA-DRlow phenotype described ex vivo in ALF 








Figure 2.9. Resolution-like MerTK+ hepatic macrophages are expanded in the liver of ALF 
patients. 
(A) Representative confocal images for MerTK (green), CD163 (red), HLA-DR (red), DAPI (blue) and co-localization 
(yellow) in pathological control (PC, n=4) and ALF (n=6) human liver tissue (100X, inset 200X). (B) Representative 
immunohistochemistry (IHC) images and data showing enumeration of MerTK+, MerTK+HLA-DR± and CD163+MerTK+ 
cells [positive cells per 5 high-power-field (HPF)] in centrilobular areas of PC and ALF liver tissue, using IHC and 
multispectral image analysis. RGB images (200X) show MerTK+ (purple), HLA-DR+/CD163+ (red) cells and 
pseudofluorescent images show MerTK+ (green), HLA-DR+/CD163+ (red) and co-localization (yellow). Non-parametric 
(Mann-Whitney) statistical analysis was used. Data are expressed as median values with interquartile range (IQR). * p< .05, 





2.3.8. MerTK+ macrophages are detected in regional lymph-node tissue of ALF patients 
 
During steady state conditions and inflammation, monocytes migrate into tissue compartments and 
may subsequently home either to regional lymph nodes or return to the circulatory pool, as discussed 
above (Gray and Cyster, 2012; Kastenmuller et al., 2012). Based on my findings that the expanded 
MerTK+ monocytes/macrophages in ALF a) have an enhanced ability to cycle in and out of tissue 
sites (Fig. 2.7) and b) express high levels of the lymph node (LN) homing receptor CCR7 (Fig. 2.1-E; 
2.6D; 2.8D), I used multispectral and confocal imaging in order to detect these cells in LN tissue 
derived from ALF patients (Fig. 2.10A-B).  
 
My results detected a marked expansion, compared to PC, in the number of MerTK+ cells populating 
sub-capsular sinus and medullary cord areas of peri-portal lymph node tissue derived from ALF 
patients (68 vs 102 cells/HPF; p<0.001) (Fig. 2.10A-B). These cells were of monocyte/macrophage 
lineage (CD163+), with a significant proportion co-expressing the newly-infiltrating monocyte-
derived macrophage marker (MAC387) (Fig. 2.10A) (Antoniades et al., 2012), as described in explant 
liver tissue (Fig. 2.9A-B). Compared to PC LN tissue, enumeration of MerTK+ HLA-DR-expressing 
cells revealed decreased numbers of MerTK+HLA-DR+ cells (57 vs 13 cells/HPF; p<0.0001) and 
increased numbers of MerTK+HLA-DR- cells (80 vs 12 cells/HPF; p<0.001) in ALF LN tissue (Fig. 
2.10B). These data support the concept that enhanced tropism of liver and circulation derived 
MerTK+ cells to regional LN in ALF, may account for the expanded MerTK+HLA-DRlow subset, 
characterized by reduced anti-microbial and efferocytic/phagocytic responses (Fig. 2.6C), within the 







Figure 2.10. Resolution-like MerTK+ macrophages are expanded in the liver and mesenteric 
lymph nodes of ALF patients. 
 (A) Representative IHC images and data showing enumeration of MAC387+MerTK+ cells [positive cells per 5 high-power-
field (HPF)] and proportion of MAC387+ within the total MerTK+ population in PC (n=4/4) and ALF (n=6/4) explant liver 
(upper panel) and lymph node (lower panel) tissue, using IHC and multispectral image analysis. RGB images (200X) show 
MerTK+ (purple) and MAC387+ (red) cells and pseudofluorescent images show MerTK+ (green), MAC387+ (red) and co-
localization (yellow). (B) Data show representative IHC images and enumeration of MerTK+, MerTK+HLA-DR±, and 
CD163+MerTK+ cells in mesenteric lymph node tissue from PC (left, n=4) and ALF (right, n=4) patients. For both groups: 
(left panel) RGB images (100X) showing MerTK+ (purple) and HLA-DR+/CD163+ (red) cells. (right panel) 
pseudofluorescent images (100X) show MerTK+ (green), HLA-DR+/CD163+ (red) cells and their co-localization (yellow). 
Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed as median values with interquartile range 






In this chapter, I identify an expansion of MerTK-expressing (MerTK+) monocytes and macrophages, 
characterized by resolution-like properties, that are detected in circulatory, hepatic and lymphatic 
compartments of patients with acetaminophen-induced ALF (AALF). The biological significance of 
this immune-regulatory subset is highlighted through its strong correlations with physiological and 
biochemical indices of hepatic injury and with the magnitude of SIRS response. Phenotypic analyses 
of monocytes and liver-derived macrophages revealed that both have a MerTKhighCD163highTie-
2highHLA-DRlow phenotype with augmented tissue/lymph-node homing (CCR2highCCR5highCCR7high) 
characteristics, results that extend previous work in the field (Antoniades et al., 2006; Antoniades et 
al., 2014; Antoniades et al., 2012; Bernsmeier et al., 2015).  
 
These findings are in line with a recent study in patients with acute-on-chronic liver failure (AoCLF), 
a form of liver failure that develops in cirrhotic, chronic liver disease, patients (Bernsmeier et al., 
2015). Similarly to ALF, patients with AoCLF exhibit monocyte dysfunction, attenuated pro-
inflammatory cytokine secretion following microbial challenge and a MerTKhighCD163highHLA-DRlow 
anti-inflammatory monocyte phenotype, echoing the one observed in ALF (Antoniades et al., 2014; 
Antoniades et al., 2012). This work also described an expanded MerTK+ monocyte/macrophage 
population in circulatory and tissue compartments and proposed that it contributes to the pathogenesis 
of AoCLF (Bernsmeier et al., 2015). 
 
My data demonstrate marked elevations in the proportion of MerTK+ monocytes in patients with 
AALF and non-acetaminophen-induced ALF (NAALF). In particular, the highest MerTK levels are 
detected in AALF, a clinical syndrome characterized by greater severity of acute liver injury and 
higher degree of hepatic regenerative capability, compared to NAALF cases (Antoniades et al., 2012). 
Furthermore, peak circulating MerTK levels are detected on admission to the liver unit, which may 
reflect the extent of hepatic tissue resolution responses following acute hepatocellular necrosis. Future 
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prospective studies are warranted to assess the utility of MerTK monocyte levels as a mechanistic 
biomarker of resolution responses and outcome in patients with acute liver injury.  
 
In line with other models of acute tissue injury (Bernsmeier et al., 2015; Choi et al., 2013; Lee et al., 
2012c; Wan et al., 2013), functional characterization of MerTK+ monocytes reveals that they possess 
suppressed innate immune responses to microbial challenge (e.g. TNF-α) but enhanced resolution 
responses, typified by augmented clearance of cellular/infective material and secretion of anti-
inflammatory/tissue-repair mediators (e.g. SLPI) (Antoniades et al., 2006; Antoniades et al., 2012; 
Bernsmeier et al., 2015). Comparison of the gene expression profiles between MerTK+ and MerTK- 
cells in steady state and ALF reveal that MerTK+ monocytes have a more differentiated lineage 
“tissue-like” profile, with increased expression of a number of genes associated with innate and 
adaptive effector functions. Furthermore, a novel finding in ALF is the identification of two MerTK+ 
subsets with differential HLA-DR expression that are phenotypically similar but functionally distinct. 
Compared to MerTK+HLA-DRlow cells, MerTK+HLA-DRhigh monocytes are characterized by higher 
phagocytic and efferocytic capabilities, with peak circulating levels detected on patients’ admission, 
whereas MerTK+HLA-DRlow cells remain persistently elevated following their admission. 
 
Although murine experimental models of acute liver injury provided little evidence that the influx of 
circulation-derived myeloid cells to areas of necrosis triggers resolution responses (Dambach et al., 
2002; Holt et al., 2008; Zigmond et al., 2014), supportive data from human studies is limited and yet 
remains largely observational (Antoniades et al., 2014; Antoniades et al., 2012). Here, I provide novel 
insights into the migratory characteristics of circulating monocytes in ALF. First, I show that a 
significantly high proportion of MerTK+ monocytes and liver-derived hepatic macrophages express 
tissue (CCR2, CCR5) and lymph-node (CCR7) homing receptors, suggesting they are fully equipped 
to migrate into tissue compartments. Second, I provide in vitro evidence supporting the hypothesis 
that monocytes in ALF have enhanced trans-endothelial migration capabilities. Particularly, I describe 
that MerTK+ monocytes efficiently migrate across the hepatic endothelium and subsequently reverse 
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migrate out of it, bearing the characteristic MerTKhighCD163high, results in agreement with the recent 
findings in AoCLF patients (Bernsmeier et al., 2015). 
 
Furthermore, I reveal that MerTK+ macrophages are significantly expanded and detected within areas 
of hepatocellular necrosis in human explant liver tissue of ALF patients. These cells form ring-like 
structures around the areas of injured liver parenchyma with MerTK+HLA-DRhigh located in the outer 
rim of necrosis whereas cells in more central and perivenular areas are predominately MerTK+HLA-
DRlow. Of note, these results bear striking similarities with other experimental models of sterile liver 
injury where the in situ reprogramming of monocytes is demonstrated (Dal-Secco et al., 2015; Mori et 
al., 2009). In particular, the transition of recruited monocytes from outer sites of injured areas towards 
their center is accompanied by a phenotypic and functional conversion, that is essential to facilitate 
tissue-repair and wound healing processes (Dal-Secco et al., 2015; Mori et al., 2009). Taken together, 
I demonstrate in human ALF a preferential recruitment of monocytes, with resolution-like properties, 
from the circulatory pool to the inflamed liver. 
 
During steady-state or inflammation, monocytes not only migrate into tissues and differentiate into 
macrophages, but also recirculate out of them homing either to regional lymph nodes or returning 
back to the systemic circulation (Bellingan et al., 1996; Jakubzick et al., 2013). Of note, lymph-node 
macrophages serve to filter other tissue and lymph borne pathogens, thus to prevent their systemic 
translocation and prime innate and adaptive immune responses.(Gray and Cyster, 2012; Kastenmuller 
et al., 2012). My findings that MerTK+ monocytes/macrophages are characterized ex vivo in ALF by 
increased expression of the lymph-node homing receptor (CCR7) and have an enhanced ability to 
migrate across hepatic endothelium in vitro, may explain why I detected an expansion of circulation-
derived MerTK+ cells in both sub-capsular sinus and medullary cord (extrafollicular) areas in the 
peri-portal mesenteric lymph node from patients with ALF. These data propose that a dynamic 
circulatory pathway exists, in which MerTK+ cells equipped with enhanced migratory abilities, home 
from the injured liver to draining regional lymph nodes and/or back into the systemic circulation in 
ALF (Antoniades et al., 2012; von Andrian and Mempel, 2003; Zigmond et al., 2014). Importantly, 
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the consequences are likely to be systemic immune suppression and anti-inflammatory responses.  
Whereas this may help to suppress ongoing systemic inflammation, it will also contribute to the 
observed immuneparesis and susceptibility to infection in these patients, which is such a devastating 
complication of ALF. 
 
Recent work from others, using the same in vitro model, indicate that migration of monocytes across 
hepatic endothelium is a critical process in shaping their phenotype, function and their subsequent fate 
(Zimmermann et al., 2015). However, I fully recognize the limitations of this assay. I acknowledge 
that future work is needed in order to assess the migratory characteristics of ALF monocytes in vivo. 
That could be done using the murine model of APAP-induced ALF and other experimental techniques 
such as live cell imaging by intravital non-invasive microscopy. Furthermore, fluorescent molecular 
tomography (FMT) could be employed in order to examine the fate of MerTK+ monocytes in vivo 
during the different phases of APAP-induced acute liver injury, thus allowing to draw more definitive 
conclusions about the above “re-circulation” hypothesis. Another experiment would be to adoptively 
transfer MerTK-labelled hepatic macrophages, obtained by flow cytometry based sorting from murine 
liver tissue at the different phases of APAP-induced acute liver injury, and use the FMT technology to 
track their fate. 
 
Here, I also detect expanded numbers of MerTK+HLA-DRlow cells, in both circulatory and tissue 
compartments, a subset with impaired both phagocytic and innate immune responses to microbial 
challenge, during the evolution of human ALF. Given their enhanced lymph-node and tissue homing 
receptor expression, it is tempting to speculate that these cells are generated following reprogramming 
within the inflamed liver and subsequently home to extra-hepatic and circulatory compartments where 
they serve to suppress antimicrobial responses (Kastenmuller et al., 2012). Further work is required to 
delineate the recruitment and subsequent fate of these MerTK+ myeloid cells during acute liver 
injury.   
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To date, the majority of clinical and experimental studies in ALF have focused in drug-induced acute 
liver injury, in particular AALF, with therapeutic strategies not necessarily being applicable to other 
cases of ALF. This may be explained by the distinct mechanisms underlying the pathophysiology of 
liver injury which vary according to the different etiologies of ALF (Tuncer et al., 2013; Wu et al., 
2010). In this study, most of the phenotypic and functional analyses in monocytes/macrophages were 
performed using samples derived from AALF patients. However, the function and role of these cells 
may differ in other causes of ALF, for example in SALF, an increasingly well-recognized type of 
ALF with yet unknown etiology (Bernal et al., 2010; Bernal et al., 2013).  
 
SALF is proposed to be caused by a dysregulated immune response to an unidentified hepatotropic or 
environmental trigger (Donaghy et al., 2013) while it is associated with a lymphocytic infiltrate of 
effector T cells, NK cells and B cells, suggesting that this drives immune-mediated damage cytotoxic 
to hepatocytes which culminates in liver necrosis and failure (Tuncer et al., 2013; Wu et al., 2010). I 
provide recent evidence that SALF is a Th1-cell driven disease, characterized by a macrophage/Th1-
lymphocytic rich infiltrate, a profound elevation in circulating and hepatic levels of macrophage and 
lymphocyte activation markers (Triantafyllou et al., 2014), as it will be discussed below in the present 
thesis. These histological features and the detection of circulating autoantibodies in SALF are also 
suggestive of an autoimmune-mediated disorder (Stravitz et al., 2011). Of note, MerTK is crucial for 
the effective clearance of apoptotic immune cells, thus it has also been implicated in autoimmune 
disease such as systemic lupus erythematosus and multiple sclerosis (Mukherjee et al., 2016). 
 
Taken together, further work should expand the findings of the present study and investigate the role 
and function of this prorestorative, MerTK+, monocyte/macrophage subset in SALF or other ALF 
causes. It would be also interesting to explore this signaling pathway in patients with autoimmune 
hepatitis who are characterized by impaired immune-regulation and excessive liver inflammation and 
immune-mediated damage. Future studies, using human and experimental models, could assess the 
utility of MerTK as an immune-therapeutic target in a variety of hepatic disorders, aimed to quell 



































3. CHARACTERIZATION OF HEPATIC MACROPHAGES IN 
MICE WITH ACETAMINOPHEN-INDUCED ACUTE LIVER INJURY 
 
3.1 Background and aims 
 
MerTK is predominantly by monocytes/macrophages and following acute tissue injury it suppresses 
innate immune responses and by specifically recognizing the exposed phosphatidylserine on apoptotic 
cells it mediates clearance of apoptotic cells and debris (Rothlin et al., 2015; Zagorska et al., 2014). 
Experimental studies using models of sterile and pathogen-induced inflammation (e.g. endotoxemia & 
bleomycin-induced lung injury) show that MerTK loss results in exaggerated immune activation and 
ineffective resolution, thus leading to excessive inflammatory tissue damage (Camenisch et al., 1999; 
Lee et al., 2012b; Mukherjee et al., 2016). However, the impact of MerTK on the resolution of hepatic 
inflammation following acute liver injury is not yet explored.  
 
Hypothesis and aims: 
Given my previous human data in ALF (Chapter 2), showing a significant expansion of MerTK+ 
monocytes and tissue macrophages with resolution-like features, I hypothesized that this MerTK+ 
macrophage subset may also evolve during the time-course of APAP-induced acute liver injury in 
mice and that is of significant biological relevance for the resolution of acute hepatic inflammation. 
Hence, in this chapter I aimed to: 
§ Examine the phenotypic profile of hepatic macrophages isolated from WT mice, following 
APAP-induced acute liver injury, and determine the MerTK expression of the two distinct 
(MoMF vs KC) macrophage populations.  
§ Investigate the biological relevance of MerTK+ macrophages during acute liver injury, by 
using APAP-treated WT and Mer-deficient (Mer−/−) mice and assessing the hepatic myeloid 
cell infiltrate and biochemical/histological indices of liver injury. 
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3.2 Materials and methods 
 
3.2.1 Animal treatments and sample collection 
 
 
All animal experiments were conducted in accordance with the UK laws and with approval of the 
Home Office and local ethics committees (PPL 70/7578). B6.129-MerTKtm1Gr1/J (Mer−/−) and wild-
type (WT) mice with an identical background (B6.129SF2/J) were obtained from The Jackson 
Laboratory. Mer−/− and WT mice were age/sex matched (male, 8-10 week-old) for all experiments. 
Mice were fasted overnight, received an intraperitoneal (i.p.) injection of APAP (300 mg/kg, Sigma-
Aldrich, UK) or saline (baseline mice) and were studied at 8, 24 and 48 hours post APAP dose 
(n=4/group). Groups of mice were culled at the different time points post APAP dosing, being placed 
under terminal anaesthesia receiving single i.p. injection of 0.2 ml of Pentoject (Centaur Services, 
UK). Blood was collected from the right ventricle and plasma levels of alanine transaminase were 
measured using an AU680 chemistry analyzer (Beckman Coulter, UK). The left ventricle was 
catheterized, an incision was made in the right ventricle and PBS was perfused through the 
circulation. After visual inspection of blanching of the liver and adequate perfusion, the liver was 
excised. The median lobe with the gallbladder was separated from the rest of the liver; half was kept 
in formalin for fixation and half was snap frozen in liquid nitrogen. The remaining liver tissue was 
kept in cold PBS and was placed on ice to proceed later with the isolation of hepatic immune cells, as 
described below.  
 
3.2.2 Liver tissue H&E staining and quantification of necrosis 
 
Haematoxylin and eosin staining. Formalin-fixed liver tissue was paraffin-embedded (FFPE) and then 
was sectioned at 4 µm thickness, using a Leica RM2235 rotary microtome (Leica Biosystems, UK).  
Liver sections were next stained with haematoxylin and eosin using the following protocol: dewaxing 
(10 min), rehydration (3 consecutive Et-OH baths with decreasing concentrations followed by a 10 
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min immersion in distilled water), Harris haematoxylin (5 min), washing (3 min in tap water), acid 
alcohol (rinse), washing in tap water (3 min), eosin (5 min), washing in tap water (3 min), dehydration 
(3 different 100% ethanol baths – rinsing), clarification (10 min in xylene), mounting with DPX.  
 
Quantification of necrosis. For the assessment of liver parenchymal injury, H&E stained sections 
from FFPE liver were imaged and assessment was carried out using ImageJ software. Fifteen low 
power fields (100X) completely filled with liver were selected, avoiding overlapping and large vessels 
as much as possible. All micrographs were saved as jpeg. files and randomized. The software was 
calibrated using a micrograph of a calibration slide taken with the 10× objective. At this magnification 
and image quality 1mm = 1082.0809 pixels giving each image a field area of 1,236,383.191 µm2. 
Large vessels and non-liver parenchyma were hand selected and their area measured using the 
Analyze → Measure tool. By subtracting this value from the 100× field area we obtained the surface 
of the liver parenchyma. Then areas of necrosis were hand selected and measured, again by using the 
Analyze → Measure tool. The measurement was recorded in an Excel spreadsheet. The Edit → Clear 
Outside tool was used to exclude the non-necrotic liver tissue. Any large vessels or non-liver 
parenchyma areas within the remaining necrotic areas were again hand selected and measured. 
Measurements were recorded in the same spreadsheet. The area of necrosis in each field was 
calculated as the difference between the two recorded measurements. Necrosis was then expressed as 
percentage within liver parenchyma, on 15 consecutive low power fields (100×) in all groups, using 
the ImageJ software (Bethesda, Maryland, USA). Micrographs were obtained using a Leica DMR 
microscope equipped with a Leica DFC300 FX digital camera (Leica Biosystems, UK). 
 
3.2.3 Liver tissue immunohistochemistry and imaging 
 
MPO single epitope enzymatic immunohistochemistry. FFPE tissue was cut at 4 µm and picked up on 
poly-l-lysine coated slides which were manually stained using a rabbit polyclonal anti-MPO primary 
antibody (catalog number ab9535, Abcam, UK; dilution 1:50). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate buffer, pH 6, for 
 121 
20 minutes, and allowed to cool, followed by 18-hour incubation at 4°C with the primary antibody. 
The signal was detected using the EnVisionTM G/2 Doublestain System, Rabbit/Mouse 
(DAB+/Permanent Red) (product number K536111-2, Dako, UK), and visualized with the Vector 
VIP peroxidase kit (catalog number SH-600, Vector Laboratories, UK). The slides were then 
dehydrated with alcohol, cleared with xylene and cover slipped with DPX (Leica Biosystems, UK) 
after hematoxylin counterstaining. Images were captured and processed with a Nikon Eclipse E600 
microscope using the Nuance™ 3.0.2 (PerkinElmer, UK) multispectral imaging technology. 
 
3.2.4 Flow cytometry of hepatic immune cells 
 
Following excision, liver tissue was mechanically dissociated and passed through a 100 µm cell 
strainer. Tissue homogenates were centrifuged at 60xg for 1 min to pellet the hepatocytes. The 
remaining cells in the supernatant were harvested and next purified using density gradient, prepared 
from Optiprep (Sigma, UK). Mononuclear cells at the interface were collected, washed and red blood 
cells in the cell pellet were lysed following incubation with ACK lysis buffer (Lonza, Switzerland). 
Cells were then blocked with normal mouse serum (Sigma, UK) and were phenotypically 
characterized using antibodies and flow cytometry [F4/80 - AF488 (Serotec, UK); CD11b - PE-
CF594, Ly6G - BV605 (BD Biosciences, UK); Ly6C - PE-Cy7, CD 45.2 - eFluor 450, FVD –eFluor 
506, MerTK – PE, MHC II - eFluor 780 (eBioscience, UK)]. Cell acquisition was performed on an 
LSR Fortessa flow cytometer (BD Biosciences, UK) and data analysis using FlowJo 10.1 software 












3.3.1. Characterization of the hepatic myeloid cell infiltrate following APAP-induced acute liver 
injury 
 
Given my data showing a marked expansion of MerTK+ monocytes and hepatic macrophages with 
resolution-like properties in human ALF (Chapter 2), I sought to determine the phenotype of hepatic 
macrophages isolated from WT mice following APAP-induced acute liver injury. For these 
experiments, WT mice were administrated intraperitoneally (i.p.) with a single APAP dose (0 hours), 
and were sacrificed at several time-points (8, 24 and 48 hours) for tissue sampling while untreated 
mice served as the baseline control group (Fig. 3.1A).  
 
I examined the hepatic (CD45+CD11b+) myeloid cell infiltrate of mice administrated with or without 
APAP using flow cytometry (Fig. 3.1B-C). As discussed above (Chapter 1), infiltrating monocytes 
give rise to monocyte-derived macrophages (MoMF), which are separate from the tissue-resident KC 
population (Scott et al., 2016; Zigmond et al., 2014). Also, following APAP-induced liver injury in 
mice, Ly6Chigh monocytes strongly accumulate in the liver and differentiate into MoMF (Holt et al., 
2008; Mossanen et al., 2016; Song et al., 2004; You et al., 2013; Zigmond et al., 2014). In line with 
these murine experimental data, I confirmed by flow cytometry analysis that (CD11b+Ly6G-F4/80+) 
total hepatic macrophages had a Ly6ChighMHCII+ expression profile following APAP administration 
(Fig. 3.1B). Compared to baseline levels, peak hepatic CD11b+Ly6G+ neutrophil (8.2 vs 16.6 %; p< 
0.05) and CD11b+Ly6G-F4/80+ macrophage (20.9 vs 38.5 %; p< 0.05) influx, as proportion of total 




Figure 3.1. MerTK+ hepatic macrophages are expanded during the resolution phase following 
APAP-induced acute liver injury. 
Wild-type (WT) mice dosed with APAP were studied at 8, 24 and 48 hours while untreated mice served as baseline controls 
(n=4/group). (A) Schematic of experimental dosing, representative flow cytometry gating strategy used to identify 
(CD45+CD11b+Ly6G-) F4/80+ hepatic macrophages and determine their surface marker expression. (B) Representative 
flow cytometry plots and data show Ly6C and MHCclassII expression of F4/80+ macrophages, as determined by flow 
cytometry. (C) (CD45+CD11b+) Ly6G+ neutrophils and (CD45+CD11b+Ly6G-) F4/80+ macrophages as percentage (%) of 
total liver CD45+ leukocytes, determined by flow cytometry. (D) Representative flow cytometry plots and data show MerTK 
expression of F4/80+ macrophages, as determined by flow cytometry. Non-parametric (Mann-Whitney) statistical analysis 
was used. Data are presented as median values with interquartile range (IQR). * p< .05. SSC: side scatter. 
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3.3.2. MerTK+ hepatic macrophages increase during the resolution phase following APAP-
induced acute liver injury. 
 
Phenotypic characterization of (CD11b+Ly6G-F4/80+) hepatic macrophages revealed a significant 
increase in the overall proportion (%) of MerTK-expressing cells at 24 and 48 hours (6.9 vs 19.1 and 
26%; both p< 0.05) (resolution phase) post APAP administration, compared to baseline levels (Fig. 
3.1D). It is previously established that F4/80highCD11blow cells represent the liver-resident KCs while 
F4/80lowCD11bhigh cells are the MoMFs (Holt et al., 2008; Mossanen et al., 2016; Ramachandran et 
al., 2012). Therefore, I used this KC vs MoMF macrophage gating strategy and found that WT mice 
had an increased proportion of MoMFs at 24 hours (56.3 vs 77.1 %; p< 0.05) after APAP application 
while the KC proportion decreased within 24h (42.7 vs 16.3 %: p< 0.05) after injury induction (Fig. 
3.2A), in keeping with experimental data from other groups (Holt et al., 2008; Mossanen et al., 2016; 
Zigmond et al., 2014).  
 
Next, I assessed the levels of MerTK expression in hepatic macrophages based on the KC vs MoMF 
sub-classification. I demonstrate that the increase in MerTK+ cells (Fig. 3.1D) is predominantly on 
the liver-resident KC population (Fig. 3.2B). Compared to MerTK+ MoMFs, MerTK+ KCs are 
characterized by a distinct MHCclassIIhigh Ly6Clow expression profile, that was observed at all time 
points (Fig. 3.2B). This phenotype has not only been associated with highly phagocytic (David et al., 
2016; Stutchfield et al., 2015) and prorestorative capabilities (Dragomir et al., 2012; Ramachandran et 
al., 2012), but also bears striking similarities to MerTK+HLA-DRhigh hepatic macrophages observed 
in patients with ALF (Chapter 2). Furthermore, I show that liver-resident KCs greatly contribute to 
the increased proportion of MerTK+MHCclassIIhigh macrophages detected at 24 and 48 hours (3.5 vs 
11.0 and 17.5 %; both p< 0.05), in contrast to the low contribution of MoMFs (0.5 vs 2.2 and 2.5; 





Figure 3.2. Immune-phenotypic characterization of MerTK+ hepatic macrophages during 
APAP-induced acute liver injury. 
Wild-type (WT) mice dosed with APAP were studied at 8, 24 and 48 hours while untreated mice served as baseline controls 
(n=4/group). (A) Representative flow cytometry analysis and gating strategy used to identify (CD11blowF4/80high) resident 
Kupffer cells (KC) and (CD11bhighF4/80low) monocyte-derived macrophages (MoMF) in order to determine their MerTK 
expression, and data show their relative proportion (%) within the total F4/80+ macrophage population. (B) Further flow 
cytometry sub-analysis examined the MHC class II and Ly6C expression levels of MerTK+ macrophages in both MoMF 
(grey bars) and KC (black bars) subsets. (C) Data show MerTK+MHCII+ macrophages as proportion of total F4/80+ hepatic 
macrophages and the relative contribution of MoMF (grey bars) or KC (black bars) within this subset. Non-parametric 
(Mann-Whitney) statistical analysis was used. Data are presented as median values with interquartile range (IQR). *or # p< 







3.3.3. Mer−/− mice display increased and persistent liver injury following APAP overdose 
 
Having shown that MerTK+ hepatic macrophages are expanded during both human and experimental 
ALF, I next examined the biological relevance of these cells in APAP-induced acute liver injury by 
using WT and Mer−/− mice. For these experiments, WT or Mer−/− mice were administrated i.p. with 
APAP (0 hours) and were sacrificed at several time-points (8, 24 and 48 hours) for tissue sampling 
while untreated mice served as the baseline control group (Fig. 3.3A). I analyzed biochemical and 
histological indices of liver injury in both study groups, including plasma alanine transaminase (ALT) 
levels and quantification of liver necrosis (%), respectively (Fig. 3.3B-D). My data reveal that APAP 
administration in Mer−/− mice led to significantly increased and persistent liver injury, compared to 
APAP-treated WT mice. Specifically, Mer−/− mice exhibited a significantly higher score of hepatic 
necrosis (%) (32.9 vs 19.8 %; p< 0.05) at 8 hours post APAP dose, compared to WT mice (Fig. 3.3B-
C). Moreover, APAP-treated WT and Mer−/− mice were typified by increased plasma ALT levels at 8 
and 24 hours, compared to untreated mice (baseline) in both study groups (Fig. 3.3D). 
 
3.3.4 Mer−/− mice show reduced proportion of macrophages and increased numbers of 
neutrophils following APAP overdose 
 
I demonstrate that Mer-/- mice had a significantly lower proportion of F4/80+ hepatic macrophages, at 
both steady state and following APAP-induced liver injury, when compared to WT (Fig. 3.4A). In 
addition, using the KC vs MoMF gating strategy described above (Holt et al., 2008; Mossanen et al., 
2016; Ramachandran et al., 2012), I reveal that this was attributable to a reduced proportion of the, 
MHCclassIIhighLy6Clow  (Fig. 3.2B) expressing KC population (Fig. 3.4A-B). These differences were 
also reflected in the immune profile of F4/80+ hepatic macrophages of Mer-/- mice, in both KC and 
MoMF subsets, where these cells were characterized by reduced MHCclassII expression levels (Fig. 
3.4C). Furthermore, I studied the hepatic neutrophils of both WT and Mer-/- mice. In keeping with the 
role and importance of MerTK in neutrophil homeostasis and clearance (Hong et al., 2012), Mer-/-  
mice displayed a significantly higher proportion (Ly6G+) (8 hours, 20.7 vs 9.5 %; p< 0.05) (Fig. 
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3.5A) and number of activated (MPO+) neutrophils at peak [(8 hours) 10 vs 3 cells/HPF; p< 0.05] and 
resolution phases [(24 hours) 36 vs 21 cells/HPF; p< 0.01] during APAP-induced liver injury, when 
compared to WT mice (Fig. 3.5B-C). 
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Figure 3.3. Mer−/− mice are characterized by increased and persistent liver injury following 
APAP overdose. 
Wild-type (WT, black bars) and MerTK-deficient (Mer−/−, grey bars) mice dosed with APAP were studied at 8, 24 and 48 
hours and untreated mice served as baseline controls (n=4/group). (A) Schematic of experimental dosing for both study 
groups. (B) Representative images of H&E stained murine liver tissue.  (C) Quantification of necrosis (%) in murine liver 
tissue. (D) Quantification of plasma alanine transaminase (ALT) levels. Non-parametric (Mann-Whitney) statistical analysis 






Figure 3.4. Mer−/− mice are characterized by reduced proportion of hepatic macrophages 
following APAP-induced acute liver injury. 
Wild-type (WT, black bars) and MerTK-deficient (Mer−/−, grey bars) mice dosed with APAP were studied at 8, 24 and 48 
hours and untreated mice served as baseline controls (n=4/group). (A) Data show F4/80+ hepatic macrophages, resident 
Kupffer cells (KC) and monocyte-derived macrophages (MoMF) as percentage (%) of total liver CD45+ leukocytes, 
determined by flow cytometry. (B) Representative flow cytometric analysis from liver CD45+ leukocytes showing the 
detection of (CD11bhighF4/80low) MoMF and (CD11blowF4/80high) KC. (C) Data show the MHC class II and Ly6Clow 
expression of F4/80+ hepatic macrophages, sub-analyzed into the resident KC and MoMF subsets. Non-parametric (Mann-





Figure 3.5. Mer−/− mice are characterized by increased proportion of hepatic neutrophils 
following APAP-induced acute liver injury. 
Wild-type (WT, black bars) and MerTK-deficient (Mer−/−, grey bars) mice dosed with APAP were studied at 8, 24 and 48 
hours and untreated mice served as baseline controls (n=4/group). (A) (CD45+CD11b+) Ly6G+ hepatic neutrophils as 
percentage (%) of total liver CD45+ leukocytes and (B) enumeration of MPO+ neutrophils using flow cytometry and 
immunohistochemistry, respectively. (C) Representative images of liver tissue stained for MPO+ (purple) cells (200X). 
Non-parametric (Mann-Whitney) statistical analysis was used. Data are presented as median values with interquartile range 





The MerTK receptor signaling pathway is an essential regulator of the immune system, functioning at 
the interface of both innate and adaptive immunity aimed to restore tissue homeostasis (Lemke and 
Rothlin, 2008). Following acute tissue injury, MerTK dampens innate immune responses and by 
recognizing the exposed PtdSer on apoptotic cells it mediates their clearance and promotes resolution 
of inflammation (Rothlin et al., 2015; Zagorska et al., 2014). Several experimental studies on sterile 
and pathogen-induced inflammation demonstrate that loss of MerTK results in exaggerated immune 
activation and ineffective resolution, thus may lead to excessive inflammatory tissue damage.  
 
For instance, in a model of endotoxemia, Mer−/− mice almost uniformly succumbed to septic shock 
and died as a result of tissue damage mediated by increased TNF-α and IL-1 levels (Camenisch et al., 
1999). Bleomycin-induced lung injury was reduced when MerTK macrophage expression was 
enhanced in mice, that were typified by increased anti-inflammatory mediators such as TGF-β, HGF 
and reduced TNF-α and IL-1 levels (Lee et al., 2012c). MerTK signaling is also studied in liver 
inflammation; in a murine model of hepatic ischemia, serum Gas6 levels rose shortly after arterial 
ligation and western blot analyses after ischemic insult revealed increased hepatic phosphorylated 
MerTK levels, over Axl, indicating preferential activation of MerTK signaling (Llacuna et al., 2010). 
However, the temporal evolution of macrophage MerTK expression during acute liver injury and its 
impact on resolution of hepatic inflammation are not yet explored. 
 
Here, my findings using the murine model of ALF are first to provide novel insights into the identity 
and role of the MerTK-expressing macrophage population that is significantly expanded in the livers 
of mice following APAP-induced acute liver injury. I demonstrate that the proportion of MerTK+ 
hepatic macrophages are specifically increased in the liver-resident Kupffer cells, and not MoMF, 
population post APAP dose. My data reveal that MerTK+ Kupffer cells exhibit a MHCclassIIhigh 
Ly6Clow expression profile, prior to and during the time course of APAP-induced acute liver injury. 
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This Ly6Clow phenotype is previously associated with prorestorative macrophage properties in murine 
models of acute and chronic liver injury (Dragomir et al., 2012; Ramachandran et al., 2012). Of note, 
experiments using flow cytometry, multi-photon intravital microscopy and gene expression analyses 
have shown that resident Kupffer cells are the dominant phagocytic macrophage population in the 
liver (David et al., 2016; Stutchfield et al., 2015). Interestingly, the phenotypic data described here in 
mice bear striking similarities with the expanded pro-phagocytic MerTK+HLA-DRhigh monocyte and 
macrophage subset I have identified above in human ALF. 
 
In contrast to KCs, I demonstrate that the MerTK expression levels of the MoMF population do not 
substantially increase during APAP-induced liver injury. Although MerTK+ MoMFs possess initially 
a MHCclassIIlowLy6Chigh immune-phenotype at baseline, these cells acquire a MHCclassIIhighLy6Clow 
expression profile during the resolution phase of inflammation post APAP administration in mice. 
These results agree with others revealing that MoMFs upregulate pro-inflammatory proteins such as 
MHC class II, important for antigen presentation, post APAP dose (Mossanen et al., 2016). This study 
indicated that Ly6Chigh MoMFs are distinct from Ly6Clow MoMFs and resident KCs, characterized by 
expression of pro-inflammatory genes, including chemokines, pattern-recognition receptors but also 
genes involved in liver repair processes (Mossanen et al., 2016).   
 
Accordingly, Ly6Chigh macrophages show a classically activated pro-inflammatory phenotype typified 
by increased TNF-α expression, inducible nitric oxide synthase (iNOS) and CCR2, whereas Ly6Clow 
macrophages are alternatively activated, expressing high IL-10 levels, following ALF (Dragomir et 
al., 2012). As mentioned above, the Ly6Clow phenotype is related with prorestorative macrophage 
functions in liver injury (Dragomir et al., 2012; Ramachandran et al., 2012). Prorestorative Ly6Clow 
hepatic macrophages are key players in resolving fibrosis, shown to accumulate in the liver during the 
resolution phase following tissue damage, particularly deriving from infiltrating Ly-6Chigh 
monocytes/macrophages, following an in vivo functional switch during the course of liver injury 
(Ramachandran et al., 2012). Taken together, the phenotypic transition observed here in MerTK+ 
MoMFs, from a pro-inflammatory towards a pro-restorative state, during the resolution phase of 
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APAP-induced acute liver injury is in accord with previous findings on MoMFs and their proposed 
role in resolving hepatic inflammation (Holt et al., 2008; Zigmond et al., 2014). 
 
The data presented here highlight a significant biological relevance of MerTK+ cells for the effective 
resolution of hepatic inflammation following ALF, since APAP dosing in MerTK-deficient mice led 
to markedly increased and persistent liver injury. My results echo recent findings demonstrating that 
MerTK promotes resolution after acute tissue injury by dampening innate responses and crucially 
augmenting the clearance of neutrophils (Arandjelovic and Ravichandran, 2015; Choi et al., 2015b; 
Hong et al., 2012). In a model of sterile zymosan-induced acute inflammation, in vivo inhibition using 
anti-MerTK neutralizing antibody or MerTK deficiency in mice exacerbated local and systemic 
inflammatory responses, that were associated with reduced abundance of the transcription factors 
liver-X-receptor LXRα and LXRβ and decreased expression of their target genes in peritoneal 
macrophages, spleens, and lungs (Choi et al., 2015b). Hence, enhanced MerTK signaling during the 
recovery phase increases the abundance and activity of LXR to suppress macrophage inflammatory 
responses (Choi et al., 2015b).  
 
Also, I report a considerably lower proportion of total (F4/80+) hepatic macrophages in Mer-/- mice at 
both steady state and post APAP dose compared to WT mice. In particular, I demonstrate a significant 
depletion in prorestorative, MHCclassIIhigh Ly6Clow, liver-resident KCs, which are protective against 
acute liver injury (Ju et al., 2002b; You et al., 2013) and exhibit high phagocytic capacity (Stutchfield 
et al., 2015). This reduction may account for the exaggerated liver injury and inflammation observed 
in Mer-/- mice post APAP administration. Differences were also detected in the immune profile of 
hepatic macrophages in Mer-/- animals, as both KC and MoMF subsets were characterized by reduced 
MHC class II expression levels, which may translate into reduced antigen presentation capacity of 
macrophages and thereby reducing CD4+ T-cell activation in the liver. To confirm this hypothesis 
and convince that the lack of the hepatoprotective KCs in Mer-/- mice exaggerates liver injury post 
APAP, further work is needed to provide evidence that reconstitution of Mer-/- with MerTK+ KCs 
may revert the phenotype observed in the disease murine model. This could be achieved through bone 
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marrow transplantation experiments into recipient mice which have previously undergone clodronate-
induced liver-resident KC depletion. Furthermore, it would be interesting to investigate if MerTK+ 
ΜοMFs and MerTK+ resident KCs have distinct phenotypic and functional profiles throughout the 
time-course of APAP-induced liver injury. This could be addressed using flow cytometry based 
sorting of the two subsets, followed by gene expression analyses and time-of-flight mass cytometry 
(CyTOF) experiments. Furthermore, in view of the role of MerTK in promoting cell survival through 
activation of anti-apoptotic pathways (Anwar et al., 2009), the above data suggest that activation of 
MerTK in liver-resident KCs may be important for their differentiation and restoration following 
acute liver injury. Future studies are warranted to identify the precise mechanisms through which 
MerTK regulates this process in both human and experimental models of the disease.  
 
The reduction in resident KCs in the liver of Mer-/- mice was detected concomitantly with a reciprocal 
increase in the proportion/numbers of hepatic neutrophils, importantly not at steady state conditions 
but only following APAP-induced acute liver inflammation. It is worthy to mention that both MerTK 
and LXR signaling pathways are shown to coordinately control neutrophil homeostasis (Hong et al., 
2012). In this study, in vitro and in vivo gain- and loss-of-function experiments revealed that LXR 
positively regulates the efficient clearance of senescent neutrophils by peripheral tissue antigen 
presenting cells in a MerTK-dependent manner (Hong et al., 2012). In addition, MerTK deficiency 
was recently associated with reduced LXRα/LXRβ abundance and decreased expression of their 
target genes in mice (Choi et al., 2015b). Hence, it possible down-regulation of LXR signaling in Mer-
/- mice, prior to and post APAP dose, may be responsible for the insufficient clearance of apoptotic 
neutrophils during liver inflammation and may account for the increased numbers of hepatic detected 
in the liver of these animals. However, the LXR pathway was not examined in the present study and 
warrants future work that will perform gene expression analyses of liver tissue from both WT and 
Mer-/- animals, aimed to assess LXRα/LXRβ levels during the time-course of APAP-induced liver 
injury. If LXR signaling is down-regulated, it would be interesting to assess if administration of an 
LXR agonist in vivo would protect APAP-treated Mer-/- mice against liver injury.  
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Together, the experimental data presented and discussed in this chapter indicate that the expanded 
prorestorative MerTK+ hepatic macrophage population, with enhanced phagocytic capabilities, 
evolves following acute hepatocellular necrosis, in particular during the resolution phase, and 
critically serves in driving and promoting the resolution of hepatic inflammation in APAP-induced 



















4. LIVER MICRO-ENVIRONMENTAL TRIGGERS INDUCING 
MERTKHIGH MONOCYTES AND MACROPHAGES IN ACUTE LIVER 
FAILURE 
 
4.1 Background and aims 
 
SLPI is a small protein secreted by epithelial and myeloid cells that can suppress macrophage pro-
inflammatory responses through inhibition of the NF-κB signaling pathway (Ashcroft et al., 2000; 
Nakamura et al., 2003; Sallenave, 2010; Scott et al., 2011b). Both human and experimental studies 
have revealed key immune-modulatory functions of SLPI during tissue inflammation, in a variety of 
diseases including sepsis, asthma and cancer (Majchrzak-Gorecka et al., 2016), as described (Chapter 
1). SLPI was recently identified as a key micro-environmental modulator of monocytes towards anti-
inflammatory responses in human ALF. Compared to HC and CLD, elevated hepatic and circulatory 
levels of SLPI were detected in ALF that importantly correlated with poor outcome (Antoniades et al., 
2014).  
 
Immunohistochemistry-based analysis of ALF liver explant tissue revealed that SLPI is crucially 
expressed by biliary epithelial cells (BECs) and hepatic macrophages located in areas of necrosis in 
ALF (Antoniades et al., 2014). Although the involvement of BECs in the pathophysiology of chronic 
liver disease (CLD) is well documented (Lleo et al., 2014; O'Hara et al., 2013), their role in acute 
liver injury has not been explored and this study was the first to suggest a potential role for BECs in 
the pathophysiology of ALF (Antoniades et al., 2014). It is also shown that macrophages secrete SLPI 
following phagocytosis of apoptotic cells and in response to anti-inflammatory cues such as IL-6 and 
IL-10 (Ashcroft et al., 2000), that are present in the ALF inflamed liver (Antoniades et al., 2012) 
 
This work also found that monocytes in ALF exhibit an anti-inflammatory phenotype (CD163high 
HLA-DRlow) and functional characteristics, typified by reductions in NF-κΒp65, TNF-a, and IL-6 
levels and preserved IL-10 production following microbial challenge. Culture of healthy monocytes 
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with ALF liver homogenates, plasma, or rh-SLPI induced monocytes with similar to the ex vivo anti-
inflammatory characteristics, that were reversed by inhibiting the activity of SLPI (Antoniades et al., 
2014). This study proposed that the excessive production of SLPI in the acutely inflamed liver of in 
ALF is of sufficient magnitude to “spill-over” to the systemic circulation and render monocytes hypo-
responsive to microbial challenge, thus may increase the susceptibility to infection encountered in 
these patients (Antoniades et al., 2014; Possamai et al., 2014a). Furthermore, it was also postulated 
that SLPI may modulate in an autocrine/paracrine fashion the tissue-resident and newly-infiltrating 
myeloid cells present in the ALF liver (Antoniades et al., 2014; Possamai et al., 2014b)  
  
Hypothesis and aims: 
Given the previous data and proposed role for SLPI in human ALF, I postulated that different micro-
environmental triggers within the inflamed ALF liver, including biliary epithelial cells, apoptotic cell 
debris and SLPI, can re-program both liver-infiltrating monocytes and resident macrophages towards 
MerTKhigh resolution-like type. Hence, in this chapter I aimed to: 
§ Examine the inflammatory cytokine and SLPI secretion levels of BECs isolated from liver 
tissue of CLD and ALF patients and also to assess their paracrine effects on monocytes.  
§ Assess the immune-modulatory effects of human apoptotic neutrophils and hepatocytes on 
monocyte phenotype and function. 
§ Determine the effects of SLPI on the phenotypic/functional profile of monocytes undergoing 
migration across hepatic endothelium and of liver-derived hepatic macrophages in culture. 
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4.2 Materials and methods 
 
4.2.1 Isolation of biliary epithelial cells (BECs) and paracrine effects on monocytes 
 
Biliary epithelial cells (BECs) were isolated from approximately 120-150g of human liver tissue, as 
previously described (Liaskou et al., 2014). Liver tissue was digested enzymatically with collagenase 
type 1A (Sigma, United Kingdom), filtered and then was further purified using density gradient 
centrifugation over 33%/77% Percoll (Amersham Biosciences, United Kingdom). BECs were 
extracted from the mixed non-parenchymal population via magnetic selection using antibodies against 
the cholangiocyte-specific receptor HEA-125 (50 µg/mL; Progen Biotechnik, Heidelberg, Germany). 
Highly pure isolates of HEA-125–positive BECs were next plated in rat-tail collagen-coated flasks 
and cultured (37 oC with 5% CO2) for a week (Liaskou et al., 2014). After first passage, BECs from 
ALF (n=3) and CLD (n=6) were transferred into rat-tail collagen-coated 6-well plates (500.000 
cells/mL) and were cultured (37 oC with 5% CO2) up to 24h. Following centrifugation to spin down 
the cell pellets, BEC culture supernatants were collected at different time points (4h, 8h, and 24h) and 
were stored at -80oC in order to determine the BEC SLPI and cytokine secretion levels.  
 
Furthermore, BEC culture supernatants (24h) from CLD (n=6) and ALF (n=3) patients were used to 
culture healthy CD14-isolated monocytes in medium containing 25% BEC supernatants for 48h (37oC 
with 5% CO2) which were studied phenotypically and functionally by flow cytometry. In blocking 
experiments, CD14-isolated healthy monocytes were cultured in medium containing 25% ALF BEC 
culture supernatants which was pre-incubated with anti-human SLPI neutralizing antibody (α-SLPI) 
(R&D Systems, UK) (0 and 5 µg/mL) for 1 hour at room temperature, before addition to monocyte 
cultures, as previously (Antoniades et al., 2014). Phenotype and function of cultured monocytes were 




4.2.2 Effects of apoptotic neutrophils and hepatocytes on monocytes 
 
Human neutrophils were isolated (2.2.2) and were re-suspended at 106 cells/ml in complete medium, 
labeled with CellTracker Green CMFDA (Life Technologies, UK) (5 µM in serum-free medium, 45 
min, dark) and incubated for 20h (37 ̊C in 5% CO2) in 24-well plates (Corning, USA) to become 
apoptotic, as previously described (Zizzo et al., 2012). Human primary hepatocytes (Life 
Technologies, UK) were thawed using Cryopreserved Hepatocyte Recovery Medium (CHRM) (Life 
Technologies, UK) and viability was determined using trypan blue staining. Cells were then plated 
using CHPM medium in a 96-well collagen pre-coated plates at a 0.9x106 cells/ml density for 4h to 
allow cell adherence, before wash and replacement of CHPM with Williams’ E supplemented 
medium (Life Technologies, UK). Hepatocytes were allowed to further adhere overnight. Cultures 
were then checked for their cell morphology and monolayer integrity, before being washed and then 
be supplemented with fresh medium only or medium containing 20 mM acetaminophen (APAP) 
(Sigma-Aldrich, UK). Annexin V kit (BD Biosciences, UK) was used to determine the percentage of 
cultured cells that are actively undergoing apoptosis. Next, CD14-isolated healthy monocytes, at 106 
cells/ml in 24-well plates (Corning, USA) (37oC in 5% CO2) in fresh complete medium, co-incubated 
in 1:2 ratio for 4 hours with apoptotic neutrophils or hepatocytes and flow cytometry was used to 
examine their phenotype. 
 
4.2.3 SLPI effects on migrating monocytes and liver-derived macrophages in culture 
 
Effects of SLPI on migration of healthy monocytes across hepatic endothelium were assessed using 
the in vitro migration assay described above (Bernsmeier et al., 2015; Zimmermann et al., 2015), with 
the only difference that the collagen plugs were formed containing (rh)-SLPI (0 and 0.5 ug/mL) 
(R&D Systems, UK). Non-migrated, sub-endothelial and reverse-migrate monocytes were harvested, 
washed and analyzed further by flow cytometry. In addition, normal liver-tissue derived HMCs and 
CD14-isolated healthy monocytes were cultured for 48h at 106 cells/ml in 24-well plates (Corning, 
USA) (37oC in 5% CO2) in fresh complete medium [RPMI-1640 medium containing 10% heat-
 141 
inactivated FBS medium and 1% antibiotics (L-glutamine, penicillin, and streptomycin)] (Life 
Technologies, UK). Effects of recombinant human (rh)-SLPI (R&D Systems, UK) (0 and 0.5 µg/mL) 
in these culture experiments were assessed. After culture period, cells were harvested, washed with 
PBS and analyzed for their surface phenotype and function by flow cytometry.  
 
4.2.4 Measurement of SLPI and inflammatory cytokine levels 
 
Human Quantikine ELISA was used for detection of SLPI and HGF levels in HMC and BEC culture 
supernatants (R&D Systems, UK). The MSD Human Pro-inflammatory 10-plex panel was used to 
assess (IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-α) inflammatory 
cytokine levels as well. ELISA microplates were read using the SoftMax® Pro software (Molecular 
Devices, USA). MSD plates were read on the Sector Imager 2400 apparatus (Gaithersburg, MD). All 







4.3.1 Biliary epithelial cells exhibit an anti-inflammatory secretion profile in ALF 
 
Following acute liver injury, biliary epithelial cells (BECs) can modulate the local inflammatory 
microenvironment by secreting growth factors, cytokines and chemokines that recruit and activate 
immune cells (O'Hara et al., 2013). Therefore, in order to evaluate the in vitro secretion of 
inflammatory cytokines and mediators by BECs, I isolated BECs from human explant liver tissue and 
cultured them for up to 24 hours. Compared to CLD, BECs from ALF patients secreted significantly 
increased levels of SLPI at all time points [(4 hours) 4.405 vs 14756,  (8 hours) 4.859 vs 15.108, (24 
hours) 6.473 vs 26.912; all pg/ml, p< 0.0001] (Fig. 4.1A), in line with previous data showing high 
intrahepatic SLPI expression by BECs in ALF (Antoniades et al., 2014). Furthermore, I found that 
compared to CLD, BECs in ALF secreted reduced levels of pro-inflammatory cytokines [TNF-α (6.2 
vs 15.2), IL-8 (20.840 vs 39.020) and IL-12p70 (9.3 vs 16.6); all pg/ml, p< 0.05] while IL-10 levels 
were similar between CLD and ALF (Fig. 4.1B). These findings extend the previous human data 
regarding a skewed anti-inflammatory micro-environmental milieu in the ALF liver (Antoniades et 
al., 2014; Antoniades et al., 2012).  
 
4.3.2 Biliary epithelial cells induce MerTK+ resolution-like monocytes/macrophages in ALF 
 
I also examined the paracrine effects of BEC-derived supernatants on healthy monocyte phenotype 
and function. I show that monocytes cultured in ALF BEC-derived supernatants, but not in CLD, 
were characterized by significantly increased MerTK (82.6 vs 67.5 %; p< 0.05) and CD163 (52.8 vs 
40; p< 0.05) and lower HLA-DR (79.4 vs 68.4 %; p< 0.05) expression levels, particularly in the 
CD14++CD16 subset, as observed ex vivo in ALF patients (Chapter 2). Also, monocytes cultured in 
ALF BEC-derived supernatants exhibited reduced secretion of pro-inflammatory cytokines [TNF-α 
(12.2 vs 27.3 %; p<0.05) and IL-6 (29.5 vs 21.2%; p<0.01)] following LPS challenge, compared to 
CLD (Fig. 4.2A-B). In order to evaluate whether the SLPI levels derived by ALF BECs serve in 
 143 
shaping monocyte function, I next cultured healthy monocytes in ALF BEC supernatants that were 
pre-incubated with anti-SLPI blocking antibody (α-SLPI). I found that inhibition of SLPI’s activity in 
BEC supernatants reversed the up-regulation in CD163 (29.4 vs 16.1 %; p< 0.05) and MerTK (49.3 
vs 40.8 %; p< 0.05) monocyte expression, without affecting HLA-DR levels, while concomitantly 




Figure 4.1. Biliary epithelial cells induce monocyte/macrophage MerTK+ resolution responses 
in a paracrine manner in ALF. 
BECs from CLD (n=6) and ALF (n=3) patients were isolated and cultured at different time points (4, 8 and 24 hours). Data 
show the levels of (A) SLPI and (B) inflammatory cytokines (pg/ml) that were determined in BEC culture supernatants by 
ELISA (24h). Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed as median values with 





Figure 4.2. Biliary epithelial cells induce monocyte/macrophage MerTK+ resolution responses 
in a paracrine manner in ALF. 
BECs from CLD (n=6) and ALF (n=3) patients were isolated and cultured at different time points (4, 8 and 24 hours). 
Paracrine effects of ALF and CLD BEC supernatants (A-B) and effects of blocking SLPI in BEC supernatants (C) were 
examined on monocytes in culture (n=3 independent experiments). ALF BEC supernatants were pre-incubated with anti-
human SLPI neutralizing antibody (+α-SLPI) (0 and 5 ug/mL). Data show LPS-stimulated (100ng/ml, 6h) intracellular 
cytokine levels, representative flow cytometry histograms and surface marker expression of cultured monocytes. Results 
expressed as percentage of positive cells. Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed 
as median values with interquartile range (IQR). * P< .05, ** P< 0.01, *** P< .001. 
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4.3.3 Apoptotic cells reprogram monocytes/macrophages towards MerTK+ resolution-like 
responses 
 
Cell death triggers innate immune activation in ALF where monocytes/macrophages infiltrate necrotic 
areas to clear cell debris and resolve tissue injury (Antoniades et al., 2012; Possamai et al., 2013; 
Zigmond et al., 2014) and observational data in humans support this, showing that hepatic 
macrophages in areas of necrosis contain phagocytosed cell debris (Antoniades et al., 2012). Thus, I 
hypothesized that monocyte/macrophage reprogramming can occur locally, after exposure and uptake 
of apoptotic cells and cellular debris that is released following acute liver injury. Therefore, I 
examined in co-culture experiments the immune-modulatory effects of apoptotic neutrophils and 
human primary hepatocytes on monocyte phenotype and function (Fig. 4.3A-B).  
 
I demonstrate that monocytes are modulated following phagocytosis of either apoptotic neutrophils or 
hepatocytes. In particular, this functional switch post exposure to apoptotic cells involved acquisition 
of a MerTKhigh CD163high HLA-DR+ phenotype (Fig. 4.3A-B), characteristic of ALF patients, as 
shown previously (Chapter 2). This change was associated with secretion of higher concentrations of 
anti-inflammatory and tissue-repair mediators, including SLPI (39 vs 234; pg/ml, p< 0.001) and HGF 
(23 vs 281; pg/ml, p< 0.001), and reduced levels of pro-inflammatory (TNF-a, 1.618 vs 1.192; pg/ml, 
p< 0.05) cytokines (Figure 4.3C). Taken together, I have identified both biliary epithelial cells and 
areas of hepatic necrosis containing cell debris in ALF, as key micro-environmental triggers that 
reprogram monocytes and macrophages towards resolution-like responses within the acutely inflamed 





Figure 4.3. Apoptotic cells induce monocyte/macrophage reprogramming towards MerTK+ 
resolution responses in ALF. 
CD14-isolated healthy monocytes co-cultured (4h) in 1:2 ratio with apoptotic neutrophils or apoptotic human primary 
hepatocytes and their phenotype was determined by flow cytometry (n=3 independent experiments). (A-B) Data show 
representative flow cytometry histograms and total monocyte surface marker expression following co-culture. (C) Data 
show the levels of inflammatory mediators (pg/ml) in monocyte with apoptotic neutrophil co-culture supernatants, as 
determined by ELISA (n=5). Non-parametric (Mann-Whitney) statistical analysis was used. Data presented as median values 




4.3.4 SLPI induces MerTK+ resolution-like monocytes/macrophages 
 
Given the anti-inflammatory role of SLPI on monocytes in ALF (Antoniades et al., 2014) and having 
identified above the liver micro-environmental triggers of its secretion (Fig. 4.1-4.3), here I sought to 
examine whether SLPI directly induces resolution responses in human circulating monocytes and 
liver-derived hepatic macrophages, freshly isolated from blood and explant tissue, respectively (Fig. 
4.4). Several studies in ALF demonstrate that the hepatic macrophage pool is expanded not only due 
to proliferation of resident Kupffer cells but also through chemokine-dependent recruitment of 
circulating monocytes (Antoniades et al., 2012; Choi et al., 2015a; Dambach et al., 2002; Zigmond et 
al., 2014).  
 
I used an in vitro migration assay (Fig. 4.4A-B) to evaluate the effects of SLPI, present as a micro-
environmental mediator, on the phenotype of monocytes migrating across cytokine-stimulated (TNF-
α and IFN-γ) hepatic endothelium (Bernsmeier et al., 2015; Zimmermann et al., 2015). I reveal that 
following trans-endothelial migration, SLPI induced a significant increase in monocyte expression of 
the pro-resolution markers CD163 [49.3 vs 77.6 (MFI); p< 0.05] and MerTK [236.3 vs 303.1 (MFI); 
p< 0.05] selectively within the CD14++CD16+ subset, and only in sub-endothelial cells (Fig. 4.4B). 
Expression levels of HLA-DR remained unaffected while no changes were detected in the monocyte 
subset frequencies (data now shown) across different migratory compartments and treatments, in line 
with previous findings (Antoniades et al., 2014). 
 
Culture of normal liver-derived hepatic macrophages with SLPI induced also a selective increase in 
the expression of CD163 (25.1 vs 43.3 %; p< 0.05) and MerTK (32.1 vs 45.9 %; p< 0.05), within the 
CD14++CD16+ subset only (Fig. 4.4C) with no changes in HLA-DR expression levels. Consistent 
with previous data on circulating monocytes (Antoniades et al., 2014), treatment of LPS-stimulated 
hepatic macrophages with SLPI led to reduced levels of pro-inflammatory cytokines [TNF-α (5.451 
vs 3737, p<0.05), IL-6 (3.313 vs 2.352, p<0.05) and IFN-γ (153 vs 43, p< 0.01 ); all pg/ml], preserved 
anti-inflammatory/tissue-repair mediator production (IL-10 and TGF-β) and significantly increased 
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HGF release (190 vs 271; pg/ml, p< 0.05) (Fig. 4.4D). Taken together, I identify SLPI as a liver 
micro-environmental trigger produced by epithelial cells and hepatic macrophages that promotes the 





Figure 4.4. SLPI induces a MerTKhighHLA-DRhigh phenotype in monocytes/macrophages. 
(A-B) Effects of (rh)-SLPI (0 and 0.5 ug/mL) on monocyte migration across hepatic endothelium were determined (n=3 
independent experiments). (A) Schematic of migration assay: CD14-isolated monocytes are added on top of a pre-formed 
hepatic endothelium monolayer; non-migrated monocytes are harvested 1.5 hours after while sub-endothelial monocytes are 
obtained 24h later. (B) Data show HLA-DR, CD163 and MerTK expression levels and representative histograms of the 
CD14++CD16+ subset, for (top panel) non-migrated and (lower panel) sub-endothelial monocytes. Results expressed as 
mean fluorescence intensity (MFI). (C-D) Effects of (rh)-SLPI (0 and 0.5 ug/mL) on hepatic macrophages isolated from 
normal liver explant tissue were assessed (n=5). (C) Data show representative histograms and surface marker expression in 
the CD14++CD16+ subset and intracellular cytokine levels in total monocytes following microbial challenge (LPS 
100ng/ml). (D) LPS-stimulated inflammatory cytokine levels (pg/ml) in hepatic mononuclear cell culture supernatants, as 
determined by ELISA. Non-parametric (Mann-Whitney) statistical analysis was used. Data presented as median values with 







In this chapter I have identified three key micro-environmental processes that may take place in the 
inflamed liver of ALF patients and can drive monocytes/macrophages towards a resolving program. 
First, the secretion of immune-regulatory/anti-inflammatory molecules (e.g. SLPI) by biliary 
epithelial cells (BECs). Second, the exposure/phagocytosis of apoptotic immune and epithelial cells 
and debris that can cause a functional switch in MerTK+ cells from an HLA-DRhigh to HLA-DRlow 
expression status. Third, the induction of a MerTK+HLA-DRhigh phenotype by SLPI, which is 
produced by both BECs and post-phagocytic macrophages, that counter-regulates the production pro-
inflammatory cytokines whilst promoting resolution/tissue-repair mediator release 
 
BECs actively sense and react to the inflammatory environment associated with liver injury as well as 
to bile bioactive and exogenous (microbe-derived, xenobiotic) molecules (Lleo et al., 2014; O'Hara et 
al., 2013). They respond through the secretion of a repertoire of pro-inflammatory cytokines and 
growth factors and TGF-β (Hirschfield et al., 2010). These molecules act in an autocrine and/or 
paracrine manner to mediate proliferation, apoptosis and fibrosis, processes that are associated with 
the biliary repair response. Secretion of such mediators can also modify the local microenvironment 
surrounding BECs and leads to activation and recruitment of innate and adaptive immune cells, in 
order to protect against liver injury and/or infection (O'Hara et al., 2013).  
 
Although the function and involvement of BECs in the pathophysiology of chronic liver disease 
(CLD), such as primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC), are well 
documented (Lleo et al., 2014; O'Hara et al., 2013), their role in acute liver injury is not explored. 
Here, my data highlight a novel immune-regulatory role for BECs in the ALF liver, as I show that 
they drive monocytes/macrophages towards resolution responses in a paracrine fashion, recapitulating 
the phenotype detected ex vivo in monocytes and hepatic macrophages in ALF. In particular, these 
epithelial cells induce the development of the prorestorative MerTK+ phenotype and exhibit an anti-
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inflammatory cytokine/mediator profile, including the release of high SLPI levels, results that agree 
with the anti-inflammatory liver micro-environmental milieu in ALF (Antoniades et al., 2014; 
Antoniades et al., 2012). It would be interesting to assess in future work with co-culture experiments 
also the direct, cell-to-cell contact, effects of  ALF BECs on monocyte phenotype and function, that 
was not addressed in the present study. 
 
Phagocytosis of apoptotic cells or cell debris can trigger a macrophage functional switch towards an 
immune-regulatory phenotype, associated with pro-resolution and tissue-repair properties, aimed to 
maintain immune tolerance and restore tissue homeostasis (Bellingan et al., 2002; Bystrom et al., 
2008). Human and experimental models in ALF indicate that cell death is a central trigger of hepatic 
innate immune activation where monocytes/macrophages infiltrate necrotic areas in the liver in order 
to clear cell debris and resolve tissue injury (Antoniades et al., 2012; Possamai et al., 2013; Zigmond 
et al., 2014). In addition, observational data in humans support this hypothesis by demonstrating 
through scanning electron microscopy in liver tissue that hepatic macrophages in areas of necrosis 
contain phagocytosed cellular debris (Antoniades et al., 2012). Here, I recapitulate the resolution-like 
phenotype described ex vivo in ALF patients, showing that phagocytosis of both apoptotic neutrophils 
and hepatocytes induces a macrophage phenotypic switch, typified by loss of HLA-DR and up-
regulation of MerTK expression levels. Similar to other models of sterile acute liver injury (Dal-
Secco et al., 2015), I demonstrate that MerTK+ hepatic macrophages form ring-like structures around 
necrotic areas in ALF. MerTK+HLA-DRhigh cells that possess avid phagocytic and efferocytic 
capabilities are localized around the rim of areas of necrosis whereas MerTK+ cells that populate 
more central areas of necrosis bear an HLA-DRlow phenotype, similar to the in vitro “post-phagocytic” 
subset observed.  
 
Phagocytosis of cellular debris not only induces a phenotypic switch from an HLA-DRhigh to HLA-
DRlow expression status but is also associated with enhanced secretion of immune-regulatory/anti-
inflammatory mediators (e.g. SLPI, HGF) and reduced pro-inflammatory cytokines (e.g. TNF-α), in 
line with data from others (Antoniades et al., 2014; Molnarfi et al., 2015; Odaka et al., 2003a; Park et 
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al., 2012). These results indicate that, whilst monocytes/macrophages are recruited to sites of acute 
liver injury to clear necrotic debris, they also undergo local reprogramming following phagocytosis, 
which enables them to further amplify resolution and tissue-repair processes (Antoniades et al., 2012; 
Gilroy and De Maeyer, 2015; Holt et al., 2008; Stables et al., 2011; Zigmond et al., 2014). However, 
this hypothesis is based on in vitro findings here, in post-phagocytic monocytes, thus I cannot draw 
definitive conclusions. Future studies are needed to assess in vivo the local phenotypic/functional 
switch of monocytes/macrophages in areas of necrosis, when they are recruited to sites of liver injury 
and contact cell debris, using the murine model of APAP-induced ALF and live cell imaging via 
intravital non-invasive microscopy. 
 
Although anti-inflammatory programs initiated following phagocytosis of apoptotic cells and debris 
are beneficial in resolving tissue injury and inflammation, they may have the undesirable potential to 
dampen anti-microbial responses (Fullerton and Gilroy, 2016; Grabiec and Hussell, 2016). My data 
support this notion where I demonstrate that acute liver injury can reprogram hepatic myeloid cells 
towards MerTK+ resolution responses, that quell tissue inflammation and promote the clearance of 
debris. As discussed above, MerTK+ monocytes highly express the lymph-node homing receptor 
(CCR7) and have enhanced abilities to trans-migrate across hepatic endothelium. Accordingly, both 
MerTK+HLA-DRhigh and MerTK+HLA-DRlow subsets are significantly elevated in the circulatory, 
hepatic and crucially in lymphatic tissue compartments in ALF patients. Noteworthy, lymph-node 
macrophages serve to filter other tissue and lymph borne pathogens in order to prevent their systemic 
translocation and prime innate/adaptive immune responses (Gray and Cyster, 2012; Kastenmuller et 
al., 2012). Of note, MerTK+HLA-DRlow cells, characterized by suppressed anti-microbial responses, 
remain persistently elevated following patients’ admission and are markedly increased in regional 
lymph nodes in ALF.  
 
Taken together, one can postulate that the functional re-orientation of immune cells in the inflamed 
ALF liver may lead to expansion of this immune-suppressive MerTK+ subset not only in the hepatic 
compartment, but given its augmented migratory characteristics, also in regional lymph nodes. Hence, 
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this local monocyte/macrophage reprogramming is likely to be of biological significance in AALF 
that is characterized by systemic immune dysregulation, immuneparesis and a marked susceptibility 
to secondary infections (Antoniades et al., 2014; Antoniades et al., 2012). However, as argued above, 
this hypothesis is based only on in vitro findings and I fully recognize its limitations. Future work 
could assess the in vivo migratory characteristics of ALF monocytes, where for example by using 
fluorescent molecular tomography (FMT) the fate of MerTK+ monocytes during the different phases 
of APAP-induced acute liver injury could be examined, thus allowing to draw more definitive 
















































5. SLPI SUPPRESSES NEUTROPHILS AND PROMOTES THEIR 
CLEARANCE VIA MERTKHIGH MONOCYTES AND MACROPHAGES 
 
5.1 Background and aims 
 
Acute tissue inflammation is characterized by the presence of neutrophils which rapidly migrate to 
sites of infection or injury. Importantly, these leukocytes exert key innate immune functions such as 
bacterial phagocytosis, release of antimicrobial proteins, inflammatory cytokines and cytotoxic ROS 
(oxidative burst) while they also form NETs to target and kill bacteria (Sorensen and Borregaard, 
2016; Xu et al., 2014). However, exaggerated influx of these leukocytes can be deleterious and may 
disrupt tissue homeostasis (Headland and Norling, 2015). Accordingly, neutrophils play an essential 
role in liver inflammation while their excessive recruitment at sites of liver injury contributes 
fundamentally to the pathogenesis of a variety of liver diseases, including ALF (Kubes and Mehal, 
2012).  
 
The key histological feature of resolution of inflammation is the removal of neutrophils from inflamed 
or injured sites (Headland and Norling, 2015). This is achieved through a network of coordinated and 
active processes that occur in an overlapping fashion aimed at the restoration of tissue integrity and 
function (Sugimoto et al., 2016). Neutrophils and monocytes/macrophages are key cellular 
components of this resolving process following tissue injury. Induction of neutrophil apoptosis and 
clearance of apoptotic neutrophils (efferocytosis) by macrophages are critical steps for successful 
resolution of inflammation (Fullerton and Gilroy, 2016; Headland and Norling, 2015). 
 
Hypothesis and aims: 
Given the suggested role for SLPI, as a liver micro-environmental mediator in ALF, in modulating 
liver-resident and newly-infiltrating myeloid cells (Antoniades et al., 2014) and having demonstrated 
here that it crucially modulates monocytes/macrophages towards MerTKhigh resolution responses 
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(Chapter 4), I hypothesized that SLPI also modulates the function and survival of neutrophils. Hence, 
in this chapter I aimed to: 
§ Investigate if SLPI exerts direct or indirect effects, through MerTKhigh cells, on the innate 
immune function and survival (apoptosis) of neutrophils. 
§ Examine the effects of SLPI on altering the phagocytosis of apoptotic cells capacity in 




5.2 Materials and methods 
 
5.2.1 SLPI effects on neutrophils 
 
Human neutrophils were isolated as described in Chapter 2 (2.2.2) and cultured for 6h at 106 cells/ml 
in 24-well plates (Corning, USA) (37oC in 5% CO2) in fresh complete medium. Effects of 
recombinant human (rh)-SLPI (R&D Systems, UK) (0 and 0.5 µg/mL) were assessed. For surface and 
intracellular marker expression, neutrophils were harvested, washed and re-suspended in PBS 
supplemented with 1% fetal bovine serum. Next, they were incubated with mouse anti-human 
monoclonal antibody against CD66b (BD Biosciences, UK) for 20 min at room temperature in the 
dark, and following fixation and permeabilization (BD Biosciences, UK) their TNF-α, IL-6 and IL-8 
(BD Biosciences, UK) levels were determined by flow cytometry using intracellular cytokine staining 
(BD Biosciences, UK) following 6h stimulation with LPS (100 ng/ml) (Sigma-Aldrich, UK).  
 
In addition, effects of SLPI-conditioned and ALF plasma-conditioned monocyte culture supernatants 
on healthy neutrophil survival and function were examined. CD14-isolated monocytes were cultured 
for 48h at 106 cells/ml in 24-well plates (Corning, USA) (37oC in 5% CO2) in fresh complete medium 
containing (rh)-SLPI (R&D Systems, UK) (0 and 0.5 µg/mL) or 25% human plasma from ALF 
patients (n=10). The plasma samples were pre-incubated with anti-human SLPI neutralizing antibody 
(R&D Systems, UK) (0 and 5 µg/ml) for 1 hour at room temperature, as previously described  
(Antoniades et al., 2014). 
 
5.2.2 Measurement of cytokine levels 
 
Human quantikine ELISA was used to measure IL-6, IL-8 and TNF-α levels (R&D Systems, UK) in 
neutrophil culture supernatants following 6h stimulation with LPS (100 ng/ml) (Sigma-Aldrich, UK). 
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ELISA microplates were read using the SoftMax® Pro software (Molecular Devices, USA). All 
experiments were performed in duplicates and according to the manufacturer's instructions. 
 
5.2.3 Neutrophils apoptosis and oxidative burst 
 
Cell apoptosis kit (BD Biosciences, UK) was used to quantitatively determine the percentage of 
neutrophils in culture that are actively undergoing apoptosis. Discrimination of total apoptotic cells 
(Annexin-V+), early apoptotic cells (7-AAD-Annexin-V+) and end stage apoptotic cells (7-
AAD+Annexin-V+) was based on 7-AAD and Annexin-V staining. Phagocytosis and oxidative burst. 
Neutrophil oxidative burst was assessed using the Phagoburst kit (Glycotrope, Germany) by flow 
cytometry, according to the manufacturer's instructions.  
 
5.2.4 Neutrophil extracellular traps (NETs) 
 
NET formation and extracellular DNA quantification. Neutrophils (2 x 105) were stimulated with 25 
nM PMA (Sigma-Aldrich, UK) or 100 ng/mL LPS (Sigma-Adlrich, UK) in the absence and presence 
of (rh)-SLPI (0, and 0.5 µg/mL) (R&D Systems, UK) for 3 hours, 37°C, 5% CO2. Supernatants were 
then removed and centrifuged at 2,200xg for 10 min. Extracellular DNA content was analyzed by 
incubation with 5µM SYTOX Green Dye (Life Technologies, UK) for 10 min and fluorometrically 
examined using a BioTek Synergy HT plate reader (NorthStar Scientific Ltd, UK) at 485/528nm. 
Samples were calibrated to a λ-DNA (Fisher Scientific, UK) standard curve.  
 
NET visualization by fluorescent microscopy. Neutrophils (2 x 105) were seeded onto glass coverslips 
(VWR International, UK) and were stimulated with 25 nM PMA (Sigma-Adlrich, UK) or 100 ng/mL 
LPS (Sigma-Aldrich, UK) with and without the presence of (rh)-SLPI (0, and 0.5 µg/mL) (R&D 
Systems, UK) for 3 hours, 37°C, 5% CO2 before fixation with 4% paraformaldehyde. Neutrophils 
were then permeabilised with 0.1% Triton X-100, stained with 1µM SYTOX Green Dye (Life 
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Technologies, UK), fixed with fluoromount medium and visualized by Zeiss Axiovert 200M 
microscope (Carl Zeiss Ltd, UK).  
 
5.2.5 Μonocyte uptake of apoptotic neutrophils and hepatocytes 
 
Human neutrophils were isolated, as described in (2.2.2), and were re-suspended at 106 cells/ml in 
complete medium, labeled with CellTracker Green CMFDA (Life Technologies, UK) (5 µM in 
serum-free medium, 45 min, dark) and incubated for 20h (37 ̊C in 5% CO2) in 24-well plates 
(Corning, USA). Annexin V kit (BD Biosciences, UK) was used to quantitatively determine the 
percentage of neutrophils in culture actively undergoing apoptosis. The composition of neutrophils 
obtained after incubation was over 70% apoptotic cells, according to Annexin V staining (BD 
Biosciences, UK).  
 
Huh-7 hepatoma cells were cultured in DMEM medium (containing 1% PenStrep, 1% NEAA, 
pyruvate, 1% L-glutamine and 10% FBS) (Life Technologies, UK) in vented culture flasks under 
normal culture conditions (37°C, 5% C02). Cells were passaged no more than 3 times before used in 
experiments. Huh-7 cells were seeded on glass cover slips in 24-well plates and allowed to grow until 
confluent (~0.2x106). Huh-7 cells were washed with PBS and then were labeled with CellTracker 
Green CMFDA (Life Technologies, UK) (5 µM in serum-free DMEM, 45 min, dark). Cells were 
washed again and then were given 300 µl serum-free DMEM containing 20 µM staurosporine (STS) 
(Sigma-Aldrich, UK), which is shown previously to induce apoptosis in murine hepatocytes (Feng 
and Kaplowitz, 2002), or equal volume of DMSO. Cells were cultured for 16h, as described (Feng 
and Kaplowitz, 2002), and then were fixed with 1% PFA (Sigma-Aldrich, UK) in PBS for 5 min, and 
mounted on microscope slides with Prolong Gold antifade mounting reagent (Life Technologies, UK). 
Cells were imaged using a Zeiss LSM 780 microscope at x40 magnification using 0.6 zoom or x63 
magnification under normal zoom.  
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Human primary hepatocytes (Life Technologies, UK) were first thawed using Cryopreserved 
Hepatocyte Recovery Medium (CHRM) (Life Technologies, UK) in order to determine cell count and 
viability using trypan blue staining. Cells were then plated using CHPM medium in a 96-well 
collagen pre-coated plates at a 0.9x106 cells/ml density for 4 h to allow cell adherence, before wash 
and replacement of CHPM with Williams’ E supplemented medium (Life Technologies, UK). 
Hepatocytes were allowed to further adhere overnight. Cultures were then checked for their cell 
morphology and monolayer integrity before being washed and then be supplemented with fresh 
medium only or medium containing 20 mM acetaminophen (APAP) (Sigma-Aldrich, UK) (Khamri et 
al., 2017). After completion of the 24h treatment period, cells were washed and pre-labeled with 
CellTracker Green CMFDA (Life Technologies, UK) (5 µM in serum-free medium, 45 min, dark) 





5.3.1 Effects of SLPI on neutrophil function and survival  
 
Having demonstrated that SLPI induces MerTKhighHLA-DRhigh  monocytes/macrophages (Chapter 
4), I determined whether SLPI can also modulate the function and survival of neutrophils, a critical 
step to initiate resolution of inflammation (Fullerton and Gilroy, 2016). First, I assessed the numbers 
of hepatic neutrophils in human liver explant tissue. Compared to pathological controls, I found that 
ALF patients are characterized by an increased infiltrate of (MPO+) neutrophils (98 vs 336 cells/HPF; 
p< 0.05), with a significantly higher degree of apoptosis (MPO+TUNEL+ cells, 3.7 vs 15.2 %; p 
<0.0001) (Fig. 5.1A). Next, I examined in culture the direct effects of SLPI on healthy neutrophil 
survival and innate immune functions. I found that neutrophil treatment with SLPI did not alter their 
apoptosis rate (Fig. 5.1B) neither impaired their LPS-stimulated pro-inflammatory (TNF-α, IL-6 and 
IL-8) cytokine secretion (Fig. 5.1C) or oxidative burst (Fig. 5.1D). However, in line with a recent 
report describing an inhibitory effect of SLPI on formation of NETs (Zabieglo et al., 2015a), I also 
show that SLPI, used at physiological concentrations detected in ALF patients (Antoniades et al., 
2014), reduced the formation of NETs either without stimulation [73.3 vs 32.4 (DNA, ng/ml), p< 
0.01] or following stimulation with phorbol-myristate-acetate (PMA) [148.7 vs 77.8 (DNA, ng/ml), 
p< 0.05] or microbial challenge (LPS) (59.2 vs 22.8 (DNA, ng/ml), p< 0.05) (Fig. 5.1E).  
 
5.3.2 SLPI-induced MerTKhigh monocytes/macrophages suppress neutrophil function and 
survival in a paracrine manner  
 
In order to investigate whether SLPI could modulate neutrophils in a paracrine manner through the 
induction of a MerTKhighHLA-DRhigh monocyte/macrophage phenotype, I evaluated the: (a) direct 
effects of untreated or SLPI-treated monocytes in co-culture (cell-to-cell-contact) with neutrophils 
and (b) the indirect (paracrine) effects of soluble mediators released from untreated or SLPI-treated 
 163 
monocytes, on neutrophil survival and innate immune responses. My data here demonstrate that 
neutrophils co-cultured with SLPI-treated monocytes had a similar survival rate, LPS-stimulated pro-
inflammatory cytokine levels and oxidative burst, compared to those co-cultured with untreated 
monocytes (Fig. 5.1F).  
 
However, I found that neutrophils cultured in supernatants derived from SLPI-treated monocytes had 
unaltered oxidative burst, significantly increased apoptosis (19.1 vs 24.4 %, p< 0.05) and decreased 
PMA-induced NETosis [265.9 vs 157.3 (DNA, ng/ml), p< 0.05], compared to neutrophils cultured in 
supernatants derived from monocytes treated with medium only (Fig. 5.2A-B). Taken together, these 
data suggested a SLPI monocyte-exerted paracrine suppression of neutrophil activation and function. 
Finally, to determine whether the elevated levels of SLPI, (Antoniades et al., 2014) could account for 
the observed changes, I repeated these in vitro experiments by culturing neutrophils in supernatants 
derived from ALF-plasma conditioned monocytes following neutralization of SLPI, using an anti-
SLPI blocking antibody (α-SLPI). Importantly, I demonstrate that inhibition of SLPI’s activity in 
ALF-derived monocyte supernatants crucially reversed neutrophil apoptosis (26.8 vs 20.5 %, p< 0.05) 
(Fig. 5.2C), augmented PMA-evoked NETosis [173.3 vs 239.3 (DNA, ng/ml), p< 0.05)] (Fig. 5.2D) 










Figure 5.1. Effects of SLPI and SLPI-treated monocytes on neutrophil survival and innate 
immune responses. 
(A) Representative immunohistochemistry (IHC) (left) and confocal (right) micrographs and enumeration of (MPO+) 
hepatic neutrophils and (MPO+TUNEL+) apoptotic neutrophils in centrilobular areas of pathological control (PC, n=4) and 
ALF (n=6) human liver tissue. IHC images (400X) show MPO+ (purple) cells. Confocal images show MPO (green), 
TUNEL (red), DAPI (blue) and co-expression (yellow) (400X). (B-F) Effects of (B-E) (rh)-SLPI (0 and 0.5 µg/ml) in 
culture and (F) (rh)-SLPI treated (0 and 0.5 µg/ml) monocytes in co-culture, on healthy neutrophil survival and innate 
immune responses were examined (n=5 independent experiments each). (B) Representative Annexin-V/7-AAD staining and 
percentage of apoptotic neutrophils after 6h culture. (C) Levels of LPS-stimulated (LPS 100ng/ml) cytokines (TNF-α, IL-6 
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and IL-8) detected (pg/ml) in culture supernatants by ELISA. (D) Representative histograms of neutrophil oxidative burst in 
response to E. coli after different treatments (3h). Results expressed as mean fluorescence intensity (MFI). (E) Neutrophil 
extracellular trap (NET) formation was determined in culture with or without SLPI after neutrophil stimulation for 3h with 
PMA (25nM) or LPS (100ng/ml). (left) Representative fluorescence microscopy imaging of NETs using SYTOX Green Dye 
(1µM). (right) Neutrophil supernatants were stained for extracellular DNA content (ng/ml) with SYTOX Green Dye (5µM) 
and were fluorometrically examined. (F) Effects of (rh)-SLPI treated (0 and 0.5 µg/ml) monocytes were examined in co-
culture (4h, 2:1 ratio) with healthy neutrophils. Data show the percentage of apoptotsis, intracellular cytokines (LPS-
stimulated TNF-α, IL-6 and IL-8 levels as %) and oxidative burst (MFI) after co-culture, all determined by flow cytometry. 
Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed as median values with interquartile range 







Figure 5.2. SLPI suppresses neutrophils in a paracrine manner through MerTK+ monocytes. 
Paracrine effects of untreated or SLPI-treated (0 and 0.5 µg/ml) healthy monocyte supernatants, cultured for 48h, on healthy 
neutrophil survival and innate immune responses were examined (n=3 independent experiments each). (A) Schematic graph 
describing the paracrine experimental approach undertaken. (D) (upper panel) representative Annexin-V/7-AAD staining 
and percentage of apoptotic neutrophils after 6h culture period, (lower panel, left) representative histograms of neutrophil 
oxidative burst in response to E. coli; results expressed as mean fluorescence intensity (MFI) and (lower panel, right) NET 
formation (DNA, ng/ml) after stimulation with PMA or LPS of neutrophils cultured (3h) in ± SLPI-treated monocyte 
supernatants. (C-E) Paracrine effects of monocytes on neutrophils were assessed also by blocking the activity of SLPI on 
monocytes cultured (LPS 100ng/ml for 6h) in ALF plasma (α-SLPI, 5 ug/mL) (n=5 independent experiments each). (C) 
Representative Annexin-V/7-AAD staining and percentage of apoptotic neutrophils (6h), (D) NET formation (DNA, ng/ml) 
after stimulation with PMA or LPS and (E) LPS-stimulated (100 ng/ml) intracellular cytokine levels of neutrophils (n=5) 
cultured in ALF plasma-conditioned monocyte supernatants with or without α-SLPI. Non-parametric (Mann-Whitney) 




5.3.3 SLPI enhances the efferocytosis of apoptotic neutrophils  
 
Clearance of apoptotic neutrophils by monocytes and macrophages (efferocytosis) is another key step 
for successful resolution of inflammation (Fullerton and Gilroy, 2016; Headland and Norling, 2015). 
Having described that SLPI exerts paracrine mediated suppression of neutrophil function, I next 
aimed to investigate its effect on the process of efferocytosis in vitro. For this reason, monocytes 
previously treated with or without SLPI co-cultured with apoptotic neutrophils and their efferocytosis 
index was measured using flow cytometry. I demonstrate that similar to MerTKhigh monocyte analyses 
in ALF (Chapter 2), SLPI-treated monocytes were characterized by significantly increased MerTK 
expression and by enhanced efferocytosis of CMFDA-labeled apoptotic neutrophils, compared to 
cells cultured in medium only (37.5 vs 24.5 %; p< 0.05) (Fig. 5.3A-C). Monocyte treatment with 
dexamethasone, which is previously shown to augment monocyte/macrophage MerTK expression and 
efferocytosis (Zizzo and Cohen, 2013), served as a positive control for the assay and not surprisingly 
led to higher monocyte MerTK expression and efferocytosis index, compared to untreated or SLPI-
treated monocytes (Fig. 5.3A-C). Furthermore, in separate co-culture experiments, I demonstrate that 
SLPI did not alter monocyte phagocytosis of CMFDA-labeled staurosporine-treated apoptotic (Feng 
and Kaplowitz, 2002) Huh7 hepatoma cells (Fig. 5.3D-E), when compared to untreated monocytes. 
Also, treatment of monocytes with SLPI did not affect their phagocytosis of CMFDA-labeled APAP-






Figure 5.3. SLPI enhances monocyte clearance of apoptotic neutrophils. 
CD14-isolated healthy monocytes were pre-cultured with fresh medium, (rh)-SLPI (0.5 µg/ml) or dexamethasone (100nM) 
and co-incubated with apoptotic neutrophils or Huh-7 hepatoma cells (n=3 independent experiments each). Data show (A) 
Representative confocal microscopy images of CMTPX-labelled monocyte engulfment of CMFDA-labelled apoptotic 
neutrophils (original magnification x63); merge/z-stack images: arrows showing co-localized/engulfed cells. (B) Monocyte 
MerTK expression in monocyte subsets after 48h culture with different treatments. (C) Representative flow cytometry 
analysis and percentage of monocytes that phagocytosed CMFDA-labeled apoptotic neutrophils. (D) Representative 
confocal microscopy images of CMFDA+ Huh-7 cells treated with or without 20uM STS (50 um, scale bars). (E) 
Representative flow cytometry analysis and percentage of monocytes that phagocytosed CMFDA-labeled (STS-treated) 
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apoptotic Huh-7 cells. (F) (Left) Data show the percentage of CD14-labeled monocytes that phagocytosed CMFDA-labeled 
APAP-treated (20mM) apoptotic primary hepatocytes (n=2). (Right) Light microscopy images of hepatocytes cultured 
with/without acetaminophen (APAP, 20mM). Non-parametric (Mann-Whitney) statistical analysis was used. Data are 





Recent studies, using the experimental murine model of APAP-induced liver injury, indicate that 
intrahepatic monocytes/macrophages dampen innate immune activation and promote the clearance of 
neutrophils following ALF (Arandjelovic and Ravichandran, 2015; Holt et al., 2008; Zigmond et al., 
2014). The role of neutrophils during ALF remains controversial, with some experimental studies 
suggesting these cells promote and others they have no effect on the severity of acute liver injury 
(Jaeschke et al., 2013). Also, supportive human studies on the role of neutrophils and their clearance 
during resolution of inflammation following ALF are currently missing. Here, using in vitro models 
of human ALF, I provide novel insights into the role of SLPI as a pro-resolving mediator in the liver 
micro-environment on shaping the function of myeloid cells and regulating the interplay between 
them in order to promote resolution of acute hepatic inflammation. 
 
Resolution of inflammation is an active and coordinated anti-inflammatory/pro-resolving program 
aimed at restoration of tissue homeostasis, integrity and function. Hence, pro-resolving mediators 
should ideally exert desired pro-resolution actions and fulfill some of the recently established criteria, 
as further reviewed (Fullerton and Gilroy, 2016; Ortega-Gomez et al., 2013; Sugimoto et al., 2016). 
Here, I provide evidence that identify SLPI as a pro-resolving mediator in ALF, which fulfills some of 
these criteria, through induction of MerTK+HLA-DRhigh monocytes/macrophages, which via both 
autocrine and paracrine mechanisms: a) counter regulate the production pro-inflammatory cytokines 
whilst promoting resolution/tissue-repair mediator release b) suppress neutrophil activation and NET 
formation c) induce neutrophil apoptosis and promote their subsequent clearance.  
 
To date, little is known about the ability of SLPI in modulating apoptosis of myeloid cells. A recent 
study demonstrated that SLPI can inhibit TNF-α-induced apoptosis in monocytes and this effect is not 
dependent on its anti-protease activity, since anti-protease deficient variants of SLPI could also inhibit 
TNF-α-induced apoptosis (McGarry et al., 2015). Another study revealed that SLPI, used at super 
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physiological concentrations (20–80 mg/mL), induces neutrophil chemotaxis and decreases neutrophil 
apoptosis rate in vitro, without any effects on neutrophil IL-8 secretion or adhesion to fibronectin 
(Subramaniyam et al., 2011). In contrast to these findings, I show that SLPI, used at the physiological 
concentrations (0.5 ug/mL) detected in ALF patients (Antoniades et al., 2014), has no direct effect on 
neutrophil survival. However, I identify a paracrine mechanism of neutrophil suppression whereby 
SLPI induces neutrophil apoptosis through induction of MerTKhigh monocytes/macrophages. These 
results corroborate my analyses of ALF liver tissue where I detect an increased proportion of MerTK+ 
hepatic macrophages and apoptotic (MPO+TUNEL+) neutrophils within areas of hepatic necrosis 
(Antoniades et al., 2014).  
 
Furthermore, I show that SLPI promotes the induction of MerTKhigh monocytes/macrophages whilst 
concomitantly augments their capacity to efferocytose apoptotic neutrophils, which is critical for the 
initiation of resolution and tissue-repair processes (Ortega-Gomez et al., 2013; Sugimoto et al., 2016). 
However, the effect of SLPI on apoptotic cell clearance appears to be highly selective, in view of the 
fact that SLPI enhances only the efferocytosis of apoptotic neutrophils capacity but does not alter the 
phagocytosis/clearance of staurosporine-treated apoptotic (Feng and Kaplowitz, 2002) Huh7 cells and 
APAP-treated apoptotic/necrotic (Khamri et al., 2017) primary hepatocytes, thus providing further 
support for its importance in hepatic resolution responses. Future work is needed to understand the 
distinct mechanisms that govern the clearance of parenchymal and non-parenchymal cells following 
liver injury.  
 
During infectious conditions, in addition to bacterial phagocytosis and antimicrobial protein release, 
neutrophils form web-like structures composed of decondensed DNA decorated with histones and 
neutrophil granule proteins, termed NETs, which can trap and kill bacteria (Sorensen and Borregaard, 
2016). Peptidyl-arginine-deiminase-4 (PAD4) and NE are essential for NETosis, as NE is shown to 
cleave histones during this innate process (Papayannopoulos, 2015; Papayannopoulos and Zychlinsky, 
2009). Intravital imaging of the liver in mice revealed that following systemic infection, NETs are 
formed in the liver, in particular within the hepatic sinusoids where they remain anchored to the 
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vascular wall via von Willebrand factor (VWF), thus enabling the organ to protect the body from 
infection by efficiently clearing bacteria (Kolaczkowska et al., 2015; McDonald et al., 2012) and viral 
particles (Jenne et al., 2013). Another study showed that DAMPs released during liver ischaemia-
reperfusion result in the formation of NETs, which subsequently exacerbate tissue damage through 
inflammasome activation (Huang et al., 2015). SLPI, an endogenous inhibitor of NE, was recently 
described to inhibit both in vitro and in vivo the formation of NETs (Zabieglo et al., 2015a). Here, I 
confirm these findings by showing that SLPI, used at physiological concentrations detected in ALF 
(Antoniades et al., 2014), exerts another pro-resolving function by attenuating in vitro NET formation 
in ALF. Future studies, using human and murine models, might confirm in vivo these effects and 
would allow to examine the systemic and intrahepatic role of NETs during ALF, by addressing if their 
presence or absence can alter antimicrobial immunity and exaggerate liver tissue injury or promote 
























6. SLPI INDUCES MERTK+ MACROPHAGES AND PROMOTES 
HEPATIC RESOLUTION DURING ACETAMINOPHEN-INDUCED 
ACUTE LIVER INJURY IN MICE 
 
6.1 Background and aims 
 
My previous data indicated that SLPI modulates in vitro the function of monocytes/macrophages and 
alters the activation and survival state of neutrophils, thereby regulating the interplay between those 
myeloid cells and promoting resolution responses (Chapters 4 & 5). In particular, SLPI induces a 
MerTK+HLA-DRhigh hepatic macrophage phenotype that suppresses neutrophils and promotes their 
apoptosis, in a paracrine manner, whilst enhancing their subsequent clearance. 
 
Hypothesis and aims:  
Based on the above findings, I hypothesized that SLPI could exert in vivo similar pro-resolving effects 
in mice, following APAP-induced acute liver injury, and promote resolution of hepatic inflammation. 
Hence, in this chapter I aimed to: 
§ Investigate the effects of exogenous SLPI administration in WT mice, at both steady state 
conditions and following APAP overdose, by assessing biochemical and histological indices 
of acute liver injury. 
§ Examine if the SLPI-exerted pro-resolving effects could be associated in vivo with changes in 
the hepatic myeloid cell compartment, particularly if it could alter the macrophage phenotype 





6.2 Materials and methods 
 
6.2.1 Animal treatments and sample collection 
 
All animal experiments were conducted in accordance with the UK laws and with approval of the 
Home Office and local ethics committees (PPL 70/7578). Wild-type (WT) mice (male, 8-10 week-
old, C57BL/6J) were obtained from The Jackson Laboratory. Fasted WT mice received an i.p. 
injection of APAP or recombinant-human (rh)-SLPI (16.5 µg/kg) (R&D Systems, UK) or APAP plus 
SLPI at baseline, based on the plasma SLPI levels detected in mice at 8 hours post APAP dose. Mice 
sacrificed at 24 or 48 hours received a second i.p. injection of saline/SLPI at 8 hours post APAP dose 
while mice sacrificed at 48 hours received an additional third i.p. injection of saline/SLPI at 24 hours. 
Groups of mice were culled at the different time points post APAP dosing, being placed under 
terminal anaesthesia receiving single i.p. injection of 0.2 ml of Pentoject (Centaur Services, UK). 
Blood was collected from the right ventricle and plasma levels of alanine transaminase were measured 
using an AU680 chemistry analyzer (Beckman Coulter, UK).  
 
6.2.2 Liver tissue H&E staining and quantification of necrosis 
 
Haematoxylin and eosin staining. Formalin-fixed liver tissue was paraffin-embedded (FFPE) and then 
was sectioned at 4 µm thickness, using a Leica RM2235 rotary microtome (Leica Biosystems, UK).  
Liver sections were next stained with haematoxylin and eosin using the following protocol: dewaxing 
(10 min), rehydration (3 consecutive Et-OH baths with decreasing concentrations followed by a 10 
min immersion in distilled water), Harris haematoxylin (5 min), washing (3 min in tap water), acid 
alcohol (rinse), washing in tap water (3 min), eosin (5 min), washing in tap water (3 min), dehydration 
(3 different 100% ethanol baths – rinsing), clarification (10 min in xylene), mounting with DPX. 
Quantification of necrosis. For the assessment of liver parenchymal injury, H&E stained sections 
from FFPE liver were imaged and assessment was carried out using ImageJ software, as previously 
described in Chapter 3 (3.2.2). 
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6.2.3 Liver tissue immunohistochemistry and imaging 
 
MPO single epitope enzymatic immunohistochemistry. FFPE tissue was cut at 4 µm and picked up on 
poly-l-lysine coated slides which were manually stained using a rabbit polyclonal anti-MPO primary 
antibody (catalog number ab9535, Abcam, UK; dilution 1:50). Slides were dewaxed in xylene, 
rehydrated, subjected to heat-induced epitope retrieval (HIER) using sodium citrate buffer, pH 6, for 
20 minutes, and allowed to cool, followed by 18-hour incubation at 4°C with the primary antibody. 
The signal was detected using the EnVisionTM G/2 Doublestain System, Rabbit/Mouse 
(DAB+/Permanent Red) (product number K536111-2, Dako, UK), and visualized with the Vector 
VIP peroxidase kit (catalog number SH-600, Vector Laboratories, UK). The slides were then 
dehydrated with alcohol, cleared with xylene and cover slipped with DPX (Leica Biosystems, UK) 
after hematoxylin counterstaining. Images were captured and processed with a Nikon Eclipse E600 
microscope using the Nuance™ 3.0.2 (PerkinElmer, UK) multispectral imaging technology. 
 
TUNEL/MPO double-epitope fluorescent immunostaining. FFPE tissue cut at 4 µm using a Leica 
RM2235 rotary microtome (Leica Biosystems, UK) was picked up on poly-L-lysine coated slides 
which were manually stained using an apoptosis staining kit (# C10618, Molecular Probes, UK), 
according to manufacturer’s instructions, followed by an immunofluorescent stain using a rabbit 
polyclonal anti-MPO antibody (# ab9535, Abcam, UK; dilution 1:25). After TUNEL staining, the 
slides were incubated overnight at 4°C with the anti-MPO antibody. The second day the slides were 
incubated for 2 hours at room temperature with a biotinylated goat-anti-rabbit secondary antibody (# 
E043201-8, Dako, UK; dilution 1:100). This was followed by a 1hour incubation at room temperature 
with Alexa Fluor 488-conjugated streptavidin (Life Technologies, UK; dilution 1:100). All slides 
were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (# D1306, Life Technologies, UK), 
cover slipped using a fluorescence mounting medium (# S302380-2, Life Technologies, UK) and 




6.2.4 Flow cytometry of hepatic immune cells 
 
Following excision, liver tissue was mechanically dissociated and passed through a 100 µm cell 
strainer. Tissue homogenates were centrifuged at 60xg for 1 min to pellet the hepatocytes. The 
remaining cells in the supernatant were harvested and next purified using density gradient, prepared 
from Optiprep (Sigma, UK). Mononuclear cells at the interface were collected, washed and red blood 
cells in the cell pellet were lysed following incubation with ACK lysis buffer (Lonza, Switzerland). 
Cells were then blocked with normal mouse serum (Sigma, UK) and were phenotypically 
characterized using antibodies and flow cytometry [F4/80 - AF488 (Serotec, UK); CD11b - PE-
CF594, Ly6G - BV605 (BD Biosciences, UK); Ly6C - PE-Cy7, CD45.2 - eFluor450, MerTK - PE 
(eBioscience, UK)]. Cell acquisition was performed on an LSR Fortessa flow cytometer (BD 








6.3.1 SLPI administration reduces indices of liver injury in mice with APAP-induced acute liver 
injury 
 
Having shown that SLPI acts as pro-resolving mediator in human ALF (Chapters 4 & 5), I aimed to 
assess in vivo the effects of exogenous SLPI administration in WT mice, following APAP-induced 
acute liver injury, regarding the resolution of hepatic inflammation. For these experiments, APAP-
treated WT mice were given SLPI (or saline) at 0 and 8 hours post APAP dose and were sacrificed at 
24 hours for tissue sampling while untreated mice served as the baseline controls. WT mice that were 
sacrificed at 48 hours were additionally dosed with SLPI (or saline) at 24 hours post APAP dose (Fig. 
6.1A).  
 
I first analyzed biochemical and histological indices of liver injury, including plasma ALT levels and 
quantification of hepatic necrosis (%), respectively. Here, I demonstrate that administration of SLPI 
alone did not induce any liver injury in mice, compared to the control animals, either at 24 or 48 hours 
post SLPI dose, as indicated by their similar ALT levels and no detection of liver necrosis in these 
study groups (Fig. 6.1A-C). My results also showed comparable levels of those indices at the 24-hour 
time point, between APAP-treated and APAP plus SLPI treated mice (Fig. 6.1A-C). However, SLPI 
administration in APAP-mice led to a significant reduction in both ALT levels (290 vs 102; U/L, p< 
0.05) and score/percentage of hepatic necrosis (4.2 vs 1.9 %, p< 0.05) during the resolution phase (48 










Figure 6.1. SLPI administration in mice reduces indices of liver injury following APAP 
overdose. 
Wild-type (WT) mice were dosed with SLPI (-/+) or APAP (+/-) or APAP plus SLPI (+/+) while untreated mice (-/-) served 
as baseline controls (n=6/group). Mice were studied at baseline (red, BL), 24 hours (black bars) and 48 hours (grey bars). 
(A) Schematic of experimental dosing for all study groups and representative images of H&E stained livers. (B) 
Quantification of necrosis (%) murine liver tissue. (C) Quantification of plasma alanine transaminase (ALT) levels. Non-
parametric (Mann-Whitney) statistical analysis was used. Data are presented as median values with interquartile range 












6.3.2 SLPI administration in mice induces MerTK+ hepatic macrophages in vivo 
 
In order to investigate if SLPI induces prorestorative macrophages in vivo, as the in vitro human data 
describe above, here I phenotypically characterized the hepatic macrophages isolated from WT mice 
exogenously dosed with SLPI a) at steady-state conditions (no APAP treatment) and b) following 
APAP-induced acute liver injury (with or without SLPI treatment) (Fig. 6.2). Analysis of the hepatic 
non-parenchymal cell population, extracted from liver digests of mice at different time points, was 
performed using flow cytometry. Hepatic macrophages were identified as (CD45+CD11b+Ly6G-) 
F4/80+ cells while eosinophils that are characterized as F4/80int SSChigh cells were excluded by my 
gating strategy (Fig. 6.2A) (Crane et al., 2014). Compared to baseline control levels, I show that SLPI 
induces a significant increase in the overall proportion of (F4/80+) MerTK+ hepatic macrophages at 
steady state following SLPI treatment for 24/48 hours (4.1 vs 24.5/26.1 %; both p< 0.01) (Fig. 6.2A). 
I found that SLPI administration in APAP-treated mice did not alter the (F4/80+) macrophage MerTK 
expression at 24 hours post APAP (Fig. 6.2B). However, SLPI induced an increase in the proportion 
of (F4/80+) MerTK+ cells at 48 hours post APAP dose (19.2 vs 11.5 %: p< 0.05), compared to the 
APAP-treated mice at 48 hours (Fig. 6.2B).  
 
Furthermore, I used the KC vs MoMF gating strategy, as previously (Holt et al., 2008; Mossanen et 
al., 2016; Ramachandran et al., 2012), in order to identify the (F4/80highCD11blow) liver-resident KCs 
and (F4/80lowCD11bhigh) MoMFs and to determine their MerTK expression. I reveal that the increase 
in MerTK+ hepatic macrophages following SLPI treatment, either at steady state or at 48 hours post 
APAP dose, is confined to the liver-resident KC population (Fig. 6.2B). Here, my results show that 
although SLPI administration did not alter the MerTK expression levels within the KC subset at 48 
hours post APAP, it significant upregulated KC MerTK expression at 48 hours (86.2 vs 62.5 %: p< 
0.05), compared to KCs derived from APAP-treated mice at 48 hours (Fig. 6.2B). In addition, no 
differences among different groups and treatments were detected for the total (F4/80+) hepatic 
macrophages, as proportion (%) of total liver CD45+ leukocytes, or in the KC/MoMF ratio within the 




Figure 6.2. SLPI administration in mice induces MerTK expression in hepatic macrophages at 
steady state and following APAP-induced liver injury. 
Wild-type (WT) mice were dosed with SLPI (-/+) or APAP (+/-) or APAP plus SLPI (+/+) while untreated mice (-/-) served 
as baseline controls (n=6/group). Mice were studied at baseline (white bars), 24 hours (black bars) and 48 hours (grey bars). 
(A) Representative flow cytometry analysis and data showing MerTK expression of F4/80+ macrophages at baseline and 
following SLPI administration. (B) Data show MerTK expression levels of F4/80+ macrophages, sub-analyzed into 
(CD11blowF4/80high) Kupffer cells (KC) and (CD11bhighF4/80low) monocyte-derived macrophages (MoMF). (C) Data show 
F4/80+ hepatic macrophages as proportion (%) of total CD45+ leukocytes and the percentage (%) of resident KC and 
MoMF within the F4/80+ population. Non-parametric (Mann-Whitney) statistical analysis was used. Data are presented as 









6.3.3 SLPI administration in APAP-treated mice leads to increased numbers of hepatic 
apoptotic neutrophils in vivo 
 
In view of the role of SLPI in promoting neutrophil apoptosis and clearance, as shown by in vitro 
human data, I examined the number of hepatic neutrophils using liver tissue immunohistochemistry 
and confocal imaging (Fig. 6.3). I found that APAP-treated mice dosed with SLPI had a significantly 
lower number of hepatic (MPO+) activated neutrophils at both 24 hours (27 vs 23 cells/HPF, p< 0.05) 
and 48 hours (14 vs 9 cells/HPF, p< 0.0001) post APAP, compared to APAP-treated mice (Fig. 
6.3A). In addition, APAP-treated mice dosed with SLPI had a significantly higher proportion of 
hepatic (MPO+TUNEL+) apoptotic neutrophils at both 24 hours (7.5 vs 25.3 %, p< 0.0001) and 48 
hours (7.6 vs 34.6 %, p< 0.0001), compared to APAP-treated mice (Fig. 6.3B). Similarly, I previously 
detected an increased proportion of apoptotic neutrophils (MPO+TUNEL+) in areas of necrosis in 
human ALF liver tissue (Fig. 5.1A). Taken together, my results reveal that during experimental 
APAP-induced liver injury in mice, SLPI administration promotes resolution responses by imprinting 






Figure 6.3. SLPI administration in mice induces neutrophil apoptosis following APAP-induced 
liver injury. 
Wild-type (WT) mice were dosed with SLPI (-/+) or APAP (+/-) or APAP plus SLPI (+/+) while untreated mice (-/-) served 
as baseline controls (n=6/group). Mice were studied at baseline (white bars), 24 hours (black bars) and 48 hours (grey bars). 
(A) Representative liver immunohistochemistry images at baseline and 24 hours (n=5 each) and enumeration of MPO+ 
(purple) hepatic neutrophils (200X). (B) Representative liver confocal micrographs at baseline and 24 hours (n=5 each) 
stained for MPO (green), TUNEL (red), DAPI (blue); co-expression (yellow) (400X). Data show the percentage of 
(MPO+TUNEL+) apoptotic neutrophils. Non-parametric (Mann-Whitney) statistical analysis was used. Data are presented 






Several studies using human and experimental models support an immune-modulatory role for SLPI 
during tissue inflammation in a variety of diseases including sepsis, asthma and cancer (Majchrzak-
Gorecka et al., 2016). For instance, SLPI-/- mice are more susceptible to LPS-induced endotoxin shock 
and sepsis caused by cecal ligation and puncture and develop increased inflammation (Nakamura et 
al., 2003). During acute tissue injury and wound healing, SLPI is a key anti-inflammatory mediator in 
the local microenvironment by directly inhibiting the NF-κB dependent pro-inflammatory responses 
of macrophages (Ashcroft et al., 2000; Odaka et al., 2003b; Sano et al., 2000; Sano et al., 2003).  
 
Furthermore, SLPI-/- mice subjected to cutaneous injury show delayed skin wound healing that is 
reversible by SLPI administration to wounds. Use of anti-TGF-β and anti-TNF-α antibodies in vivo 
largely reversed this impaired healing, proposing that a SLPI-mediated control of TGF-β and TNF-α 
levels is required for cutaneous wound healing (Ashcroft et al., 2012; Ashcroft et al., 2000). A critical 
role of SLPI during the resolution phase of wound healing is described in TSLP-deficient mice, which 
have reduced SLPI levels in the colon and following DSS-induced colitis they fail to recover from 
colon damage. That may be due to increased NE activity during the recovery phase and an imbalance 
in proepithelin/epithelin conversion (Reardon et al., 2011). However, the role of SLPI during the 
resolution phase of APAP-induced acute liver injury and its potential pro-resolving actions on hepatic 
inflammation remain unexplored.  
 
Here, my findings are first to describe that exogenous SLPI administration in APAP-treated mice 
promotes resolution of hepatic inflammation following acute liver injury, by inducing a prorestorative 
hepatic macrophage phenotype and modulating neutrophil activation and survival. I demonstrate that 
SLPI, present as a mediator in the liver microenvironment, can increase the proportion of MerTK+ 
hepatic macrophages at steady state conditions and during APAP-induced liver injury. In particular, I 
reveal that SLPI administration selectively upregulates MerTK expression within the hepatoprotetive 
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(Ju et al., 2002b; You et al., 2013), highly phagocytic (Stutchfield et al., 2015), liver-resident Kupffer 
cell population, and not in monocyte-derived macrophages, either at both steady state or inflammatory 
conditions post APAP dose. Furthermore, although SLPI administration did not attenuate peak liver 
injury, it did ameliorate histological/biochemical indices of liver injury at the onset of the resolution 
phase of inflammation (48 hours) post APAP dose. This time course is consistent with the mechanism 
I describe by which SLPI promotes the differentiation of macrophages towards a prorestorative state. 
My data corroborate with previous observations in experimental models of acute tissue injury, which 
suggest that monocytes promote resolution of inflammation under the correct micro-environmental 
signals (Crane et al., 2014; Ramachandran et al., 2012; Zigmond et al., 2014). 
 
SLPI administration in APAP-treated mice not only increased the proportion of MerTK-expressing 
KCs during the resolution phase following acute liver injury but concomitantly decreased the numbers 
of hepatic neutrophils while increased the numbers of apoptotic neutrophils. These findings agree 
with, and may be explained by, the described role of MerTK in promoting resolution of inflammation 
after acute tissue injury by suppressing innate responses and augmenting the clearance of neutrophils 
(Arandjelovic and Ravichandran, 2015; Choi et al., 2015b; Hong et al., 2012). MerTK possesses a 
great functional importance for neutrophil clearance where the MerTK/LXR pathway signaling axis is 
shown to coordinately control neutrophil clearance and homeostasis (Hong et al., 2012). Also, lack of 
MerTK in mice is associated with reduced LXRα and LXRβ abundance and decreased expression of 
their target genes (Choi et al., 2015b). However, in the present study, the role of LXR signaling in 
ALF has not been examined. Further work, including gene expression analyses of liver tissue from 
mice treated with/without SLPI, would assess if this mediator positively modulates the MerTK/LXR 
axis during the time-course of APAP model, thus to enhance clearance of neutrophils and promote 
resolution of acute liver inflammation. 
 
The fact that SLPI administration in APAP-treated mice resulted into increased numbers of apoptotic 
neutrophils in the liver may be mechanistically explained by my previous human data on SLPI and its 
actions as a pro-resolving mediator, as discussed above. Precisely, I demonstrated that it can act as a 
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pro-resolving mediator in the liver microenvironment by modulating the function of hepatic myeloid 
cells and crucially regulating the interplay between them to promote resolution of liver inflammation. 
SLPI mediates this via induction of prorestorative (MerTK+ HLA-DRhigh) hepatic macrophages in 
vitro which counter regulate cytokine secretion towards resolution/tissue-repair, suppress neutrophil 
activation and induce neutrophil apoptosis, in a paracrine manner, whilst promoting their subsequent 
clearance. Of note, this SLPI-induced MerTK+ HLA-DRhigh phenotype in human macrophages bears 
a remarkable similarity with the in vivo effects of SLPI in mice, where it augments the proportion of 
prorestorative MerTK+ MHCclassIIhigh and highly phagocytic liver-resident KCs at steady state and 
crucially during the resolution phase following APAP-induced liver injury.  
 
The novel findings about SLPI in this study could be extended further with future work addressing if 
SLPI administration in APAP-treated mice also alters in vivo their liver micro-environmental milieu, 
as per human data above. That could be performed by using gene expression analyses of murine liver 
tissue, during the time-course of experimental APAP-induced ALF, in order to assess the expression 
levels of pro-inflammatory cytokines and resolution/tissue-repairs between the different study groups. 
In addition, it would be interesting to demonstrate ex vivo in these mice, using flow cytometry based 
techniques, if SLPI treatment leads to increased apoptosis rate of hepatic neutrophils in the liver and 





























7. IMMUNE PROFILING OF PATIENTS WITH SERONEGATIVE 
ACUTE LIVER FAILURE 
 
7.1 Background and aims 
 
Most studies in human ALF have focused in drug-induced acute liver injury, and in particular AALF, 
with therapeutic strategies not necessarily being applicable to all ALF causes. This may be explained 
by the distinct mechanisms underlying the pathophysiology of liver injury which vary according to 
the different ALF etiologies (Bernal et al., 2010; Bernal et al., 2013). As previously mentioned, SALF 
is another increasingly well-recognized cause of ALF due to yet unknown etiology. Its current clinical 
diagnosis is based on exclusion of other causes of hepatocellular injury such as viral, autoimmune or 
drug-induced hepatitis (Bernal et al., 2010; Bernal et al., 2013) while it is believed that it occurs due 
to a dysregulated immune response to an unidentified hepatotropic or environmental trigger (Donaghy 
et al., 2013).	
 
In contrast to the pathogenesis of AALF where the toxic metabolites of paracetamol induce direct 
hepatocyte damage and necrosis, SALF has been associated with a lymphocytic infiltrate of effector T 
cells, NK cells and to a lesser extent B cells (Tuncer et al., 2013). That drives immune-mediated 
cytotoxic damage to hepatocytes that culminates in massive hepatic necrosis and liver failure (Tuncer 
et al., 2013; Wu et al., 2010). These histological features and the detection of increased circulating 
levels of autoantibodies also propose SALF as an autoimmune-mediated disorder (Stravitz et al., 
2011). In both underlying etiologies of ALF, the recruited immune cells themselves contribute to 
hepatocyte damage mediated via direct activation of death receptors or cytokine secretion (Bernal et 
al., 2010; Quaglia et al., 2008). Thus, mechanisms designed to orchestrate liver regeneration and 





Hypothesis and aims: 
Given the limited data on human SALF and the unexplored role of monocytes/macrophages in its 
pathogenesis, I hypothesized that the underlying mechanisms of immune-mediated liver injury differ 
in SALF, compared to AALF, and monocytes/macrophages in SALF are typified by overwhelming 
pro-inflammatory responses and bear similarities with the macrophage activation syndrome. Hence, in 
this chapter I aimed to: 
§ Examine the circulating and hepatic micro-environmental milieu in SALF patients and HC, 
by measuring the levels of key inflammatory cytokines and mediators. 
§ Assess the pro-inflammatory cytokine secretion following microbial challenge in SALF, 
AALF and HC. 






7.2 Materials and methods 
	
7.2.1 Isolation of peripheral blood mononuclear cells 
 
Whole blood was obtained from healthy volunteers (HC, n=5) and SALF patients (n=10) (Table 7.1) 
recruited at King’s College Hospital and peripheral blood mononuclear cells (PBMCs) were isolated 
using Ficoll-Paque Plus (GE Healthcare) and were washed in PBS (Life Technologies, UK). Cell 
viability was >95% according to trypan blue staining.  
	
7.2.3 Measurement of inflammatory mediator and cytokine levels 
 
Human quantikine ELISA (R&D Systems, UK) was used to measure TNF-α and IL-6 levels in PBMC 
culture supernatants in HC, AALF and SALF patients, following 6h LPS (100 ng/ml) stimulation 
(Sigma-Aldrich, UK). Human quantikine ELISA (R&D Systems, UK) was also used to measure TGF-
β1, sCD163, IL-2Ra levels in human plasma and liver tissue homogenates from pathological controls 
and SALF patients. The MSD Human Pro-inflammatory 7-plex panel was used to assess (IFN-γ, IL-
1β, IL-4, IL-8, IL-10, IL-12p70 and TNF-α) cytokine levels in human plasma and liver tissue 
homogenates from pathological controls and SALF patients. ELISA microplates were read using the 
SoftMax® Pro software (Molecular Devices, USA). MSD plates were read on the Sector Imager 2400 
apparatus (Gaithersburg, MD). All experiments were performed in duplicates and according to the 
manufacturer's instructions. 
 
7.2.3 Tissue sampling, immunohistochemistry and imaging 
 
Human liver tissue was obtained from AALF (n=10) and SALF (n=10) patients undergoing orthotopic 
liver transplantation and from hepatic resection margins of colorectal malignancies, which served as 
pathological controls (PC, n=5). Single-epitope enzymatic immunohistochemistry for detection of 
CD68, CD3, CD4, CD8, MPO, FoxP3, T-bet, CD56 and Perforin expressing cells. FFPE tissue was 
cut at 4 µm using a Leica RM2235 rotary microtome (Leica Biosystems, UK) and picked up on poly-
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L-lysine coated slides. All slides were dewaxed in xylene, rehydrated, subjected to heat-induced 
epitope retrieval (HIER) for 20 min, allowed to cool, followed by manual staining using a) mouse 
monoclonal anti-CD68 primary antibody (# PA0273, Leica Biosystems, UK; ready-to-use), b) rabbit 
polyclonal anti-CD3 antibody (# A0452, Dako, UK; dilution 1:100), c) mouse monoclonal anti-CD4 
primary antibody (# M7310, Dako, UK; dilution 1:200), d) mouse monoclonal anti-CD8 primary 
antibody (# M7103, Dako, UK; dilution 1:200), e) rabbit polyclonal anti-MPO primary antibody (# 
ab9535, Abcam, UK; dilution 1:50), f) mouse monoclonal anti-Foxp3 primary antibody (# ab22510, 
Abcam, UK; dilution 1:100), g) mouse monoclonal anti-T-bet primary antibody (# sc-21749, Santa 
Cruz Biotechnology, UK; dilution 1:100), h) mouse monoclonal anti-CD56 primary antibody (# 
75603, Invitrogen/ThermoFisher, UK; dilution 1:500), i) mouse monoclonal anti-Perforin primary 
antibody (# 141009, Novocastra/Leica Biosystems, UK; dilution 1:20). All slides were dewaxed in 
xylene, rehydrated, subjected to heat-induced epitope retrieval (HIER) for 20 min, allowed to cool, 
followed by incubation at room temperature with the primary antibody. The signal was detected using 
EnVisionTM G/2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) (# K536111-2, Dako, 
UK) and was visualized with Permanent Red. The slides were then dehydrated with alcohol, cleared 
with xylene and cover slipped with DPX (Leica Biosystems, UK) after hematoxylin counterstaining. 
Images were captured with a Nikon Eclipse E600 microscope. 
	
	
7.2.4 Statistical analysis  
 
Analysis and graphing of data were performed using GraphPad Prism 6 software (GraphPad Software, 
La Jolla California, USA). Statistical significance was assessed with non-parametric analysis for data 
not normally distributed, unless otherwise specified in figure legends. Results are presented as median 








7.3.1 Measurement of circulating and hepatic levels of key inflammatory cytokines in SALF  
 
I examined the levels of circulating key inflammatory cytokines in serum derived from SALF patients 
(n=10) and healthy volunteers (HC, n=5) (Table 7.1). Compared to HC, my results show that SALF 
patients are characterized by significantly higher circulating levels of pro-inflammatory [IFN-γ (0 vs 
0.31), IL-1β (0 vs 0.01), IL-6 (0.02 vs 5.14) and IL-8 (0.46 vs 32.34)] and anti-inflammatory [IL-10 
(0.07 vs 17.21) and TGF-β1 (10.57 vs 162.4)] cytokines (all pg/ml; p<0.01) (Fig. 7.1A). Also, I 
quantified inflammatory cytokines in liver tissue homogenates in SALF n=10) and PC (n=5). My 
results reveal that compared to PC, hepatic concentrations of IL-8 (12.72 vs 214.4) and TGF-β1 (0.43 
vs 2.75) are significantly elevated in patients with SALF (both pg/ml; p<0.05) (Fig. 7.1B). In 
addition, I measured the circulating and hepatic levels of macrophage (sCD163) and T cell (IL-2Rα) 
activation markers; both were found significantly elevated in SALF in comparison to HC and PC 
samples (both p<0.01) (Fig. 7.2). 
 
7.3.2 LPS-induced pro-inflammatory cytokine secretion is unaltered in SALF patients 
 
I determined in culture the LPS-induced pro-inflammatory (TNF-α and IL-6) cytokine secretion of 
PBMCs in SALF, AALF patients and HC (n=10 per group). In accordance with previous findings 
(Antoniades et al., 2014), I found that patients with AALF exhibit significantly reduced levels of 
TNF-α (733 vs 2382) and IL-6 (804 vs 2466) following microbial challenge, compared to HC (pg/ml; 
p<0.01) (Fig. 7.3). However, LPS-simulated TNF-α/IL-6 secretion levels of PBMCs were comparable 









Abbreviations: INR: international normalized ratio; AST: aspartate aminotransferase; MELD: Model for End stage Liver 
Disease; WCC: white (leukocyte) cell count. 
	
  












































A) Circulating levels of key inflammatory cytokines in SALF patients 
 
 
B) Hepatic levels of key inflammatory cytokines in SALF patients 
 
 
Figure 7.1. Circulating and hepatic levels of key inflammatory cytokines in SALF patients. 
Levels of pro-inflammatory (IFN-γ, TNF-α, IL-6, IL-8, IL-12p70) and anti-inflammatory (TGF-β1, IL-10) cytokines (pg/ml) 
were determined (duplicates) using ELISA in (A) serum from SALF patients (n=10) and healthy controls (n=5), and (B) 
liver tissue homogenates from SALF patients (n=10) and pathological controls (n=5). Non-parametric (Mann-Whitney) 









Figure 7.2. Circulating and hepatic levels of macrophage/T-cell activation markers in SALF. 
Levels of macrophage (sCD163) and T cell activation (IL-2Ra) markers (pg/ml) were determined (duplicates) using ELISA 
in a) serum from SALF patients (n=10) and healthy controls (n=5) and b) in liver tissue homogenates from SALF patients 
(n=10) and pathological controls (n=5). Non-parametric (Mann-Whitney) statistical analysis was used. Data are expressed as 





Figure 7.3. Pro-inflammatory cytokine secretion of PBMCs following LPS stimulation in SALF. 
PBMCs isolated from patients and healthy volunteers were stimulated with LPS (100 ng/ml) for 6h in culture. Levels of 
TNF-α and IL-6 (pg/ml) were determined (duplicates) using ELISA in cell culture supernatants from SALF (n=10) and 
AALF (n=10) patients and healthy controls (n=10). Non-parametric (Mann-Whitney) statistical analysis was used. Data are 
expressed as median values with interquartile range (IQR). ** p< 0.01, ns: non-significant. 
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7.3.3 Characterization of the hepatic immune cell infiltrate in SALF  
 
In order to fully characterize the hepatic immune cell infiltrate in SALF patients, I performed single-
epitope immunohistochemistry for different markers (CD68, CD3, CD4, CD8, T-bet, MPO, CD56, 
Perforin and FoxP3) on liver tissue derived from SALF (n=10), AALF (n=10) patients and PC (n=5). 
My analysis revealed that hepatic macrophages (CD68+) are the predominant inflammatory cell 
population in SALF, detected in centrilobular and periportal areas at significantly higher numbers 
compared to PC tissue (Fig. 7.4). In addition, lymphocytes (CD3+) and neutrophils (MPO+) were 
concentrated in portal tracts in SALF, in comparison with PC (Fig. 7.4). Interestingly, I demonstrate 
that there is a Th1 lymphocytic (T-bet+) rich infiltrate in both centrilobular and periportal areas only 
in the liver of SALF patients, compared to liver tissue derived from AALF patients and PC (Fig. 7.4). 
Finally, SALF patients exhibited lower number of hepatic NK (CD56+) and Perforin+ cells whereas 
FoxP3+ cells were significantly increased, in both centrilobular and periportal areas, compared to PC 













Figure 7.4. Characterization of the immune cell infiltrate in liver tissue of SALF patients. 
The characterization of the immune cell infiltrate was performed using single-epitope immunohistochemistry on human 
explant liver tissue. Left panel: data show the quantification of immune cells within areas of necrosis [C] and portal tracts 
[P] in tissue from SALF (n=10), AALF (n=10) and pathological controls (n=5). For each section, 10 randomly chosen portal 
tracts or areas of centrilobular necrosis were assessed at high magnification and the cumulative number of positive cells in 
10 fields was recorded. Right panel: representative immunostain images and patterns of expression (red+) of CD68+, CD3+, 
MPO+, T-bet+, positive cells (magnification X40). Non-parametric (Mann-Whitney) statistical analysis was used. Data are 








To date, the underlying mechanisms of immune-mediated liver injury in SALF are poorly understood. 
Phenotypically, these patients present with a marked SIRS response and previous analyses of liver 
tissue suggest overwhelming pro-inflammatory responses, which in combination with the detection of 
circulating autoantibodies in SALF, propose that it shares similarities with autoimmune liver disease 
(Stravitz et al., 2011). Hence, to further characterize this rare cause of ALF, I analyzed the circulating 
and hepatic inflammatory microenvironment in SALF. My results reveal that SALF patients exhibit 
higher circulating levels of pro-(IFN-γ, IL-1β, IL-6, IL-8) and anti-(IL-10 and TGF-β1) inflammatory 
cytokines, compared to healthy controls. Also, they have high levels of macrophage (sCD163) and T 
cell (IL-2Rα) activation markers. Furthermore, I demonstrate that hepatic concentrations of IL-8, 
TGF-β1, IL-2Rα and sCD163 are elevated in SALF, compared to pathological controls, while the 
TNF-α and IL-6 secretion is comparable between SALF and HC, suggesting intact pro-inflammatory 
responses in SALF patients. The immunohistochemical analysis reveals a macrophage and Th1-
lymphocytic rich infiltrate, in both centrilobular and periportal areas in the SALF liver, compared to 
AALF and pathological controls. Taken together, these data indicate that SALF is a Th1-cell driven 
disease, as distinct to AALF, characterized by a profound activation of pro-inflammatory responses 
(Triantafyllou et al., 2014). 
 
Clinically and pathologically, SALF bears similarities with macrophage activation syndrome (MAS). 
The main pathophysiologic feature of MAS is excessive activation and expansion of T lymphocytes 
and macrophages, as observed in SALF (Ravelli et al., 2012; Schulert and Grom, 2015). Importantly, 
these activated immune cells produce large amounts of pro-inflammatory cytokines (IL-1β, IL-6, IL-
18, TNF-α, and IFN-γ), creating a “cytokine storm” which is central to the pathogenesis of MAS 
(Ravelli et al., 2012; Schulert and Grom, 2015). Whatever the upstream events that trigger SALF, the 
end product is escalating production of pro-inflammatory cytokines that lead to excessive liver 
damage. Interestingly, cytokine-targeted biologic therapies have been tried in patients with MAS 
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(Ravelli et al., 2012; Schulert and Grom, 2015). Similarly, monoclonal antibodies directed against 
pro-inflammatory cytokines (e.g. IL-1β, IFN-γ) or T cell activation marker (IL-2Rα) that is detected 
here, could be used for therapeutic intervention in SALF. Hence, immunotherapeutic strategies could 
be assessed in SALF in order to attenuate pro-inflammatory responses and severity of liver failure.  
 
Most clinical and experimental studies in ALF focus in drug-induced acute liver injury, in particular 
AALF, with therapeutic strategies not necessarily being applicable to all ALF causes. This may be 
explained by the distinct mechanisms underlying the pathophysiology of liver injury which vary 
according to the ALF etiologies (Bernal et al., 2010; Bernal et al., 2013). In the present study, most 
analyses were performed on AALF samples, however the function of monocytes/macrophages may 
differ between ALF cases (Donaghy et al., 2013), for instance in SALF patients, while the evidence I 
provide here support also this notion (Triantafyllou et al., 2014). These histological features of SALF 
and the detection of circulating autoantibodies also suggest it may be an autoimmune-mediated 
disorder (Stravitz et al., 2011). Of note, MerTK is crucial for the effective clearance of apoptotic 
immune cells, and has been implicated in autoimmune disease such as SLE and multiple sclerosis 
(Mukherjee et al., 2016).  
 
Taken together, further studies are needed to characterize the phenotype and function (phagocytosis, 
efferocytosis and cytokine production) of circulating and hepatic monocytes/macrophages in SALF 
patients. Future work should expand the findings in AALF of this study, and investigate the role of 
the prorestorative, MerTK+, monocyte/macrophage subset in SALF or other ALF causes. It would be 
also interesting to explore this signaling pathway in patients with autoimmune hepatitis that are 
characterized by impaired immune regulation and excessive liver inflammation and damage. Studies, 
using human and experimental models, could assess the utility of MerTK as an immune-therapeutic 
target in a variety of hepatic disorders, aimed to quell tissue destructive responses and promote 























8. GENERAL DISCUSSION 
 
The data presented in this thesis describe a significant expansion of monocytes/macrophages that have 
a prorestorative MerTK+ phenotype, detected in circulatory, hepatic and lymphatic compartments of 
ALF patients. The biological significance of this immune-regulatory subset is highlighted through its 
strong correlations with physiological/biochemical indices of hepatic injury and with the magnitude of 
SIRS. Immune-phenotypic analyses revealed that MerTK+ cells possess a CD163highTie-2highHLA-
DRhigh expression profile with augmented tissue (CCR2highCCR5highCCR7high) homing characteristics, 
results that extend previous findings (Antoniades et al., 2006; Antoniades et al., 2014; Antoniades et 
al., 2012; Bernsmeier et al., 2015). Comparison of the gene expression profiles between MerTK+ and 
MerTK- cells in steady state and ALF reveal that MerTK+ monocytes have a more differentiated 
lineage “tissue-like” profile, with increased expression of a number of genes associated with innate 
and adaptive effector functions. My data demonstrate marked elevations in the levels of MerTK+ 
circulating cells in patients with both acetaminophen (AALF) and non-acetaminophen (NAALF) 
induced ALF. It is noteworthy that the highest MerTK expression levels are detected in monocytes 
from AALF patients who exhibit a greater severity of acute liver injury. Peak circulating MerTK 
levels are detected on admission to the Liver Unit, which may reflect the extent of hepatic tissue 
resolution responses following acute hepatocellular necrosis. Prospective clinical studies are 
warranted to assess the utility of MerTK circulating levels as a mechanistic biomarker of resolution 
responses and outcome in ALF patients.  
 
In keeping with other models of acute tissue injury (Bernsmeier et al.; Choi et al., 2013; Lee et al., 
2012c; Wan et al., 2013), functional analyses show that these prorestorative cells suppress innate 
immune activation whilst concomitantly promote resolution responses by augmenting clearance of 
cellular/infective material and secreting anti-inflammatory/tissue-repair mediators (e.g. SLPI). Here, I 
identify two MerTK+ monocyte subsets with differential HLA-DR expression that are phenotypically 
similar but functionally distinct. Compared to MerTK+HLA-DRlow, MerTK+HLA-DRhigh cells are 
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characterized by higher phagocytic/efferocytic capabilities with peak circulating levels detected on 
admission whereas MerTK+HLA-DRlow cells remain persistently elevated following admission. 
 
My results show that MerTK+ macrophages are expanded in areas of hepatocellular necrosis in ALF, 
forming ring-like structures around the areas of injured liver parenchyma, with MerTK+HLA-DRhigh 
located in the outer rim of necrosis whereas cells in central and perivenular areas are predominately 
MerTK+HLA-DRlow. This echoes recent findings from other experimental models of sterile liver 
injury where the in situ reprogramming of monocytes is shown; the transition of recruited monocytes 
from outer sites of injured areas towards their center is associated with a phenotypic and functional 
conversion, essential to facilitate tissue-repair and wound healing processes (Dal-Secco et al., 2015; 
Mori et al., 2009). Further work is currently planned where by using the APAP experimental model 
and advanced imaging techniques, including intravital non-invasive microscopy and fluorescent 
molecular tomography (FMT), I aim to investigate in vivo if monocytes/macrophages possess this 
resolution-like identity prior to homing or acquire, even augment, their phenotypic and functional 
characteristics in situ following recruitment from the circulation to sites of acute liver injury. 
 
Experimental models of acute liver injury provide evidence that the influx of circulatory myeloid cells 
in areas of necrosis triggers resolution responses (Dambach et al., 2002; Holt et al., 2008; Zigmond et 
al., 2014), however human data is currently limited (Antoniades et al., 2014; Antoniades et al., 2012). 
Here, I provide novel insights into the migratory characteristics of ALF monocytes. I show that a high 
proportion of MerTK+ monocytes/macrophages express tissue and lymph-node (CCR2, CCR5 and 
CCR7) homing receptors, suggesting they are equipped to migrate into tissues compartments. I 
provide also evidence that monocytes, particularly MerTK+ cells, efficiently migrate across hepatic 
endothelium and subsequently reverse migrate out of it, bearing the characteristic MerTKhighCD163high 
phenotype. Accordingly, these cells are expanded in hepatic and lymphatic tissue compartments in 
ALF patients. These findings suggest a dynamic circulatory pathway, in which MerTK+ cells home 
from the inflamed liver to regional lymph nodes and/or back into the circulation (Antoniades et al., 
2012; von Andrian and Mempel, 2003; Zigmond et al., 2014). To support and prove such hypothesis, 
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further in vivo research is warranted to assess the migratory characteristics of ALF monocytes. This 
could be also achieved using the APAP experimental model and intravital non-invasive microscopy. 
Furthermore, FMT could be employed to examine in vivo the fate of MerTK+ monocytes during the 
different phases of acute liver injury in order to draw more definitive conclusions regarding the “re-
circulation” story. In another experiment, I could adoptively transfer MerTK-labelled macrophages, 
obtained by flow cytometry based sorting from murine liver, during the different phases of APAP-
induced acute liver injury and use the FMT technology to track their fate. 
 
This work has identified three key micro-environmental processes in the ALF inflamed liver that 
drive monocytes/macrophages towards a resolving program. First, I highlight a novel regulatory role 
for biliary epithelial cells, which through their skewed anti-inflammatory molecule secretion (e.g. 
SLPI) induce the development of the MerTK+ phenotype. Second, phagocytosis of apoptotic cells 
triggers a macrophage functional switch towards an immune-regulatory phenotype associated with 
resolution and tissue-repair properties (Bellingan et al., 2002; Bystrom et al., 2008). Accordingly, I 
demonstrate that exposure/phagocytosis of apoptotic neutrophils and hepatocytes, detected in the 
injured ALF liver, cause a functional switch in MerTK+ cells from an HLA-DRhigh to HLA-DRlow 
expression status, recapitulating the prorestorative phenotype described in ALF. Third, the induction 
of MerTK+HLA-DRhigh macrophages by SLPI, that is produced by BECs and hepatic macrophages 
(Antoniades et al., 2014), which via autocrine/paracrine mechanisms counter regulate cytokine 
release, suppress neutrophil activation and induce neutrophil apoptosis while promoting their 
subsequent clearance. 
 
Although anti-inflammatory programs initiated following phagocytosis of apoptotic cells and debris 
are beneficial in resolving tissue injury and inflammation, they may have the undesirable potential to 
dampen anti-microbial responses (Fullerton and Gilroy, 2016; Grabiec and Hussell, 2016). My data 
support this notion where I demonstrate that acute liver injury can reprogram hepatic myeloid cells 
towards MerTK+ resolution responses, that quell tissue inflammation and promote the clearance of 
debris. Both MerTK+HLA-DRhigh and MerTK+HLA-DRlow cells, characterized by suppressed anti-
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microbial responses, are significantly elevated in the circulatory, hepatic and crucially in lymphatic 
tissue compartments in ALF. Noteworthy, lymph-node macrophages serve to filter other tissue and 
lymph borne pathogens in order to prevent their systemic translocation and prime innate/adaptive 
immune responses (Gray and Cyster, 2012; Kastenmuller et al., 2012). The consequences are likely to 
be systemic immune suppression and anti-inflammatory responses. Whereas this may help to suppress 
ongoing systemic inflammation it will contribute to the observed immuneparesis and susceptibility to 
infection in these patients, which is such a devastating complication of ALF.  
 
My data from the experimental model for this disease are first to provide novel insights into the origin 
and biological relevance of these regulatory cells during acute hepatic injury. Here, I show that the 
proportion of MerTK+ cells are specifically increased in the resident Kupffer cell, and not infiltrating 
macrophage, population following APAP-induced acute liver injury. Moreover, MerTK+ Kupffer 
cells bear a MHC class IIhigh Ly6Clow phenotype which is not only the dominant phagocytic (David et 
al., 2016; Stutchfield et al., 2015) and prorestorative (Dragomir et al., 2012; Ramachandran et al., 
2012) hepatic macrophage population but also bears similarities with “pro-phagocytic” MerTK+HLA-
DRhigh cells identified in humans. Whilst the proportion of MerTK+ MoMFs do not substantially 
increase over the time course, these cells transit from a (baseline) MHC class IIlow Ly6Chigh phenotype 
during resolution the resolution phase towards an pro-restorative MHC class IIhigh Ly6Clow phenotype 
(Dragomir et al., 2012; Ramachandran et al., 2012), in accord with previous findings and consistently 
with their proposed role in resolving hepatic inflammation (Holt et al., 2008; Zigmond et al., 2014). 
 
I demonstrate that Mer-deficient mice have a reduced proportion of resident Kupffer cells prior to and 
following APAP administration. In view of its role in promoting cell survival through activation of 
anti-apoptotic pathways (Anwar et al., 2009), this data suggest that activation of MerTK in Kupffer 
cells is of importance in differentiation and restoration following acute liver injury. Further studies are 
warranted to identify the precise mechanisms through which MerTK regulates this process in both 
human and experimental models of disease. My findings in APAP-treated Mer-deficient mice echo 
recent data showing that MerTK promotes resolution of inflammation by dampening innate responses 
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and augmenting the clearance of neutrophils following experimental acute tissue injury (Arandjelovic 
and Ravichandran, 2015; Choi et al., 2015b; Hong et al., 2012). In the absence of MerTK, I report a 
significant depletion in the hepatoprotective MHC class IIhigh Ly6Clow liver-resident macrophages (Ju 
et al., 2002b; You et al., 2013), with the highest phagocytic capabilities (Stutchfield et al., 2015), with 
a reciprocal increase in hepatic neutrophils and persistent necrosis following APAP administration. 
Together, these data indicate that the MerTK-bearing cells identify a hepatic macrophage population 
with enhanced phagocytic capabilities, that evolve following acute hepatocellular necrosis serving to 
drive hepatic resolution responses.   
 
In both experimental and human models of ALF, I identify SLPI as a micro-environmental mediator 
that critically regulates the interplay between myeloid cells to promote hepatic resolution responses 
through the induction of a MerTKhigh phenotype. Specifically, I demonstrate that SLPI selectively 
induces MerTK expression in the liver-resident Kupffer cells whilst concomitantly increasing the 
number of apoptotic neutrophils. However, there is no data on how SLPI modulates neutrophil 
function. Here, I show that SLPI induces neutrophil apoptosis in a paracrine manner and augments 
their subsequent clearance through MerTKhigh cells. The effect of SLPI on cell clearance appears to be 
highly selective in view of the fact it does not alter the clearance of APAP-treated apoptotic/necrotic 
parenchymal cells. Future studies could delineate the distinct mechanisms that govern the clearance of 
parenchymal and non-parenchymal cells following liver injury. Furthermore, I determined that SLPI 
also drives pro-resolution responses through attenuation of NET formation in ALF; a neutrophil 
process that exacerbates acute tissue damage through activation of the inflammasome in ischaemia-
reperfusion injury (Huang et al., 2015). Human and murine models might confirm in vivo these effects 
and would allow to examine the systemic and liver-specific role of NETs in ALF, addressing if their 
presence, or absence, can alter antimicrobial immunity, modulate myeloid cell function and promote 
resolution of liver inflammation in ALF. 
   
Most clinical and experimental studies in ALF focus on drug-induced acute liver injury, in particular 
AALF, with therapeutic strategies not necessarily being applicable to all ALF causes. This may be 
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explained by the distinct mechanisms underlying the pathophysiology of liver injury which vary 
according to the etiologies (Bernal et al., 2010; Bernal et al., 2013). Here, most analyses were 
performed on AALF samples, however the function of monocytes/macrophages may differ between 
ALF cases, for instance in SALF, another cause of ALF with yet unknown etiology (Donaghy et al., 
2013). SALF is proposed to be due to a dysregulated immune response to an unidentified hepatotropic 
or environmental trigger (Donaghy et al., 2013) while it is associated with a lymphocytic infiltrate of 
effector T cells, NK cells and B cells, suggesting that this drives immune-mediated damage cytotoxic 
to hepatocytes which culminates in liver necrosis and failure (Tuncer et al., 2013; Wu et al., 2010).  
 
I provide recent evidence that SALF is a Th1-cell driven disease, characterized by a macrophage/Th1-
lymphocytic rich infiltrate, a profound elevation in circulating and hepatic levels of macrophage and 
lymphocyte activation markers and intact PBMC pro-inflammatory responses (Triantafyllou et al., 
2014). These histological features and the detection of circulating autoantibodies in SALF are also 
suggestive of an autoimmune-mediated disorder (Stravitz et al., 2011). Of note, MerTK is crucial for 
the effective clearance of apoptotic immune cells, thus it has also been implicated in autoimmune 
disease such as SLE and multiple sclerosis (Mukherjee et al., 2016). Together, further work should 
expand the findings of the present study and investigate the role and function of this prorestorative, 
MerTK+, monocyte/macrophage subset in SALF or other ALF causes. It would be also interesting to 
explore this signaling pathway in patients with autoimmune hepatitis who are characterized by 
impaired immune-regulation and excessive liver inflammation and immune-mediated damage. Future 
studies, using human and experimental models, could assess the utility of MerTK as an immune-
therapeutic target in a variety of hepatic disorders, aimed to quell tissue destructive responses and 
promote resolution of hepatic inflammation. 
 
 
This work identified the induction of an immune-regulatory MerTK+ cell subset in ALF that may 
promote tissue-repair responses, with implications for therapeutic intervention where enhancing the 
local function of these cells could promote liver repair and regeneration. In this study, I utilized the 
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pro-resolving actions of SLPI as proof-of-principle in order to highlight the biological significance of 
the MerTK+ phenotype in promoting resolution responses following acute liver injury. Using targeted 
strategies to harness the prorestorative abilities of MerTK+ cells represents a promising therapeutic 
avenue in promoting tissue repair potentially in a number of acute hepatic inflammatory disorders. 
However, caution would need to be exercised when considering any of these therapeutic approaches 
given the evidence of peripheral monocyte suppression in ALF (Antoniades et al., 2006; Antoniades 
et al., 2014), indicating that the timing of therapy would need to be carefully calibrated in order to 
promote resolution whilst minimizing the impact on immuneparesis. The balance of these biological 
processes must be rationalized when considering interventional strategies that promote liver repair 
processes whilst not exacerbating the risk of infection.  
 
In conclusion, the data in this thesis describe a marked expansion of a prorestorative MerTK+ 
phenotype in circulating monocytes and tissue macrophages during ALF. These immune-regulatory 
cells evolve in response to micro-environmental cues within the injured liver, as summarized in (Fig. 
8.1), and represent a novel immunotherapeutic target in acute liver injury to quell tissue destructive 
responses and promote resolution. Furthermore, I show that SLPI acts as a key micro-environmental 
mediator by regulating the function of hepatic myeloid cells and promoting resolution responses 





Figure 8.1. Proposed model of hepatic macrophage resolution responses in ALF. 
Bone-marrow derived monocytes (MerTK-; green) home to the inflamed liver and acquire a MerTK+ phenotype (MerTK+; 
orange). Following exposure to multiple micro-environmental triggers, including inflammatory mediators secreted by biliary 
epithelial cells, notably SLPI [A], and contact/uptake of cellular debris [B] monocytes/macrophages acquire a resolution-like 
phenotype (MerTKhigh; purple). These MerTKhigh cells [C] suppress myeloid cell activation in auto/para-crine manner by: a) 
counter-regulating the production pro-inflammatory cytokines whilst promoting resolution/tissue-repair mediator release b) 
suppressing neutrophil activation and NET formation and c) inducing neutrophil apoptosis and enhancing their subsequent 
clearance [D], thereby promoting hepatic resolution responses. Whilst acute liver injury reprograms tissue-infiltrating 
myeloid cells in a MerTK-dependent manner this may have the undesirable potential to impair anti-microbial responses in 
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